var title_f6_39_6768="Low back flexion test";
var content_f6_39_6768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Testing for low back flexion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schober test to measure the forward flexion of the lumbar spine in a patient with suspected or proven ankylosing spondylitis. With the patient standing erect, make a mark over the spinous process of the 5th lumbar vertebra or on the imaginary line joining the posterior superior iliac spine. Make another mark 10 cm above it in the midline. When the patient bends maximally forward, the distance between the two points normally exceeds 15 cm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig W Wiesenhutter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6768=[""].join("\n");
var outline_f6_39_6768=null;
var title_f6_39_6769="Trans-ethmoidal encephalocele";
var content_f6_39_6769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trans-ethmoidal encephalocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 222px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Metrizamide CT cisternography images show a trans-ethmoidal encephalocele.",
"    <br/>",
"    (A) Sagittal view.",
"    <br/>",
"    (B) Coronal view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Tadanori Tomita.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6769=[""].join("\n");
var outline_f6_39_6769=null;
var title_f6_39_6770="Patient information: Small bowel obstruction (The Basics)";
var content_f6_39_6770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16718\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/38/11875\">",
"         Patient information: Colostomy care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/62/42977\">",
"         Patient information: Inguinal and femoral (groin) hernias (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/33/34321\">",
"         Patient information: Intussusception (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Small bowel obstruction (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/small-bowel-obstruction-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H25520054\">",
"      <span class=\"h1\">",
"       What is a small bowel obstruction?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A small bowel obstruction (SBO) is a condition in which the small intestine gets blocked. &ldquo;Small bowel&rdquo; is another term for the small intestine (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). In an SBO, air, fluid, and food get stuck in the intestine. They can&rsquo;t move through the small intestine the way they normally would.",
"     </p>",
"     <p>",
"      The intestine can be partly or completely blocked in an SBO. A complete block can lead to serious problems. That&rsquo;s because:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The intestine can get swollen from the trapped air, fluid, and food. This swelling can make the intestine less able to absorb fluid, which can lead to dehydration and kidney failure. &nbsp;",
"       </li>",
"       <li>",
"        If the intestine wall tears, the fluid in the intestine can leak out. This can cause a belly infection.",
"       </li>",
"       <li>",
"        When the intestine is blocked, the blood vessels that bring oxygen to the intestine get blocked, too. Without blood, parts of the intestine can die.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In rare cases, the small intestine looks on tests like it is blocked even when it isn&rsquo;t. That is called intestinal &ldquo;pseudo-obstruction.&rdquo; This article is only about real obstruction.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25520069\">",
"      <span class=\"h1\">",
"       What causes a small bowel obstruction?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common causes of an SBO are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Past surgery in the belly &ndash; After surgery, scar tissue can form in the belly and press on the intestine.",
"       </li>",
"       <li>",
"        Cancer &ndash; Cancer can grow inside or outside the intestine and block it.",
"       </li>",
"       <li>",
"        Hernias &ndash; A hernia is an opening in the muscle or tissue that covers the muscle. Part of the intestine can get trapped and stuck in a hernia.",
"       </li>",
"       <li>",
"        Twisting of the intestines",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25520084\">",
"      <span class=\"h1\">",
"       What are the symptoms of a small bowel obstruction?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms depend on where your intestine is blocked and how blocked it is. The most common symptoms are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Belly pain",
"       </li>",
"       <li>",
"        Belly swelling and bloating &ndash; The belly can get big, swollen, and feel hard when you touch it.",
"       </li>",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"       <li>",
"        Not being able to have a bowel movement or pass gas",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25520099\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor will ask about your symptoms and do an exam. If your doctor thinks that you have an SBO, he or she will do blood tests and imaging tests of your belly and chest.",
"     </p>",
"     <p>",
"      The imaging tests can include an X-ray, CT scan, or a series of X-rays called a &ldquo;GI series.&rdquo; For the CT scan and GI series, you will drink a liquid called &ldquo;contrast&rdquo; beforehand. The contrast will show up on the CT scan or X-rays. It can help the doctor see what&rsquo;s causing the blockage.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25520114\">",
"      <span class=\"h1\">",
"       How is a small bowel obstruction treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the blockage and your symptoms.",
"     </p>",
"     <p>",
"      If you have an SBO, you will be treated in the hospital. Your doctor will give you fluids and medicines. You will also get a nasogastric tube. This is a thin tube that goes in your nose, down your esophagus, and into your stomach. The tube can suck up the fluid and air in your stomach. This will make your stomach feel better and help keep you from vomiting.",
"     </p>",
"     <p>",
"      Many people, especially those with a partial SBO, will not need any other treatment. That&rsquo;s because, many times, an SBO gets better on its own.",
"     </p>",
"     <p>",
"      Some people will need surgery. You are likely to need surgery if your SBO gets worse or you have a complete blockage.",
"     </p>",
"     <p>",
"      During surgery, your doctor will remove the blockage and any unhealthy parts of your intestine. After your doctor removes the unhealthy intestine, he or she will usually reconnect your intestines so they work normally. But sometimes the doctor can&rsquo;t reconnect the intestines right away. If that&rsquo;s the case, the doctor will make a small hole in your belly and attach your intestine to the hole. Your bowel movements will come out through this opening into a bag that is attached to your skin. The hole in your belly is called a &ldquo;stoma.&rdquo; Some people need a stoma only for a short time until their doctor can do surgery to reconnect their intestines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25520128\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/62/42977?source=see_link\">",
"       Patient information: Inguinal and femoral (groin) hernias (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/38/11875?source=see_link\">",
"       Patient information: Colostomy care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/33/34321?source=see_link\">",
"       Patient information: Intussusception (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?6/39/6770?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16718 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6770=[""].join("\n");
var outline_f6_39_6770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25520054\">",
"      What is a small bowel obstruction?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25520069\">",
"      What causes a small bowel obstruction?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25520084\">",
"      What are the symptoms of a small bowel obstruction?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25520099\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25520114\">",
"      How is a small bowel obstruction treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25520128\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16718\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/38/11875?source=related_link\">",
"      Patient information: Colostomy care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/62/42977?source=related_link\">",
"      Patient information: Inguinal and femoral (groin) hernias (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/33/34321?source=related_link\">",
"      Patient information: Intussusception (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_39_6771="Black tongue Addison";
var content_f6_39_6771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Black tongue in Addison disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6771=[""].join("\n");
var outline_f6_39_6771=null;
var title_f6_39_6772="Anterior uveitis due to ocular TB";
var content_f6_39_6772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Anterior uveitis due to ocular TB",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 389px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGFAgQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oievKfgN8HvC3jr4f6p4h8TajqtmbK8lhY2ssaRrEkUbliGjY5+du/QDigD1b/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq4r4XfBz4W/EnTLy80HUfGEItJhDLDdy2ySDK5VsLGw2nnHP8ACeK+X6APtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/BH/QK8S/+A8H/wAer4rHWtrSdGkuIRdM0O0HiJz97646ConNQV5FRi5uyPr0ftTeCyu7+yfEu31NvAP/AGtWq37Q3h4W6Tr4f8SvE2cNHHbPnH0nNfMlv4daz0eKaWS0uLnzDm1lV8xpgYYPjBz6Y4Hc1qf2Vp6vbNp4MF55TfaCJzHGSxIbaBj5dpAPGTzXDUx1naP+f6o644VdWfQ+lftC+HtVvobOy0DxI1xKyoqvHax8scLktOAMkjrirVx8ddIt7mW3n8NeJkmiYo6lLXgg4P8Ay3rwnXpI21idYroX8O1YRdAkJOqABWVOwGAOe4zUG2a4B+XYmOW3c1zVs0lD3Ulc2hgYy1ue9N8e9EXGfDniXnnhLU/+1/agfHrRT/zLniTpn7lr/wDH68R0u4NjMjx7tyHcCGxk4xn8uKngsmvJA1vGQB94k7VX8egrlecVtopfc/8AM2jl1N7t/wBfI9rHx10jt4a8S/8AfNp/8kU9PjfpjsFXwx4lJPTC2n/yRXmukeGJriMMIml5/hGE/EnrXV2fhW6AUA28A9QCxrenjsZP7KXyf+YPA4eO8n+H+R1C/GG0cZXwn4nI+ln/APJFTj4rxEZ/4RHxNj1zZf8AyTWJH4YdsCXUJSMc+WirUw8MQjO+8vCvoXzXXGvibapfd/wSHhKHS/3r/I0f+Fu23P8AxSfibjr/AMef/wAkUjfF62UZPhPxNj6Wf/yRWXN4Xj/5Z3V0Mnjc2cfpWRrejXOmWwkivi3+/ED+eKUsRiF0X3P/ADH9Uw/n96/yOl/4XTp+8IfC/iQEnGWFmB+ZuMVqRfElpkjeHwh4ikRztVllsCM/X7VXmtvZahcW/mTW9vOT08tip/I0xfD2olDd6fHd28kD4G0jeG9QAeR70UcfON1Whzf4f8n/AJg8DQl8EmvX/M7W4+N2mW880M3hjxKksMjRyIVtMqwOCP8Aj4qxYfGK01BLhrPwp4mlW3jMspUWfyoOp/4+K8t1u5jv4Fj1eKK11OM/utRjUgSKOqTKOuf73UH24rCtdY1HQ5o3gzbTYyD95ZEYd+xHXmsv7S5KlpNOD6pO/wA03v3FLL4paXv8j3iT4qJHBbTSeEfEqxXJAhYmy+ckZAH+k9SBkDvUWs/Fu30bTmvtR8KeI4rVeTIrWT/otyT3rgdD8aadPokEGuxGe6D/ADsy7lcdjn6YGPauV1y/uPFthefb9TsdOjVUh+wi23ZUyBnCn+6u3OcjNejKvB/wpJ6f8OcksOorqek3P7Rfhy1SVrrw94ogMRxIstvboy8ZGVM2entVW6/aa8J2sEU1xofihIZc7HNtBtbHXB87rXlfxSlvNRuoNOvLeOSCBv3F5EfNSWNf77/iMZ55Fc3ZaSb2O9s9TsneKxO8W5j2yMFH7z6YUgjjnHWuaOMalaS0JnQvG8N/66nt3/DVfgf/AKBXiT/wHg/+PUf8NV+B/wDoFeJP/AeD/wCPV8oeNfC1x4du43XM2m3WXtbgKQGA6qQeQwyMg+x5BBrma701JXRzH2r/AMNV+B/+gV4k/wDAeD/49R/w1X4H/wCgV4k/8B4P/j1fFVFMD7V/4ar8D/8AQK8Sf+A8H/x6tDw9+0r4P17X9M0iz03xAlzqF1FaRNLBCEV5HCgsRKTjJGcA18NV1fwm/wCSp+Df+wzZf+j0oA+6fiv8VdD+GX9l/wBvWupXH9o+b5X2KNH2+Xs3btzrj/WDGM964D/hqvwP/wBArxJ/4Dwf/Hq5T9uf/mSf+37/ANt64/wv8MPBLfCLw34u8Sy+KJbvV7xrFbfS5bcDzTNKiYEqjAIjGSW6n06AHrf/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1efP8G/AV94N8a6lpU/i611Tw3Dcia01CW2O2aOJnAJjRlZeBna35V810Afav/DVfgf8A6BXiT/wHg/8Aj1A/aq8EE4GleJSf+veD/wCPV8WxozsFUZJrb06xWPDONzn9Kic1BXY0ruyPsGP9prwlIoKaL4lIP/TC3/8Aj1Sr+0n4WbpofiU/9sbb/wCP18oW8ZC4Uc+9XEXAHrXHLFyWyNlSR9Tp+0b4ZY8aF4k/79Ww/wDa9WI/2gNBkUNH4e8SEHvstf8A4/Xy5GyE4IwcVtaVKgj25Ix3rCeOqrZL+vmP2Ktc+jv+F9aLjP8AwjfiXH+5a/8Ax+mH4+6GF3Hw54mx/wBc7X/4/XhMMycKGbBHT0NK0wVse2DgdRWX9pVey/EFSR7kf2g9AAyfD3iXH/XO1/8Aj9OX9oDQW6eHvEh/4Ba//H68K8sSLkCo5LcbcKSD7Uf2lU7L8f8AMpUYM96Hx90PGf8AhHfEv/fFr/8AH6X/AIX7of8A0LviT/vi1/8Aj9eAmOZcAFWX0NA84jiLHqd3FJ5lV7L+vmUsNF9T30/H7Qx18O+JP++LX/4/QPj7oZOB4d8S5/3LX/4/XgogdvmZsn0FEsbqiyKCSnUeoo/tKt2X4/5lrCwfU95f9oDQUOH8PeJB/wAAtf8A4/TB+0J4fPTw/wCJP+/dr/8AH68EneOVc4Oe9Z8qH5cZznNNZlVfRfj/AJkrDRvZn0d/wv7Qsf8AIveJP++LX/4/Sf8ADQGg/wDQveJf++LX/wCP188qx9KlPI46Uv7Srdl+P+ZDoRR7+f2g/D46+H/En/fu1/8Aj9NP7Q/h1Rk6B4k/7923/wAfr5/Ee4HioJY+QO4NP+0qvZfj/mJUEfQjftF+G1+9oPiX/v1bf/H6r3f7S/hO0QPcaJ4mVD38i3P8pq+epIeMn86rLa/aHYOAydCCOtaRzGe8krEyo/yn0F/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1fJ3ifQfsMnm2gZoj95QMlP/rVzdenSqRqx5omGq0Z9q/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUVoB9q/8NV+B/8AoFeJP/AeD/49Wh4e/aV8H69r+maRZ6b4gS51C6itImlghCK8jhQWIlJxkjOAa+Gq6v4Tf8lT8G/9hmy/9HpQB+lNFFFAHgH7a3/JLNK/7DUX/oieuP8AgJoOs+KP2b/E+h+Hbi0tbu/1h4JJrlmVVhMNv5mNqkklcjHuea7D9tb/AJJZpX/Yai/9ET18VUAff/gT4Zah4H+IUupaVqi3fh+70yKzuorrYk4lhAWJlWKNUKhAF555JOa+AaSpYE8yVVIY57L1NA0ruxp2WjXbTx/uJGdhvCxgMwHqR9Oa6TRtN0to5Nkl3PeGQL+7h5hABJYn7pGcAg845FZ+m6XfGVJTb3ce05VgoJY+nJx09fcV0djb3zwmG5PkwDny1Pljr6R4z+Jrza9f+8v6/ryO+jSaWxtLbP5YeTUFmXylVYmdA5AJB2EDkA9VODg06dFaZrmTaJ5DkkKACcYqtbxBERIfkjzuEaLwp74Hv+da1rbxtCTI7bt2dhHX39q8arUvsd0Icu5FFaSSxiSMMIxxkeuKuWrTbHhjJYtjcp6DHqals4Jp5VgtQ7K3QL1P0HYe9ek+EvBAVEm1BQQORH0A/wAayjSlUZcqiitTD8G+EItQDTXplkVMeXDH8gkJ6ln7KPbk13On+F7W1iSMKJJsgBnHAxySB0FdRBbRwxiOJAi9MAUrwlSWU/OuSCf5V6EKUKcUra9zJ1XJ6hDbLGoVcKnYY6VOsQXJ4A6U0MoXf2Pc04zIvOMjGfauiNWKJuOXaTxTttQm7i3AA5+lKLgF8Ajn35rRYqK0bHckKEimmEMPmGfXNPDjIDZBPanKyEkA5703Wpy3C5CbeLg+WnHI4pfIQ4yoyO/pUykGnAZqqc4rWIm+5l6nottf2jW865izkDAO0+o9K8y8V+AJobctYM7BWLIGOUAPUEfw885HHrXsYFBWpxGFp1teoKo47Hy9JazC2ngni8ue0kxNHnLAHoRjqvuKoG5MEgOEcYDAnkN9R3Fe9+K/B8d64vtM32+oW582GSPAZX6grnjGQMqeD9a8u8Wad/bskmo21t9j1a3WNNTsguBJKx2+dEB2Y4yo7nPrXmSwfJFzi9V0/VfqV7VS0f8AX9f150NPv7K4E8V1aLDBqMkJujGc+QUYnMY+6QxxwRwBWj4xnVdbt57HT9W1KIoiLPHBgmFAMkno7bSyHOOi1yNtM9pemKQSRldykMuCG6EEH8Qa9A0HxPoE+jfZbS4tNHvblkSSGWJmKEDDEOT90EBhzzuIPSumi3iIvRaHJVSpPrqeaTaTqusm6s76W0SGKYpDDKw3KmP3fPQAAj5hkDoeBXm/iDw7c6aPOEEq2+4xsW6q68Mp9D7Ht617L4m1mz8Pamt1YahaXaXcKmOcjkqeCNo+7yGBU9ia4rW9WgaW6s9Atp3sZHElqsoIATaCwJb7wHK/h1rtwtWVN++tOvS33nNWgpq8N/zPL6K0NWsRaTboXMtuxwH2kYPdT71n16LOZO4V1fwn/wCSp+Df+w1Zf+j0rlK6v4Tf8lT8G/8AYZsv/R6Uhnv/AO3P/wAyT/2/f+29avgXwbf+N/2ZvA9hpi6e8lrqb3skV+7JFLGlzcbkJCP1zjlSOtZX7c//ADJP/b9/7b18q0AfdE3gu/8AC3gD4r3t2NOsbTVNMuJLbR9MdntbMJbSKSpKJy5OThVHHft8MqpZgFGSaStbTbXaN7fePT2qZSUVdgld2RPptmI+SMt3NbNvDj271FbqAB6VfQHI25+lebUm5PU3jGyFRAmemD+lTBRtz1A5qPOcheT/ACp6KTkucn24ArnZql3LEWAQzcnH5VaSXam3YCP896qRjkAkfWrdsqn5TjPoeBUSE9zStrl5OeTxt61oWpRv9ZjPrVC0UKz7SV+bC1oxo/HyKT65wa55JDWpdjQCMhOfWo2XDHNTQMq43Y69fSp2CvzkHmsL6miRS8sHpxT1h45/OrQjU84wOxFPCAZyRkVYyn5eGGc5p88ZUBlBwR2pzlmzsxgf3v6UgMucLtOPU0maRRRms1c74/lbHQdKr/ZxtII+atVmYfeQqe/cVTaQeYGz1NJs15boo+SwfkdKmW3Zxwpq6QGPHX6VagZVXBGD+dEpGHLqZiW7DA24pHtweorUdgSVyPb3qOWIheAay5rsbjY5+/g8tcjvVe3YQQszcnoB6mtG+R2Y8cCsxvmkB42p0+tbWurMUUr3ZbitgkDGRVLuPmyM/hXnPi/RFspjcWi/uGPzKP4TXetdllIZsVk6myyRMjDKsMEHvXRg6s6M79zmxEOd8y3PMaKualam1uCo5jPKmqdfRxakro5Qrq/hN/yVPwb/ANhmy/8AR6VyldX8Jv8Akqfg3/sM2X/o9KYH6U0UUUAeAftrf8ks0r/sNRf+iJ6+Kq+1f21v+SWaV/2Gov8A0RPXxWKAJIUV3wzBVAySf6e9dho+k2DWVvcOrifJGBJtJGOD6g5rG8OpCkpmuYZGUfxDGB+ddDcajDG4Npaxy+XzJ56loY1ZcYx1PJyMegrixE5SfJH7zsoQUVzPc0lnTTogtsrySznLQ72LSDOQcnOB15rTnu1kKrbAxr2Vhkkejdie2R7VkaZEltaqEkaTfhi7DDPkdfYe1a1rEIdshb5geAeSa8iq1e2/mehGKWrL1gpSVZZtrY/hNdBomkXOrTqlrGQmeXPT/wCvVvwv4WutUdbm7Ty4SflXHX617Jo2mQ2NqixIq4HSso0XLV7GdSuo6IyvC/hi10hQ7J5kx5aRufyrrreL5QTwMcD0pqIqJxjAOakZvLjO/wCp9q6VaCsjn5nJ3ZISinkgeh9aoahqSWoAVS7MccDqayPEGsi2yFdI4FB8yR/XsAO9eb694slcOtoxJbO1zyaynWsrI0jqei3GuKkJ27dynaQWGFA9STWBqfil4ZBJJOPLAz5cJz+bevtXl17qczJm6fMnHJ6g98CsltS+VlLcdBzn8frXO5SlsXc9J/4TnyE8uErGz5+ZiTtz3x60+z8czxwqttJ0yWaZfvfl0ry9bhclwfp6077QPvO/XnngflSSn0K5kerw+Nbr7yEySfeYHjfz/DzxXXaN4isLj70hE+ckt0HHTPSvBkv4ooCh3Sk+g2j8zzU9hq7wyo28gIeADTXNF+9qPm7H0lYapbzRhgR0yxyOKvW86SqzIQQOMdDXheneLZGceWSvP3ien4V2mmeLkMm2OZZFz1KYwfr61aruIWuekRsGHH/6qewGP5VgabrqXDouz5W+9KpGM/410i4IBByMcV6mExil7s9UZSXKVzEWHLZGfwrkPG3hCLV0S6tMQajEQY5R/Wu5xkf401k3Ahh+Nb1aVN2lF/5mbkfMvifTrg6jLbaiipqURxOR/wAtOciQnvn171zkhsIbqK21SyM1vG3nSm3O2WRehVWP4EelfQ/jjwi2rxpdQMBdwLtiz/dyTt+mSeK8U1vRxcSSRTp9luYs/LtJw3bnrg+vavMlFRm5RRandWZizabpl1Yn7BFEt+ZCwllXeZlI4V8cJt4O72ORWX4njvby5tfswhiW1VlgSJ2IiVhllOf9rdxz1FT2klxBeQSRqVhIYO8S/vOvXnglSvA/xrotJ1jSla5+33e6WCeVHnVWzMrKWEgXpw2OOM57YrWDbV47kN2fvGAmhDW7XUdPYE3mqIs8D+XhDMhwdqgcN1U8V43dQSW1xJDMpWSNipBGDke1e8walDKttp9m8Zgl3XlpuxhbpV+ZBg8F1AyP74BFecfEC3XUSmvW+G+0hWn+Ug7yMH8iMHHevSwlRtezl8v8jir01GXtI7Pf16P9Dh66v4Tf8lT8G/8AYZsv/R6VyldX8Jv+Sp+Df+wzZf8Ao9K6zM9//bn/AOZJ/wC37/23r5Vr6q/bn/5kn/t+/wDbevldAWYAdTQBYsot77mzge1b9spwMp+tUrGLaqjHArUhGAOec1x1p3ZtTiWIwwYYIA/M1Y2bvvEk+9QoDkcfjVlAeMVxyNkLEfkHbjpUuDkY+maaM9KeeQPWoYmyRR7kHtU8IJwW6GoUByNuc9qniyAOg7ioZNzYtmMir5hUY+UEj07Vv6au5E3qxBHyELkEjgkeormrNwDyAxGQARnJNdDp91PaSFoZjE+Nqf7Q6EKPXNc9RaDuXzZAu7MBuTqCORSLHGSVwQR3NWrgBQqJHL50aKLksAT5jc4yPve9VVkUoxwcsSAPcVz7mqkxpjCsAHIHuaQkbiBkn0zSNKPvdhxio92ckiqsaJtkpTPAOPwpwj2DBGTRG+7nnj9alcn2IPemNbleWMsCOxrNkgdcqRz2PrW0kBkY9RipFtSe3tStY6KabdjOgj3xKR6f5FOZChz2q/ZReWXTBXnkVPeWwC545G6i6Yp0nzGIVO8t6cCpTOAAHp1yFjTA+96VRcOMs/AqXFMhxYy+KuGKkA1zjoy5APvj1rdkGQTn/wCvVGaLFXAzkrIyJfUiqEytJk5OK3msi65/lUElsE7DitoySMmc1eaYlxasjD5jypPY1xU0bRStG4wynBr0yaM88YFcn4oscYukGOzY/nXpYOv73I+pyVY2fMjm66v4Tf8AJU/Bv/YZsv8A0elcpXV/Cf8A5Kn4N/7DVl/6PSvTMz9KaKKKAPAP21v+SWaV/wBhqL/0RPXxlBbyOhlCDylPLOcL9K+zf21f+SWaV/2Gov8A0RPXxnaW81zNHFDG8rsdqIoyWPoBQ9hpNuyLNv5kypFDFukJ+Zskj/61dFYaesSkGUSnGGYDhfYdvxp1zZ3GnzLZO1nHKEHnLbSbmjP9xm+7u9QM4+tWLUIqqiKwjHYHgV5mIqPZaHqUIJK6NO2jCIGIwB0wOK9F8BeHJNSukvr9Ts6xoR0HqfeuT8Laa2qXyKQfs8ZBYHoTXu3h+2S3jRB0xyK89Ru7sK9Xl0W5t6XapAqqigAHAH9a1kXCjIHB61T007yzMMAnFXcBvfPB9qpyOJPUc7gL8gzXOeJtcg0q333MqnGSEB61f1S8+yxSOGAPoDz+FeEfEHxJnUWWE+Y+3BLcqv0H9azab2NY6uyLPizxVJdMTceSFbGzB5Re2Pf61xz6m6ybo84PO5j0rCu7smQyyv5jHnLd/UVmXV+WJGfl9M1rDDOTuzTmSVkb818pZjJKWLdcGoP7QhXlRzXMPcse9R+c3viuqOFj1FdnXRaqgbDYA9avw3SSHgDPqa4VZiT1q7Z3rwv975apYan1RL5lszvothQFkO0j7xHBqOQJ1Q4NWV8S2UngmO2eQfa0l+UbhyufT8TXHTaqS5Cn8TVVcFBbGcKszoGupEJAb5fWtnQdVMDl3b90uNxJ9f51xlvfh+GwQa0IipKupHBzjqM/SvMq4fl+JHXCqpaHvXhvVLeaCM26RpG3AP3cn2rudDvpCW3bhGMjnua+ctA1idLkM3zEEZLdvavZfDes/byvmF0kIw20Z+hrkcOV3iW30Z6XaMWQMc88nNWttZOkzhEihX94pH389fetsKCBXrYGq3Gy6HNPRldkBycj8a4nx94Tj1W3N1aqEvIxwwH3vY+orv8AZnjAqtLEcny8c9VY8H/Ct6tPmRi5W1R8eeKbOWwAjeN4hHdLLjnOd3zIcdB/ED+FZF01vKJEgWYXkcQkiWNcpKc/dbd2+nXIr6Z+InhGHUrSS+tE23UY5UDBPsR6+9fNOuW0tnczyLJtmgYyxlfTrtI/vdeO9cnLyuz3NoT5kW7P7WtjDqlvs8m2k+0QzRoI338nJXHHPAJ44IqnfxTXmnzWJFoIZIzdOclmDEkPsHvlTz6VSsL6O9kb7XLarbM2J4Q5iWQDkEkAkNnB6dqt2/iONPIjfyp440YNDKAVZcYP3eewPPzHjNax5o/CU4qSs9Ty69t2tbqSFiCUOMg5Bro/hN/yVPwb/wBhmy/9HpWb4mlFxdxz4Cs6fMN2T1PJ+vWtL4Tf8lT8G/8AYZsv/R6V7EZcyUjzuVx0fQ9//bn/AOZJ/wC37/23r5fsk3SA19Q/tzdfBP8A2+/+29fNFlGAB60puyBK7NO2TA5FXo1yMCqsIIA9KuxjjpmvPmdMSxGgzzVhQPTOBUceP7vPqDUy9RkYPfjiueRQAccDHpTgOnNKwx9cUwZAyM1ImiVWwcY/HuKmVtxyetVRyO/4VYjIxgdRSZNi1GWLDbnca6v7I6WUl5I8eYyNiLxuDLkkd+OAB3JrkYFZpVAGdxwMnj866BRefuJ/LdoosmK4A/dtIp5YH+LBwPyrmq+Q0akUjxyRi4Vhe7djtMxURDGAhHGCBzzUyiGfLmYnOdxVdqDA4C55NTteW91p/lQxR20rMz3Wo3TtK874+ZV4POewq5YQtPpwFpZ3l1axRhJLm1g2AqCWIy2QSeSW9sdq5XOxojCMgyE54/A1I5+UY9euaW6DSzoQF2kblCHdge56VA+T0Jx2q07mqL1rnB/KpwnJAyc9RUFopVcHHr1rSt3VmG7APp0qmzSKbJLK3JK4zkdF9Pxq/JZsPmLDB6g+tX9OtwYzISM9Nv8AhVyeVBkIEIxgArkVlKR6FGJzwtAmSANxJOM/nUE6FyNqnkdPT3rUnwxJ2sG9OwqukbK/Jyx71lznW6SsZi2IVS7nc/rWbfwYYrtIFdolo0kBK7Q2Ceaxb623BggIwcEt1z3xXRB3POqxs7nIvFgkdv6U14gckitKaHaxVQce3OahMJ25YfQVTVjlk0yiyYX2qjcR88/yrWkjIHSqky88AlqaMmjFmi4PAHvisfUbVZoHRhlWGOnSuguEJJ3ce1Z9xHlSFNbwk4u5lJJqzPLLiIwzPG3VTium+E//ACVPwb/2GrL/ANHpVbxbZ+VPHOuMOMHHrVn4T/8AJU/Bv/Yasv8A0elfQU588VI4/Jn6U0UUVYHgf7Z0Uk/wy0iKFGeRtaiAVRkn9xPXyHF9t06aSLP2O42YYZ/eMPTI5A/Kvrv9tF2T4X6UyMVb+2YhkHHWCcGvjK12eZy2D0z6VMti6avJG5YqYAhcB3x8voB6VuWaMgY4OW6Cuf04h5RGnRe5712elx+bdwRFeFG415OIunY9dNRjc9E8C2629pHkDf8Axcd69M09/wB2WJ4xgelea6JcJbyqHYBTzn1rv7C9RwgUgqenvXK3ocdRN6nUWDbVJBJHAqeSYQxu+4bQM8+lZlvMoOxWHTB571h+MtU+z2JhHSX5TzjjuazbMkrs5H4jeLHhaSG3OAvDEnr9K8T1K/aSR3c7ixyc962PFl55l04ycKcHnPNcXdzFj1PJ9a68PS5vekapLZBdTs/GTgVT3HJzxSFz0pQPz969BKxVuwAZIGMZ9am8v5dw6nrmkVQVGevpXSeF9Ht9QtmurjEq7yix54XH97HeolKyuN2juYG0c4GARxmn4LMAASSMAAVveKtBFjbre6erJHkLLF1Az0YenvTvBCrM14sgXzlKlSRzgg5ApXvHmRDqK2hnwW90sOPs8+SMcAf/AK6pTRyRNiZHjYn+MYr0c2nqKVtMWdCkqBkIwVI4NTzshTPNklKPxmtWxvSD8x5o8SaMdKlWSDf9ikOOedjemfQ9qyEfDAgnIqrKaKtfVHaWV3gqRyRztzjJr0DwTqxSVI8lQww2Dgye309vzryXT7gkqAMt2Fdr4duPnBywLDDbere3sK86vQ5XpsaKelmfSnh2+jX5I/mOAdzHGPYV2kLiSNWU5UjrXkHga9kdfLMeAAPvNnbXrGmOnkJGvBA6dqxw0nTnYzqMtbTnio5RIANqq+OueM1YxzSsOCK9ZJS2ZhJ6GPf20FxE6lVfPU5+YH6+tfPPxW8HGG4mnXc1tcsC7YwQw78dD619FakCEEkSKZV6EnAI7iuT163i1DTZIyh2tkFX6575rOolLVbmMKrhLyPkF4otP1GSR1L7mZH8kgPkD+Hdxn1B4xmmR3mkSBxLaB7oFNtzISoYYAK+XyM5zhs9uldV450JtHvXyP3RlEyEd+xA9eO1cvbDTpItiwSKwRh/rAVyOjKW/wDQT+FZJq2qPUptS1uZviKGCXTJIrYwyeSfOV/48Hgj8MCq/wAJ/wDkqfg3/sM2X/o9K3na3mtpba2iZre6jWNvNGDkcg8Y43cgfrWJ8LEMXxX8IIw+Zdbswf8Av+ld2EleLj2OTFR5Z37nv/7cI3P4IH/X7/7b184WceME/WvpP9twZm8E/S+/9t6+dbNe+OK1qvQwiXYUGOlXI0wC2QMe9QwqcgHp6+lW1Vu+Dt6VwyNkKgPHWp0XOKRFB69vaplUqKxkURuMDI+lMPpg1YkU7c/lTPLxjjipQMhwQOc/NTjJ5ancT/jT2HOe/wBKZLBvRigL4GcDvSYRsTWt4gkVigkVTkq44b2P+FdFos2m5lfWZbuSMg+Vb2YHyk89W+VQfYE8VykFswAZ1AY9s5rRtwV4K8+vPFY1IpmjS6HcQ3uk2DxNptgdSVNoabU0Ijz3CRqcY7Ek59hV7Udbu9QskgutSiFmpKJZ2zGOFF9NqrjHPU9a5PT4SV3vuaPowUnjP61pGDaokRCIH/hWQOwH8/zrhlTVxxRsXV60sELRS3EczRqjjLsHAGMemAAOKzvLAkYDaR2OCKsWNr50haCJpIowWPzFcgeuOfTpT5bYRy7coQQGGxiw57c9xTgrFInsY0dR1x9avw2wMoOTnt7VBYwsWXp+RrahhZlGCCM/StWaQdmXrGKaPDIRnHINMuImeY5O0nrjjNWrdJEUhPlLcYxnmlbAyspZXAyQOR+dc81c9TDStqVEULIMD5R1HrT2txvDIh+b+HPSrR2qm+OJeOS55pqXgdAFjz796yjFpanXKd9iaO2KW5aR/n/hHYfWsbVVWJJDtBz3A4rYkuFaIiU7U7EHmsfVLcN9xyw75P8ASuqkrHmYiXc5qQ75Dzj2pjxgA5HSppVIY8Ln1qFj0yM/StWrs4nYo3YAUkc/hWUWdshSQK2roAqe1Z6Rgbjjr607aEGTcQOQecNWe8RGc5+tb7YOcDn2rPuFA68+3SrRnJnIeJrfztPlABLL8wArN+E//JU/Bv8A2GbL/wBHpXV3wDRspXhgRyK5n4YJ5Xxb8Iof4dbsx/5HSvZwUrwcexxz0l6n6SUUUV2CPAP21f8Aklmlf9hqL/0RPXxnENjAkcEV9m/tqf8AJLdK/wCw1F/6Inr42kjK+XkHkcVMn0NqS1ubXh61e61KNYuSe1djpyPb3E7sOVO38qwPh/DE+qF5/N8tRz5Qyw+grZjkXa4V3OXJ5HvXjYqT52l0PSd2kju9GdZAuQDx0NdNprOLmJIZD5ZUn1wfb0rhdIudu2M5+cbRXU6bfLHOqKOVGD6Vw85KTSZ2WmXT9XyR2H+etcr46vSUkkR+VXB9M+1a8kyxQtJGRlhxjivPvE9zP9nlW4bf83BxggdgaUdZWMGup5xrE5MrDOSTk+9YE7A9DjJrQ1GXNwxPSsuU5Jr3KcbIcfhEjA6tmrCrjknj1qGPHeuo8K6YrKl5OuWPMSt0Uf3vrVTlbUaaijFe2mig814JRD13FDj860fB+oSWOp+XGsbQ3LKrhztx7g+vNeiWa5XB+YEYIPII9D7VmR+C0jnlbT5LdYpXDFZ4yzRrn5lQjjB9xWKqKzUjNz5tzo7jTUvLSSBwGV1xz+hrM8I+G7rS4bj7YkQeYqflOW4BHJ9K7KytlARV+6AAM16F4J8J2mqGSW9L+TEu4onVj6e1KnGU3yx6mLlY8paxKgZXigW42YxxXrXjrwla2Onx31jujgJIeOUjKd857ivEdT8XabZaqbUxyywKPmuohuXP+yOrD3H9KJU5Rk421CLTVx3iHT47nQr6OUDaImcE9ivINePDlA3TPvXe+JPGtje2FxY6fHcGWddhkkAUKO+BnJJFcLIoA+5gYxnNOmpR3OiC0J7KQq4rs/D115U4xznqSa4O3b5ufwFdJo0wBHOMe9aSSe5M1oe8eCtRENzHhC+/8q9v0q7SeNCqhcDBHpXzt4Mu0EakAMfr1r3HwpcE2a5Ubsde1eTXXJIzbujrQeeeKc3TiobeTeuRyacW5we9dFGsYyehUvvuMCBn19a5W6YBgqMSkhw69gexHpXU6gfkOOg9TiuM1xpJF8pB8pPPPT8e1b86uctryseZfE7TI7yKF4h8yF2GDkcL/wDrrwiRBHfDpHbuxVt3SM+v0/lX0b4hs5TbuyqCEbdtHC474FeJ+LNGFrrADbkhmJ+YDkH+vas5fF6np4Z2VrmZYxSb0ZYjJbrKqiQLlC+NwUt0yQCcemazfAiKnxq8MBMEf27aHjpzOhotQVAjZnj8tuVTkMR6p69s4qXwWS3xo8Iu33m1mxJ+XB/1ydfeurCLlm15FYxXUWe6ftrjNx4JHtff+29fO9qnQ7sYr6K/bU/4+PBXPa+/nb1892zDsRxzXRVOSJehXp3q2m0s20AD0AxVeLjGOlWUXMuSxHH51xyRqiZE5wBg471OI+nP60wAx7Wz+I7VYjwz4ByQMmsZIY3y8nBBx1p5T5eBznpTwuSwx3qcR7l7VDQNlMxgjp1pyxDaRxk1bEQLDvU6W5fACkk9scipYjPaI/Lg59sYxViOH15FXFg3buCcDJ9hUscOQuB14rKRpEbaxYYbQQ3Yg4/Wt61uSkxe9gjuSwIzPnc2e4ZcGorGxmlBRIJJs/NtjGWHGcj2xkmtgaVNbbEMpkWWFbhGVTtwTj5geVwe4rmna9mXcpRQw5WWN0VSSNjZYp9D/KrECFnBJYk/jUjRu7MZDukbl8AYP9DWjYWOMHaSO6j+lOKtuO5LaWhChmyc881p26BAeBnHQVMkAAPyDAHHrSxlFmGScAdu1Ddwi9S1aLtgLAnB4znpTjE7KqyEICeuOv8AgKliaEfOMEDrgU27dpNixjAznB71lJHdQm7lTVcpGUTG0jPHasrTziMdDk9+cV0d9CGgcBeq5zWfZ2e6MqPlBPBx0pJaHWq65SvKgMDAHtkDHINZ88hdcgjBHIPatC7KOjKfvjgmsO7dkAy27HTPUVtFWOGcubQoXZXcc8c+tZ7yFn2joTirl5GsyZYAjuDWLPA8IJjkJTsD2rdLQ5nbuT3kqIvlg8471QMxA2noaryPKJP9WXz6HmrSRR3EWUVlYdQ3UUWS0FKLtcpySYOBz9KqzMp6Ek9hVuSHaSMmqrAAnufaqsZMzLwEgnmsLwPF5Xxo8Jgd9asj/wCR0rrHRSDk/hmsTQI1T40eC2UY3atZf+j0r0MDL3mvI5qujR+g1FFFekQeC/tllR8NNHLDcP7ai4/7YT18d6lOZpo/lChFxgV9kfth7P8AhXOjeapZP7ajyAM/8u9x2r42vI4xeM0BBgZvkGc4FZS+I6KO1j1L4Atp8HikTaqZBCttMy+WAW37cDr+NVtVubRbONbMy+ZHM4YOQQynODkd+axPB+orpmr21w7FUUEbkjD44x93vXR6x4evrOxS/mhEdndBZ4C8i5kU55Cg56jpjivJrfFc9CpFKab7ITRZgZId+CPu5NbklzMJnW3IYtk7sDjHauVtHEcSE9nByK30UeUzK3y5PuDXm1V2LtqdlbNnSUEmwh0JKkZ7VxHiW4IsSjt8wG0ALtrptLuytssM4yCwAYHGQfUdq5bxTbtMkmY9hBIzjG76gUqUlzJmUo3umeaXJ3TOTxVFzhjg/pV28jKXLL2NUJhtbJzX0VPVGT2H4JXbkAMQPzr0jT0CIirwFAArzjPy5BHHPPevRNOlEkUbjoygioq9CZnQ2R6AVs6fLHMgaORJFyRlGB5HUVg2j9MVqaVa21tJJJbQRwvKd0jIMbz6mudmLOx0qyM4jPmRxl38qIMD879ce3Ucn1rpfDniG50ZnMABD4DK/Q4rhNF1ZLgSfZJJFKNtYFdvNaolVcbVC4Hr+tTzSg7olxvudF4t8QTeIIJLe6GLV1KeWnGM9a8v1LwHot1FGim8gZc5ljmyz59cjHHbGK6tpge9V5ZRSdSd73HHQx30rTobAWUdjbLaYx5fljn3J65968b8UaYdI1ie1DM8PEkTN3Q9PxHSva7mQHNeY/E9V+3WDj75jZT9AeKqjJ8/qbQ7HGRt+8wOea3rAAEBT16+1c7Hw4/pW5ppIx2OfzrqmV01PXPAcYbyi7E4PrXunh+QJCoHD4zz93H0rwnwCACGYHjoAM17LoUrF1jlIEQGdvb6V5WNavoYwVzsrTUA8rADzFYY3ow2rjrk/wCFXRK0qR4BZgMghutY1uqK0KwxLDGrBl44Yd+K0oYiJmJwd2MncVJx0+lcUJvYzqJdCtclyxAc/ewcDrWFqspA3RhSu4bcdK3bs7o2aJMFyDvJBGfauavgZJGWQncvYua7actDmcdTJv5EaIpKQGB5zXnPjnS1vLN2j5aM5HbAr0G6K+ThBgZJ/wDr/Wua1i2Vh8jcHIORkfhWt+bQ6KPuvQ8AvF23QSeM+fESQ+MbgfU55I7UeC8H4x+DShDIdXsirZOSPPTrnvW9450wKXuYedh+b1+v1rm/AMrTfF/wc8n3zrFlk+v79Oa7cE+Z3OnFO8E/M99/bS/4+vBOP7t9/wC29fPtuocYI4/WvoP9tAZuvBX+7ffzt6+frXjH0rrqnJEtQLsbGever8absEN8w6Z71UAPXHTmrkS8DNcskaX6lmHBK4GGzyD1FWVTPOPm7HvUcETuQUGZF7eoq5HtI3ZwvfNYyRRAimN9p+bOMEVciTjp0qIglxJj5Rxk/wA6uxqMc8n1rN6oJCLHghsfLjGelWIU7MTsPUdFJ9/X6UKnzqWPzEcf57VciXoCCf8APaoaER+Vx5QXGCMgdM+p9/5Vf+wrlOGyecj0/wD196S0TEg25UHg7en0FdBHA0z+ZIPl24BHGcfzxWE3Y0Qyzs0WxJTzLeUYKOjYPPBUEc9ecn6VfvJjJHb3Ekrm4UbFG7quMFfpnmmyjaxEWNpx+FJ9njMi4bd6En9K5uW7uNeZDbRDjcBjPXpj2rrNFswyqQuT15HQ1T03TDIyMqjA6V0FtEbdyQcbeTU1J6WQrlO5hETsGxjr681VltkK7x908kV0zwQ3UBK5L4zgdPwrFePZuXkovVQP1rKM7mkbPYqLsjjI2jd15NMSQtJnOFHb1qGdlkmZQTtB6AUjwyMuFVlHbsc1srHQouO5Zv78CERrkyN94A0+1YfZtq8ZGeaoR2rIysAC3qetTjIBUE56k9abt0M5zSXKirdgrL904I5NYV8FBY9q2LyRpSc9Cc+9YkvzsQBk5xgVtFGXtL6mZNIwkAZsj0AqjdMXXGRtFdBJZRwRO0+N46LmufuV3AmMc5OR61pGz2E3czejgt1z1NPuGaP97EoIP3h61FOxRvmQqB3HNJHNjAJBHY1Tj1KTsMDiZcqfw9KoXcMsb5j4PcHvWo1nBOd25o39UOKQ2VwiYEySL23rQnYPd3TMGSZkU7xg1m+HHL/GLwQT1/tey4/7bpW3qFtPEC8kayDvs/wrn/C8iv8AGTwWF7avZcen79K9HBL3m/I5a62t3P0Looor0DE8G/bIdk+Gujsn3hrUWP8AvxPXx3HOjXkjyJtY9OOhr7I/bAAb4d6MD0/tqM9P+ne4r47SLdqLI4bD9CD0/wDrVjUav8jqw/T1Ok0mCWK7tJJP3O9g0W5CAV/vD1Fdd4nigk1drmCLyoplVwhXbjI52gk8ZHrXLWbCTSGF+Z5njCx2kiv+7jGcsD6/QV3GiWMep+FLeSwF5darFMYJoWClAp/1fldyfWvIrb6HpS0XM+hz9tEDviYZY8gelb+nOAjxSdCAQR2NUI7eSVw+0JIhxIGIG0g4Ofx4rVsolkyB3G4AcVwzTIlIWOVodQHcuqkZ6E1N4itcoQvXOWOeCT3FR6kixwpIwbdu4K9vetf7I13pP2hpSMDBBPQ9BWK0ewm1ZM8Z8S2ZhuS644PQVz1xhua73XrQy+YQpOPX0rip4DHIVPbpXvYSqpRRi4te6VYz0H866zwpeh4TbMfni5UE9VrkipX6VZs5pIJknhfEiHI9Poa6Zx5kTa+h6pZvnFbdnJgCuN0XVIryINH8rj78Z6r/APW962oXk+1Ryi4KxAYMWOG981xtGUkddBNjHSrBuK56O7H96o4dYimuHhjfMidRjis+VkpM1dT1e306NJrxnSFnEZkCEqhPALY6Lnv71PJORkHrWVLMs0TxSANG6lWU9wa53T9QutHufsGs3KPaPn7Hds3OAf8AVuf72MEZ/OqULrzGdXJLnp1ryfxtqK3+uSGEhordfKVh/ERyx/P+Vb3inxOkcL2umyh53GHlXog74Pc/yrgtvy4XO3PQ1pRpu/MzaEbasdCAXytb+mREugGeOtZVnbkkHHQ11/hmweadMRllzzVzlqOekT0nwQY4rdEX75PJ68V6x4SaBJnnPO3gKqk5PTNcN4W05ISMKquMHDDiu5tJ/s0Ja0jgjmPyr5jYj3eprxMRV5pXZCj7tkM8ZassHm2kEssU5iDICM5LHH5HpiuqsL2OfTLRmct5kQIJ4ztHJ+ma5GU6fPdSS6ji/vc4EhXaoUdcAds880t5J5WkFwskLA4DBgRt7D0A9q5oPQVSKaUTptRcG3MsJVpAOOuAffFcvc3pit1eZCszfeA+Y8epqOTVHjhgRVaQsPmdW+VR0znpVDULlpkSVWOG+7n09K7YHKqbW5Xa837sg46Vg6te+XaSSMFGM4GeB+NXb2Rk2KuNznkf7I71yHjO6YaYYmOC/AFbSdk2dFKnzSSON8QXK34kEZDwdOG6muV8AY/4XL4VHORrdmDk5589M10K2ahIkb5ct0zXNfDht3xi8Kng51206f8AXwld2WxfvNbGuOaSjBeZ9B/tof8AH34J/wB2+6/9u9fP9rnbzwK9+/bU/wCPnwT9L7/23r5/szuA9K9CaucKNEDKH3FXoBuUHANVYhnvirMI52A8Hn6VzSRoi5CxLjy8cfxVdWEhvMjb5zyVYcGq8IAABHFXImweCDWEirksZEqkDIPQj0qeEjo33hwRTI41bDAhHHGT0/GrP3JFMsY6VFg9Byhgfk45/OrKqTGeue/arNlArOPMAwTjGelWJ1+UKmSiHAPrWUuwJ3Y7TSI5omAB2nIrdicSMGIy+6sZYkV1VDlSOMitW0ZoRnjjrx0rGcU9R3JlkLsURfl7ZrQ062aWQAY64ye1M0+AXDbipPr6Cugs0W3QE/e/I5rnm+VWH1sbFgiWlvmXauOrnpiqV1qkDzEocp1OBVOWVtQnEBJ8lTlvc1ditoLZCgXk9BiuXlS1e5slFay3K0msRBv3Ku57gDk/4VH5V/qADSL9mhJwM8s34Vr2dvDGC2wLkZyKm3YfeDsT61LlbZGkakY/CijaaMkDq6D5sZYsamNmjQ72Y56fWtB5lEe1AaqrcxcoQQ/bPaoTk9TKVVy3MS4XyZSuc+nH6VTuLhIlIC9BjArUlMdtqBMwysi/KxPBPpWVrc9nbx7fJy75Iwa6ab5mlYKi2MCecs2Qc4zgZzzVOO4SG6YOoJZQePXNQs205Ax1NMKecdwYiuxrQzSsT6ltuDvD4z2FY8kYToc/0NaTIQGGciqE4wcE5pxH5FGWMP1/Csm5h8okrkjPI9PettlHAWoZ4Nynsa0iwvYxopiD1yK0LecEYLfgaoXcRifgfL19x/8AWqtLOydTV8lyXqaN/KmDlx0rifDLq/xv8JhcYGs2Q4/67pWve3PmxkAgN/OuW+HcnnfGLwo5Oc65Z/8Ao9K9HBxtdnNU3R+j9FFFdYjwn9sLb/wrrRg7uinWoxuRckf6Pcdq+P7q2lt71cuJEZcqxOOK+uP202K/C7SWU4I1qI/+QJ6+P1maYRttZ8HjceF9eayqJ7o6KEknZnQabvIESqnlgjJRwVBI716f8EtDtvEfiq502e/ntZBavPZtHIFU3CsMFvUAEnA968lgW4YqohSFCu7g7sj14rrfCeuyaTqFhd2832aS0kEwlWPeSy84C989Pxry6sbM9hXlBpHpfijwtcabI+qRwGLS7+4aNkIINtc/xRkn7ysQWVhxzisuC2eMI4UgjlSf4h3x617DpEuq6zoMMXieOyfQdYg89bi3l3tGZcuqLnABiIJyPwzg1wml6lFfeHYtMuT50VrJI1pcRgLsct8xYHkq3XHUZrja5vX/AIY8/mklZ9DLW1W4jKsPlY5GKZaI1qxiY5+vcdvpW3HavbsyGPDoc7T2z/j1puo2oJSVQRuHXHes6lPqEamtjgPEsD+Uk4jyi5DnOMe2K4TVdPBLMoPv7e1ezSRrJcgyjgHlT0I/xrlvEOhfZ0ZoVVrYktu9B1/PJow9Z02bOzR5JcwnAGOaq7ShwRzXZ6jpHO5ACetYNxZkEg9a9mnVUldEb+pShmaORXhZkkXoynmuhsfEkkZCXce7/bj6/iK594GU4xzTctwOn0q2lIbSe53tvr1nKQRcKD6N8p/WpY72xhnecTRK5HPzivPlOCMnIFOJDHK4z3qfZkezR383iSygXiUysP4Y1zn8elcvrury6ttV0CW8bblj65PqaysnHOfQU4RyE8AmhQS1KUUiJ8sQMDj0qSBCxH5VYgtGJH51s6dpbykBV+vFDl2Bu2rHaVZNPJGirn6V6x4R0ZIIUd48kdh1rH8KaJtYB1AfjkivWfDeiSh/nC4wCrP0BrgxFZJWRlK8ndi2UKwkpHGDLnaQ3AUY6mthrSOWLa0MnlKAoynDMe4xnp61pjS1uLdDKwR92CSDkevTrWslva2liiRs3l5yGYkc9sAd68iV5ClVtaxxK2Vp5pMCvOWB3sBxxxtLHjr2rYRjqGjNBKiDcu2REG4A+mfapbi6E1182HVOSu3GKtbzEpEflhOc7ecflxWkIaGVWbdmcvrEajThaoANvTywQF96xLq8dosEIoQYJz97Het3V97PgElTz83PXsMc1ymsuojZdiHHX/AV2R2uOmubQpXN4pJklGCeeD0FcF4gvzc3u5vuR5OM1pa5cSRkhD15Yk9K5Ez/AGjUIrfyZZ/NcL5USlnkJ4AUDkk+gqVepLlR6FKmoLmMvXNSCQXEpKsQhG0nueAaxfhQc/FTwbn/AKDVl/6PSu/+Jq6Fpfw3tNKs7i4tNbluBPfaZqtoVuoZFUDEZAwkZ3Z55YAEdxXn/wAJ/wDkqfg3/sM2X/o9K9/C0XSpq/U8yvWVWo7dND6I/bXOLjwRnjIvh/6T18/2LHA4zXvX7cR2v4IP/X7/AO29fP8Ap8h8tWYZHrmuiSvG5lHexuw7scD9atQZWUEjrxmqEE6LjLVeimjZSM5rmlFmyRoxnn3q3Dyeg9c1SiuIwAGPI6jHNWoJy/8Aq0c/WsJRY+Vl+EHpnP1q1sZ12t0qvbW9zKMqFUk1aeOaBwJCrHvlcEVk7bAkWbR9q7TncDWgCXX5WCjHesuFZGYsEP8AKrscdySeAB65BqJJMLamhaDp3PXIHBrYt5lZCBnBPJ6ZrGhhujgBwB061et7EyDE8ze471jNItRW7ZpwXiW7MBIuCcnJq3DdSTswgwAP4jxWZDapAVKI7kdyOK27EBgCq8/TAz9O5rCaS1LvFao0tOj8lWIz6sx/z0rViCvFvmC4PIAHUdqzFlEQZTnLchR1A9avRyOSckAAfdXkAfX1rimm3cl3tdlkMZG5UKg6L/jUE8oLkZBIPU9BSzygIME89hWVdOVIdWJyemeamMLmfM2XDdHzGOGCnoKzdSnYOGiYjHPvVwxts+X5nA5Pqaw9T85PQgnBrWEU2PqQXWrNKpiuV3L2xxj3+tZbairebBI28R/cJ64qGdSXO4859az4IWa/uO+ea6lCKR0Ru4tCySDcAvSrsQ4XAx3qvPb+W6lRnnpWlAisgJyCeg/u05PQyehUnOMZHHTis+9iOPlHI6VtzRAnn0xxVZrfIAHK/qDQnYlMwVQ5JAIYVOYQVyRyB+VW7i3C7SvILcN61XuJRED71otdgk7rQwdVjZcugJ7c1h3Ug2/MuCO3pW9fSAo2T7iuYv8AG0kdu9dUI3FHsYOt3Jt4JXU8bTisz4Ukn4q+Diep1qz/APR6VB4nuPkEf8THJHtU3wn/AOSp+Df+wzZf+j0r06UeWBhP4j9KaKKKsk8A/bW/5JZpX/Yai/8ARE9fJWjPA2myI4d50fci/wAIHfOa+tf21v8Aklmlf9hqL/0RPXxnZTGOYDJCHhsHGRSlHmTXUqMuWSZ1VnElxOLiRFkcpwG+VfTtirunTrDI0EibsDaAw6fSszzIltEjQeXMpJZlLFyOo46ACnxXBiuUmiuvNLYZl5Yr/vGvMqQcro9ujKJ9QfBHxg/ijS4/BF78wtoN8d0YwG8lGUeXjpu5xu9O2a5XVrJ/C3jG/sJlC2rzEoe2xiSjD8OPqK868HeIbjw/4jsNUt7jyZLeYO7KOqHh1+hXNe0eLdLvtZ8KW+t39vMkQkcRSSurs9lM+6BiQfvKzYI7BhXFOT0fVfkKdJQqX6S39Saw8q4j8uZwkiLlJGycgdFx/I1eNp5in5cZHPHX/wCvXGeFtQds2l1j7VBxk/xCu+sLkTxKHcAKMAn+H/61OSuefiKMqcrHPXekkKdvLL0BrOW33WzRTR7kznBHOD7V6NBaC4VCYwRJznHB+lZmraGxMkkIbOMAKMEGuaUFciFf7MjxPxBpEti5miVnt27n+H/61cvPbx3GS2FPQGvZrgPHe/ZZ4QQy4OQMMPcVk6x4OtZoXmtcxv1AAyPpVU5yps7LxktTx6700jtuWqI06PcPNUsvdeldzqWjX2n7neBjGDg45/yKoARSMAyhc9jXbTxXdA6cumpx76eQx2g7T0+lMXT2LcjNd3PpyRxJI8eEbofWs6RbdWAA+U9K2liIrclRk+hzkFlJngA/WtK10xm425+laMUluvHl/NW1pUb3MvliIjHOQKxni4roV7OoUtP0Isw3AD04rsfD+htLcJEkWF7/AP660tC8OvJMFm3BG5A7/hXpmkaZaWkEZ4IAyWx2HXNc08Y2jKUVHfUqeHfDARWZoguOCW4I9q7Ozshb2u1dpwCOD19ee5qrJcJqCx2yqZbYgFpFcYK/3cd61o44obZUi3KgAVVJ5+g/w4rim3UMJyfUpSWzbVDyyiEc7SfvCq14DKRFARLg4KgkhDWtdsksTI4kb5tvDbTkegpgtLfIKowC9AW5PpUqGtjFztuYkVkYYcGR2kB6nt7A+lNlgktlMe7dkZ2t2Pp/+uujRAR8yAHH6VkaoiJISSc46itktSVNyepy2pysqukKHzTwN3IHvXGatmFCWOcfz9a7DWJkt0J3DJ6+tcFq8rXMJnLfumfy1GPv46kew6fWt1Bs7aKOO1RzLI7tkxg5+prlb4SR3UYtmIuWO9PLfDR453ZHII65r0LxFAdN8PafqtxZzjTriQpHIzIFkcZwFAO4rwctjAPFeda74httKs1OnSLeTajEy6ha3Fp5awnsiOGywGc5GOg7cV00MO+dJbnVKry03O2xxPie/k1LWri6mu7i8kcgGa4kLu2Bjknk9K1fhP8A8lT8G/8AYasv/R6VypOa6r4T/wDJU/Bv/Yasv/R6V7lktEePr1PoD9ufr4J/7fv/AG3r5v0m6KrgnpX0f+3P/wAyT/2/f+29fL1lL5UwOfarhr7on3O2tpN46KPqK1rTaQAwH41zthLuA5rctn6DsKwnCxspGufL3fuwoA6YHX3q3DMCAGxx7dazYj0Gak88RuAg3P2A7VzuPQ03NlLnYo2E5PQVaiUMQ7t8x96yrJSzbpXG/wBB2rUQbDkrgjrmspq2hOxpWz4UDJIHrWoskYjyAdxHX1FYsUhz1GKuW8o3KA/zZ6AbiaxkgUbmpCTIyswJHYHjFaEKtuBXAA7msiGYqRlR143t/SrS3SNhWOVH8PQH/GsZRbLSNWK4YhhFmWQfeYnCL+P9Kv2zKkah5S4IyQo2r/iaxPt++MKEx6AcD8qkju1Ewxn5eOaylBsrpodEtwgJ2cZOSc/5zViK7wp2hiM8CueWcNljjknjHWraT4UDpnoKwdMTXc3kmDZUsAOp74qCYqz7OrkdT0FZgnLDr8wPJHSmeexDFj14qfZk2sb0sypGG5B+6wPY96xdSkRs4J/Pio4rhpS4QguB8y54Yen19KzdQkMT8njA2+4qoU7MEtblG7OHwTk9qcy4jjuo1/eoMMP7y1F+6f77YB7k8imR3Ji+QNlRW/Lc1jJxFu5S6K6AEE9fSnW9wOBxu6cVnXUohlKRLmOQEhM/dPtVX7aIhgxuh9TyKtQ0sOUL6o3muByuec8e9SxSL1bkdDXOQ3iyPkMDjpU0l3ti+981Hsr6GMo2NO+YMikEAF+cdjWLqDDaxUfXFULu/lLMpY47+1ZtxfybCN2Qa3hSsHK7BcXAYFW6/WsHVJzHG20DafWpp7gsxJPzd8d65fxDqBjt3Ab5m4WuulS5pWCXuq5y+r3H2i9dgflHArd+E/8AyVPwb/2GrL/0elcqTkk11Xwn/wCSp+Df+w1Zf+j0rufkcx+lNFFFIDwD9tb/AJJZpX/Yai/9ET18VivtT9tb/klmlf8AYai/9ET18VUAdV4ZvrtoprezuWhmkXy3wwUyRHqhPXHtU8jx2Suu9BJna0aAEnn2rlLaYwTK4AYjsa9A09YtZtWawCRx21vhdxWIKe4JxlmJ/OuXE09eZbHdhK1vdZTsJSkWWXDueF7qPevUPAPi+7L6Pol9erHoPmGymjKgBYpjzkjkgNg9ePpXlbq9u8cszrMQSCFHy/g3etPS5kglBmiEsMyEcnjB/wAK8ytDqexFRqRtI9W8T6XeaPqdwJG/07T5fKbAx5i9Q34rg/jXSaDqcWoWizQMQ2MOoNYOiPJ4i0J7i6nuLi9sVSG9klIyIukT5x0HKkk5J9hmsvM2gal5kBLRE4dR0I9aypy0sypUPbwt9pHtWkXyyBEkLFB0BPT1xXSKiXAZI2WVSOMjBx6fWvMtH1KO5gSa2cHPJUd67XTbh4CkkhVo+GDqeM9SuOvB60SjY8GvhbMra3ocT3NrdGMsVfay9znpVp9DjHIjCjHJ9K0L/VI3uYbqVYxKuVkbs6dQQP7w/lWlFJDLGsi7Sr4bcO4/wrKa7GT54pHD6v4Whugd6ls8Fk6D2Irj9Q+Htou4xoTMB8u/oK9sa2RgWQ4B9DVaXS96HaAxYdM9qydyoYiUdz5+k8AhiFVkGAQ+Acqfp6VTm+HzswICcA5Csevbn3r6AGkKsjiTgkcEgYA9DVX+x0fcHeNj2HOB6Zo5mjpWKZ4PH4DliuISWCL0IP31/wDrV1lr4aGmSxSESe5ddoH+NemQ6PE7AyhFYHAI6txkVqrYRNbRxyYBAwCy7jWUrthPFM46z01oJU85Dvc5TByF961Zr6004bLyPJPOVjLfjx3rolskjWNPKKqvO7GcVBfRRm3dIpTJcMMqiJksexPp9T2oUW3qc/tOd6nNrYyNMsloNttL94Ekbh9PWtfRdPNqrm5kwuScEDI9P0/GtS3h8qFVMSwIABhDuJPoPUUrRnASP5O4Y9fpVqNtiJVHLQilkXzxGjgJIoYDGMsOMD3xg1Zh+XlgWPc+lRwrDDEBcfvU6lcDbn0Of51j6tqL2roscW4SDbFboCZW56qvVh79BWyhfbclQ5tEa9xdrGhzhcdcc4riPEuu28G9mkVSO+e1cp4g8Y3V3K8FmrEqSp7bSOMVy15YPdwPPf3chkHKxoPl/Emriklc66WEtrIg8UeMPPZorVXlI6leg+prlUnvLyOYT3ptYol3KoUtuJPTPRfrWlIkEbrFGdzudqovf8e31pBYhrySOZ7eOGJtrywyiQMP9g9G+vTNaQk3segoRgjEtLWzQym6s2vHZSEcXLJsPUnjr9O9cN8Q2ca2sDqsaQxhUiWPYEB5+p9cmvoKfTNGsLS2/sqIXKlsyyXcBW5G4ZBjZW59DwBXkvxk0eRjZayTKZHH2edWj27dv3SB6Y4/CvTwStJqW9tDzsZPnSa2TPLa6v4Tf8lT8G/9hmy/9HpXKV1fwn/5Kn4N/wCw1Zf+j0ruOI9//bn/AOZJ/wC37/23r5WBwa+qf25/+ZJ/7fv/AG3r5VoWgG5pV0Su0nla6SylLYrhLeUxSBgeldPZXfmqArYXHOP5VrJcyuiodjpo5S5CIeO7VciKIMAf4mse1lUABauLP71yzibLyNSNzkYNXopmGFLsMevPNYsc2eep9qsRSn2rFxKsb0DA8vuYZ5JPAq7DNsUopA9hWDFMTyT06CrFvc7ZN3pWTiO10bqTAYB+hqxJcr/yyULnrgViCcPz61Y84CMfNg9MVk4jSNaGdyOflVeNxq7bToZFYFvNxwe1c6JjwOeKlSdlYHJxUONy7HQC5ZGOD0NPOoHccselYqT5yd2eaYJstnNSoEyNsX5BOGP1FTx6ipXk/NjGa50ycHHAphmwDjPA6UOCE1c37XUDb3LOPX1603U75blvl4weM1hxzjBIOcetJJNv2sBx/OlyK9x2LZmJwPx47VIvzI5zyoznNZvnFT261HJeF2YE81SgJj7u43SwktggHIFRmc7OpI6H0qhLKHvGPdRSlwWOTWjiN9Bl1IyHfHw69QO9It6XjypJz69qhu5hk4NZZm8pmHRDyK0jApe8jWnuAR8vOevvWXcsYznPB9Kj+05Xg5qtdXgI5rSMCGrFO+uNuQOvUHPSuH1e7a5uWyeF4FdBql3ncRkE1ytwQ0rEdzmuymuVMxq9CKur+E3/ACVPwb/2GbL/ANHpXKV1fwm/5Kn4N/7DNl/6PSmYn6U0UUUAeAftrf8AJLNK/wCw1F/6Inr4qr7V/bW/5JZpX/Yai/8ARE9fFVABWhpN4La5QTPMLcn5xGcEe496z6UcUb6MabTujtZzDdWR3LGkUMeIfKBBlG7O9z/E3altLgyNtQ8xKCjAcZrI8MayljMIL0FrB871XAYEjAIPUfhWnm1c28aX1rGo+RpGkHyjP3jjk1wVqLTtv2PXwuJUt9D0H4d+JbnQ9aTUmT7XDsaG9t2P/HxA/DL7sOo969G1SyiitYHQpdWVwnm200bhzJEc7fxH3TwORXz4mp2ttIPs96r7Tjd90N7816f8OPFuiKyadrmr21npz+ZLBMZAfs0+M8r1CP3wOuOledOlOMtj0VVjF+0i/wDhjufBzQaXoOsRi3tZ7mRfPt2O5ZYWGBsJ/iXvgY5JHuOjj8R2uqxpJCJFMnzO8jBmLY5wR2J5xXDX2saGNNjv9M8VaMBOoWeH7bGk0ZPYqWywGfvLXKw69p+lSZs9a054yclPtSEfzqkm9Gip0KOIvUhJX9T2gzSZG2RSoORkZIrq9K1GGRARtCAY2jt9RXiOm+O9EkUCTVbGJ+4e5TH55rcsvHPh6GUOde0xXHGftsZH86cqLfQ86tSi1ytnslvdq15KEOVCI2B2OT+FXmueMKPm9Bwa8lsviH4cjuJS2v6OA5Bz9tj9PrWm3xH8LMpB8SaQOMZ+3RZ/9CrF0ZLocNTDq+jPQ5p42t2LoCRx8w602yKOrqDyHIyW6153H8QvC7QfP4j0UFhyBqEQI/8AHqW2+IPhiByI/E2iKh5I+3Rcn/vql7F9UQ6NlZM9K8sK26NlBUdMcf596etzCY2bevBIwT0I65rzV/if4bEmD4j0Yj1W9j/xqncfELwtcLLHL4j0lkL7xi9jHJ5/vetP2D7CVBvdnosuoySyTW1gu2YLuWViNufr3p1lGIUaVpWaeQASkkYyvA49q8t/4WJ4eSb5fEmmeUB9030ZB/WoLj4paHFlk1rTZG74u05/Wj2D7GroaWiz1qWdUbepAb6/5xWVqXiKzskczSAN6Bq8bv8A4pWl0zLBq+novqbpF/rzWJHr+mancSK/iDSiyoZD596kSAD0JPzH/ZHNT7FrozSnhIrWcj0nVfHD3Za20628+WX5Fzk4z6D19+1Jb32rRaNqAvTJZy26s91HbRN9suIgcF3lJyqLx93GR6Vyega74fEcTaNruix3+7y5L/Ub+CFIAQCTDEzZ4H8bZORxjtLr3ijwno9vf3Hh/wASW2r+IPs7NNd3N4m1oyfn27iAZG5wi7jtPTpnSNOpbRP+vz8zZ+yi+WP9f5fmYOoSSackaiAq8y7oYwQ7uuCc4BJ5HNVNHstX8R3Tw2NveNCgHmv5LYXJHDtj5OMnJB6dK0PD2t6Hc3umwXPinS9JsNUULeRQNCGtPlO0LKSSqMEwxyGUkZXBzXQ6LrfhnSfEiIvi/SUsC6oZLbUEDHad26dsYlPJQMOwBPrWtPCtfEh1MSkrLcf4c+HXl6vbjxBLpSaZKGijaGUz+YUycHaArMOclu30rnPHceheFrlJEmcWaYPnQnEsoLdQp4BA4x0PtWPrfjjR9EF3Fpmpx6xp6TNNbhrg5Mj5+cKTlSANp7Hr714n4m1661/UpLq5IG4khV6CvTwuDpyj7Wpol97f+S7nn18TUU+WD9ey/wCD+R7i/wAXtDjmeW1nuyVcY+1QKxdcdcLwCDj6muB+IXjq21+zuBBLc3E93IGkadQpQL0+6eSefavNM0V2Q9lTlzQjr01OWXNJWb/IK6r4T/8AJU/Bv/Yasv8A0elcpXV/Cf8A5Kn4N/7DVl/6PSoKPf8A9uf/AJkn/t+/9t6+Va+qv25/+ZJ/7fv/AG3r5VoAKuWNyYXxztNU6UVUZcrA621uQVyDxWnbyjAJNcXZXZiOHJ21uW1/CMAzR/iwqpRXQ2hJM6VJP1qykvQfyrCh1K2x81zCP+2gq0mpWfH+l24/7aLXO4mqaNtJOcCrUTgDHGKwYtTsQSTeWw7f61f8anXVbEA4vbX6ecv+NZuBV0b6P0NTLKC464HesJdYsMAG/tf+/wAv+NSjWtOA/wCP+1z/ANdl/wAazcB3RvCUGnefzx97+VYC6zp+f+QhaDHfzl/xqVdb00cDULP/AL/L/jUOmx3Rvh9qjnA9aX7QpU8/P/nmsJtc07GP7Rs+n/Pdf8aZ/benf9BCz/7/AC/40ezZLs2dF5oZsRt2/i4qEzEMcnkcdc1hNrenY41Czz/13X/GkXWdMBy1/Zn/ALbr/jR7MWnc3vN+VsEGnLP8ij+VYH9t6aR/x/2f/f5f8aT+29OAwNRtB/22X/Gl7JjurG40pZiOlRM3zHB7Vkf23p/GdQs/+/y/41G+s2BbI1G09/3y/wCNUqbFdF5nMd2D1DDBqQzASKc4VgQeaxpNV08shF/a5z/z2X/GkuNW08gbL6269BMv+NVyDbTLszce4OKr3BGwdPcVSOq2QVf9Ntjg5/1q/wCNQXOq2bRswu7cnP3RIP8AGrUNRXQ68TZnaxB7EVgalqRgQhh+97D+tSahq0KxbkmSRscBSDXLXM73ErSSMSxrphGyvIzqVfsoJriSVyzuxJ96izSUU22znCur+E3/ACVPwb/2GbL/ANHpXKV1fwm/5Kn4N/7DNl/6PSkB+lNFFFAHH/FD4gaV8ONAt9X1y3vp7aa6W0VbNEZw7I7AkMyjGEPf0rzD/hqvwP8A9ArxJ/4Dwf8Ax6j9tb/klmlf9hqL/wBET1438Ivhj4O8Q/CrXPGPjLUdYtItMu5IXFjJGAUWOJhgMjEsWkI6gdPrQB7J/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XO+Gv2e/BWuTIr23j7TYpYBcwT3kln5cyHHRo1fa3IO19rYPTg4+TKAPtX/AIar8D/9ArxJ/wCA8H/x6gftVeCDwNK8S5/694P/AI9XxYqliAASa7Twn4cDkXN6ucDcsf8AU09EuaWwm3stz61tP2iPDt3CJYPD/iZoz0Jhtl/nPU6/H3Q26eHfEp/4Ba//AB+vBbWDCDAGB0AqysWCCFO7vXJKu76I1jT/AJj3RvjzoqjJ8OeJAP8ActP/AJIpy/HbR2YqPDfiXI/2bT/5IrxKOPcMkZXoakgjXDhcfe6CpWIkaexVrntP/C9dIxn/AIRrxL/3zaf/ACRQnx10iQAp4a8Sn/gNp/8AJFeNyDaCT0AyahtrZro+aSyRtyFQ449TQsRN9hqjG12e0yfHfR45RE3hvxLv9Atof5XFTf8AC79M/wChY8S/laf/ACRXkEdrHHhY1UZqZIdjYJ7cUfWJD9hE9a/4XZpv/QseJfytP/kilHxr04nA8MeJPys//kivKghJG0fMPXvUc0qphQoaZv4c9Pc0niZIawyZ6z/wuvTgCf8AhGPEmB7Wf/yRSN8bdMUZbw14jH/gH/8AJFeRYLnEsrkY5CYUUPHGg/dwKPc8k/nS+sz8i/q0Fu2esn46aQOvhvxH+Vp/8kU3/he2j548N+JPwW0/+SK8naPdg7F/KopYg0ZUnjvR9al2H9Wh5nr/APwvLSf+ha8Sf982n/yRSf8AC9dI/wCha8S/982n/wAkV47ICi4fpn7w/rUMu0ZGR/hSWKn2E8NFdT2X/hfOijr4c8S/98Wv/wAfpD8e9FAyfDniTH+5a/8Ax+vFHQbfaq7rwQeSvFP61LyI9hE9vP7QGgr18O+Jf+/dr/8AH6p3/wC0n4W08BrvQvEyKe/kW7D8xNXicyqME8Vm3cCXaPEyBoTw2e/0q4Yl395aGUqLt7p7f/w1X4I/6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49Xyf4m8OvYMZ7UFrYnkd1rmq69GrrYwT6H2r/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV8VUUDPtX/hqvwP8A9ArxJ/4Dwf8Ax6tDw9+0r4O17X9M0iz03xAlzqF1FaRNLBCEDyOFBYiUnGSM4Br4arq/hP8A8lT8G/8AYasv/R6UAfpTRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeAftrf8ks0r/sNRf8AoieuZ/Z08Kp42/Zy8V+HpJzb/bdVkVJcZ2OsVu6kjuNyjI9K6b9tb/klmlf9hqL/ANET18VUAfpd4STxVEkFv4jh0WOC3txH5ljPLK88gwN+GRBGuAfl+fk9Rjn801BJAHWkrpfCukmaUXU8ZaJTwMdapJby2E323Nfwj4eEaLdXSAyHlFPau5gtfLdJFUc8GotNKSKNuAOlbkMO61PHKHmuStNzdzSlHk33Fit/3YZeAetTpBn6VNBGUXB5UnrU0YwSBWNjVMY2nsqhy2FYdAepqCytmG5lGCOvuKvXUjhEiyfn5HtSiVUhZFQGR+Eye9T6Gkb2M+5SO+v0tlEiLGMzNjj2HvWsLIqqrH249P8A9dMsLcWzybstKx3MV7mr8l1hdmNp7r3/APrU3ZJILtuyKyxqMxnH+0c1FKdsSysAiEkBicA4qOfbtd3DeWoyyqcZ+n1qGxgN5OkkmGwNoJ5VFHp9Tn8qjVm0Ut2Oe4jd1BnRQ3bNV7OJmaSWQAFjgfStiOzG0mSRAmeeM5FVLGE2r+RJGfKD8MRyR2I9eKXL1Nbq1kCsu07R27CnEMQOK2HhhhfCoDgDn1FNldduAka5HUCkxJmQsLsVA4z0zURjbnA6HkVs5HQAcVFcHdHlBgDh2zy2eBT5RcxiSxsyPj0/zioZFfGW6e9bccYWaM7AcMOD/ntUlzHFgBlIT72euaTSRDbOXkTBOMj6VSmLiQqg3kAbj/d+tbd0hwERfn7Z9PWqstoI0CDcD/FkdTRyhzIx3jBbLtvI6Z4A+gpjjI6cVdkQg81UdSPX0pMkz7qNXRg4BUjkHpivOvE+iGzkNxbKTbMeePumvSZF3MR/CD+ZqjeQiWNkdQyMMEGuihVcHZ7GFanzarc8horW8QaW2nXR2gmFuVb+lZNd7XY5U7hXV/Cf/kqfg3/sNWX/AKPSuUrq/hP/AMlT8G/9hqy/9HpSGfpTRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeAftrf8ks0r/sNRf8AoieviqvtX9tb/klmlf8AYai/9ET18VqMkAUJXAvaRZNe3aRgHZ1Y+1eo6RaeWkYRcIowB7Vz/hOxFvbqSoLvy2RXc2GIY8Y/Ks687e6ugQV3cu22m7l3KuCRyOxq9agqhU9R8pqK1nkZQq9R39anQPFcCQ/xcEVzN30NUixbsdgVxwOlD4UBlboMnPelEWyTOS0bcj2qdIDMx8tMjtUtmqj1I03SSMx4LccngCpNNX7TeyP9+OD5cr60yW1dn8qLr/ExPT6VqWtqllEsKfKRyzDgD/E0KyVzR7WEumSJsxjPoSPu+2Kpp+9YE+vTuaCst1OXIKw9FGcfjWrBAlsgMik5HAXqald2Pl5dCCOzWVvmVmXGAmcVbt7eJJgskYXA+6Bgf/XrR09hyZsR5GcY5A/xq1NPBCMj5lU8Nnke/NVdLQTuyg0AkV2hQxohB34wAfaq8sCypieQsDzgnofWrjbghV2yuSxOeASPWs24nijdQ88QJ/28/wAqnqON+gws1uVMrefEeNxHzKPU+opZI12q4fzIycq46H6VWN7AVzAd7E8KgOTVdlvIVcKwhtpGBkiX5iv+1j/CnY0fmX2Bb7oJP9aglCmCRzIihSARnOeabLaq7nNzJOoGFZGwCPaq89pEsD+TEu/bkYOSaNCVYc1ymSIUNwQeWHCj8aqzLczgefckL1CIuAKs+b8i44BGQAMDFNYkgk4P0pC5uxltZJECySTbs53b8mlle48shphIO/mL/UVamUEcZ681Wm6D3obE23uZjl41zPGX77ouQB9OuaqmaOTIjOXxkKRg1oXIxGR3J/Sq9wqupWRQwqdCuhQePap4NVZU+XmrUsMikGJyyDqjH+RqtI4LHyznHX2osS0Yms2SXlq8LgZPKn0NeaXUD21w8UgwynBr1uZQVIFcZ4u04sv2pANy8Pj09a7cPO65H8jkqxs+ZfM5Gur+E/8AyVPwb/2GrL/0elcrXVfCf/kqfg3/ALDVl/6PStjM/SmiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8A/bW/5JZpX/Yai/wDRE9fH+gWZu71crlE5NfYH7av/ACSzSv8AsNRf+iJ6+afCGnhLNXI+Zzkn+VUvdi5CersbenRNGwI6fnW9A+7G4D2PoaZaWzLgAAevcGtCG0Z+QoFcEmbotWSZwF61p3UO23VgOV+Y/SqtsGjCrtPPUium0qw+1rhx94Yz6VDfUuMbMZa24mt9wGVABB9almtXS3JT5C3AIrWsLI20Etu4+ZOAfVTW1DYJcogUAoo6n1rGdRXO2FCSV2edGB7a9WJCXypZyeq+lX47IzcO7FfTPWtqKCCB7z7QuZXmP3eTgdBVO4+2JzBaiIdnmP64pqSexpUpTX+ZGYYg4g8xQVxuCDpUt7cW1qgCl3boWUdarWVk9lavPcPubdlpDxknqfpV5iJUV8ZG3IIHWrv0OVpXKAv3dg0UErtn7zcCp5ZZ5IwIrbc/95zwppbaaKZ5AH3EnPBBA+mKdNfzXUnlxDy4lADMo+8ew+nenoNehXaG8nctdXRIHIjjA2iporOFVOArDHVlp8kdwqfK6nv8w/rVV7qSCA+ZFEVfqy5LD0wPT1p37EuTYjgLIZIVXj5fTNQeZuHH3u47inmRNmVO5eRn1Peq02CQynkcEetBPMMaFC7ZQAE5wDgflSSQwkYWFPoRT953cEEUx3G7PamHMys0b2zr85kicZUMcY/2Q3ajzUHAco/92Tg/4VNKQyRncfv8jt060x0WYNHIobKnr9KTGnfcaw3gdCfY5zVOQ5bGOgzTo7dSnzDEidWXg59abcGaPc5YS7zk7hg/nUvQta6FW4wy9DyR07VVnHpzx09KluZzGPmhkAzwAM1EzK2drqxPJx2qbjtoVJThOSMfyrOnQzEuHKMehH9fWtG4+bIBznqPaqcvqB+FNabCehmSyyQ5EyZH99Of0rNvGinidAQysMGtiUn8Kzb6GOVTlOfUcVvBq5lJKSszze+gNtdSRHseK6P4T/8AJU/Bv/Yasv8A0elVPEtl5ZSYMWB+U5q38J/+Sp+Df+wzZf8Ao9K7W769zjtbQ/SmiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeCftmRmX4Z6Og6trcQ/wDIE9fPGjROqIqsMAY6V9IftdgHwBoeen9tR/8ApPcV89aT5excOM/SpnL3bFwi73N60EsRVt24ehFWl3CTcgZc8/KeKghYBRggirNsSSPlbB7jmuKT1Nopm3paTSuvyfL3rvdHjj8gkAqQOR/hXIeHV5COCBnrjrXXSqqRrhsDHUDBFc9efKjvwtP2js0OvDsdCj5AHOTV22uljt96nbwTXO3byiKVw6uEBJJHNMtNSaN5Enw0KxrKWAxtBH+PFefzuTsfTwwV6Z13he2SUG4l2rNKxOSM4FT+J7ZJmDxxvjA3H0p+ls8JiDDYAMhehFdLIkTWJQhdz/MhPVjWqn17Hi4uynd9Ty7WButFtggAGCayWbELREkg8AZ4rc1SMLcSoyEFWIyaxrnbvbLdwNoFdcXfU8x6aIhhZY3jxGBgFc9MVr6farOjMzBQnO0Dt61kHy23KzHb+daUN2kVmqqjRqfnZjwcZ4A96uUtNCHchvJncAgMIz0OMDH9aoMxDDHAA7Gr148ktmxjiysZyCp7Gs2NN7FpAQF4wOpppmbkNeVid2AQq8jv9feonkHJKsx6D5aJHi85t+FXO1VX27+9RyNgsCXGegGBVXI5iQvkgFSDjIyOo9aYTtbP6mopJ1wgbJUH7vp+NSpJG2REcKeSrdvaqTRLkxkjDyWG05yrBiemDQ2RGxHVgQPYd6lmgV7VmibK4IIz/niqgYsqsehAoZcZXHNIAqngHbtb3FR3YMkiovRRuJP6UkoCnA5APX1FSSjIZxw5AH4Y6VMi07GVP95R0+YVVlCktuAOT+NW5gVcbvcmqjk7mJ6YqTVMqyK68phuwDHn86oyvl8NlGH8J71oSHHTIx6VTnAckOOn55oQ2ym6nk1SnGc59KtOxUMDllBxuH9RVOYhl3ZyO2K1ijN6GHrMPnWkqkDOMjNU/hRx8VPBv/Yas/8A0ela92mQcnj0rO+GkflfF3winprdn/6PSu6GsPQ46itI/SKiiigkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPDv2uv+RA0PnH/E6j/9J7ivnXTXUYzuyfSvon9r04+H2iH/AKjUf/pPcV80afcAAZPFZzNqaujrrfIUHqP9qr9mwBJHGfQ1hQXC7AxZNvuat2lykrDax2k4B7VySTuaqLPQ/Ds0e4K+MHvXVShWX5TnivPtCkYSqAcivQrNBJADgdOoNcuIhdXO3B1fZyIYooWSWOYH51Iwo5NO0W3sJbOFLtjGvmGMscDci/MA34jipXhdeV61R05QbxF2l1Rnfb9eK4FufTRqKdN2Z088sF7KDaQHOeZNx5P+FXlR7KIPIrEqMg7uD7Cq2kW6LEuGYc45PFXtYZBYMjmRo+zZxtFEY8ux5OJqKK5I7HnWrXUst1LLtALsT+NY93IFlYQs7J0yRitHUt6TNk8ZO0EdvesubGChjPOCrnjj29q9COx5KZNYw+c+0EjgdPXNWrmKRrqeGAgRlRIwfnOOpHfmqti7wyHYeCPTNOlumW5S4Odi/LnHQEcj3609bmcmaFpcQw2yrFuHzbDnk7zyfr6VTmjV5GWNgQ2QxY8k+v8AgKiumZJpLRx8pXcrD+Pvu9uBUt5OUZpHiBgY7tyjlWHb6+9NdzBox5Fkt5mSMlwRksRymTj8veqlxJsCtu25Gcg5J/8ArVoXdxEbd3Zl3SYBYDsP/r/yrkdWvvtFwqsRDEowTjk4/qTSlPlQ4x5may3Jk4EmV9BU6Pghu/WuU0maQuNwIJGSCc49q6O1PmPsBAJHeiE+YqUOU1LJ8mVkyIyMcc4BplwPJMcQOUReDjrnnNM0oM1z8pOApB59en61YLxl8ygiQDpWqaJV09CpsZl34+UDk1YkAI3HOCM4NNlnQIEYDdjgCq8kvQg4HbPOKV7o0KlyQmAevr/SqDkYJ/lVm5bP+etUpDkkd8UJGqIJG5PPHrVeRs84PTrT5j12/wA6hkI5HXI4NMCB24z3qhcKcFgdp9ulXJD8uOhqrJknnmtYkszrotg4bj3FVvAabfjB4PPXdrNken/TdKt3ACqQRUfghf8Ai7Pgo9f+JxZ/+j0rso7M5a3Q/RGiiimZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4R+2MCfhvo+Dg/21Hz/wBu89fK+nWyOR5hZj7nivqf9sg4+Gujnn/kNRf+k89fLOnSZ2nk/SpkdNB2idPYWls4AkXOOg5x/wDXrahGOAoAA4HTFY2nhhtc5A9614ZN4xk49q5Z3NNzc0q92Ff3cgI4JA4Nd5oGpl2AMbkdMHivOrKXAVYzkf7RrqdH1QQj94SGHbFZS95FppPRHoToZUG5ipY4GB39KpW8C2Wt28bE4dGy2O9QWGrvcmAOoWAHOe5pPEdyY9QspYXI3NsyTnFcXs2pI9KhiLLkb3PQLSJJLPJCKQCQcdTXNeI7qS4kG2U8cFR0NZg1e6ljaJrkRyJ0AXgj2qoEJBeSZzkdcYANONJJ3OCs2nqyHUQJoGQjkck9x7Vz0kH7zOXYDhc9h7Vv3RKxEKDuXqOtZCxzeZzKpbrgjit4mS0RVCkSlVyQPvnHX0GKkuARh1O5B2Ixx6VdS3BctIyh2Pr/ACp0kHmKwIOcdQKGDZmebHJFE7cSRDBz129vrj+VQq26MZHy5zjcfqKsm3kSTKqr8YGR2+hphOHwFUM35H6ighoztQVCd2353GTzXOahaLK3zDOK6a63oWMgJzxgf0rOlgLyZwM+metDipbgtDKsbVY/ujFaEfylQehBzUscBVgSDnHFOaP51O3cAcfnTUUthXuya2laCN9gwWwCfQU2Xlye+c0+SHaPmYZLY259PWp/LWJN7r8x7egoZcbLUozBWcnGc8bqjCcMrEKv3h6n1qaXd1UgE/rVeTe0bbEZnTk+g/GqSLK0wH8PPfFVrhSpAHDDsauMhJIkYAY4CfyzVWdlUE4HHXjmqSEUZsFeOV6/Wq0merDmrGAqc4XjJ9qqyO0nyplR3Yjk/SmirFeZsHHU+1V36ng1YcBAF28H0qtNx14rVITKdyRjNM8Ekn4qeCc/9Bqz/wDR6UXJyDjmm+CD/wAXV8Eg/wDQZsz/AOR0rsorRnNW2P0QooopGAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeC/tlnHw00gjr/bUX/oievlDTpNrA5z/Kvq79s3j4ZaRj/oNRf+iJ6+RbZzkAdfSkzpobHY2M7MwBOT1xW9YuhTAPGPTmuQsZAkeARuPU+tbunzYcDPPeueSvoayidBbsQwAOPc1qQSfMpbJ9DWTFIr4IHsSTVtXEaL03E/Lk9axauT1Ortb9Y4lD42qM/U0+6u3vF3xAkxsGArn7IEykuc55wOAK6C1ZAhWIYY9/ala2pSny7G0ltJMiO3Dv1Yen+NXJoZYrcJwyscN3qhpk8vlvCrZ9FPOavTSXqEJBEH4zsPINZSVmHM5aMeEynmW4xIB8+ejVXls9w3LgEfeHpV2yPnxJKsQRCcumeh9Rn+VW7mAS/NEyI4X/AIC1S9DJys7MwlSMyKJVVlHXI/lUk0ERbFuDGzDIAbj6Y6VK0J8sgjPr65qnLKYVDbuB0H9KdrmqfYimhNsQzM0kYGScD5T3+oqqyq4JljdWc5VduG29iPrV8HejSSfeOCsQ559WqpLI2F8xs4HB7ijyFuZ62byZ3Ag54U9h/jSfYhx8y/yqxI+OMkVVkkwudpY9gO57VSE0wliijlYOA2FGME/qahmZfliIXyiMsqcc54pWOwFpBlz2Hc9h9KW3j2qzyDMh5Y+lULl6jcIrHbEvOCdw6en40yaQbNpLEnrjvS7M/OV5ZuM9qicZc85+tGg0tSuScbVOZCdo9h6/hUEvyQmNOEAPU8k9yaej7mlkBAX7q9fmHr+NRHD5DZAHBwMk1VrGliCUghdnYZHvVC5bI2qCzEdPQepqZ5GAEaAGQcDPQD+8ah2hNxGSzfeYnkmmlYe25TkLFv3vBXkIDkex96jk9yOelTz8r94gjnIqpJK2MbRn+8O9VYCGR87h+ftVNzwcgZqedgxyOGFUpXB44BHY1pFCsVJ2BXGcim+Bmz8W/BY9NYsv/R6Uy5cJlWIGeh/pUXw9fd8X/CHtrVkP/I6V2U9ItnNX6H6OUUUVBgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgX7aJx8L9JP/AFGov/RE9fIFs+MHIya+vf21P+SWaV/2Gov/AERPXx1bONooe1zehLWxvW0xU5BOa1rO46dc1zkEuDxWhBOcc1hJHckjs9OvgGHIx/KtZp4njVjzIxxzzmuNsbnAz0GfzrYtrgSShgRsQ5z3J9qya1IlDW51cbuHHJ244UVq2Evzgs/I/Q1zUGpbVTcQqBhuJrXtbiGRnKtsQdMjB/Kp1MnHTU3HuJUlWaE7pM56da6nQNWg1CJgDsmHBX3rlbJ1kZF++eq5qWaNYbkXVszRzKdzgd/wqbKXusHFNWe53E7GxkjnWPzLZuHC9Se5PvVl/s4tjdWyhrVjgZ/hPofQ+9Zml6v9rtsJsLEZYDofwpnm3FlEJYY9iyZPzDK8fwkdPXBNZOPLozPl5tOo6/mghYScqrj649qyZT9plLRD91H3bufpU9hbtc7NSlAFs0gVoj2z3x/L0q/qlksbfaLb/VEZ/wB32NGi0LVouxiSrICCSMDn5RULNwCQoPv3q87Z4AwSOtZ90N8iQv8AdbJPPUelOxa1KjSmcMYEXaDje/AP0HWq0omE6YaIcE9Ca0ZEC8BcAdAKrTqfPiweRk59qaKumQBH8zMjA4GVAGPx+tK7AsI8/Lj5ucZ9qdO/lAleWPCjNQ42kk8k8k9PyqkiWrj5ipjyeR7cVnFjLI8b/wCrUZfH8Weg9vep3fcfvEDP1rPhcFGY87nJyPrxVJDUbC3GSdyHBAwB7ehqOKWNgd7GPbyT6DFPPJznoelU74KfLQ4JZuvoBTtcqO9hisxVnYDc5z/wHsKglYYxxUszgsTn6VQuHYDJ5QckHmmO1xsh656fzqjKxLDAyRU878ZLHnp71Wkc7SOn9aaBIrzHDE55qnMwIIOSPSp7gkEkGqEzgAEn8K1irg0U75kCHKggDpioPhad3xY8Hn/qNWf/AKPSqurzFIWwcZ4xU/wn/wCSqeDf+w1Z/wDo9K69oHDWd5WP0pooorMyCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDwD9tb/AJJZpX/Yai/9ET18Y274OK+zv21v+SWaV/2Gov8A0RPXxYhwaa7FRfK7mpFJyBV2GTkA1lRNkj/OauxNhOOprOSPQpyubMMpJ2qeOhb/AArVt7kRoABkjhVH8q56B9uOOlXoZsOnOTWDR0WTOns3AZZJW3MD+A+grajuzJNG7nc2cZNchBOQAM8d61IbjjIPSosRKNztrDUGRGjwpyevetSG8Ez7pCN3Y4ri4brcBg5FalncZOCTt4zmlYycTpfD2oLZ608IJJ3YUg8bTyB+eRXb3EgubaSNgWSRQNwzhOeteX3amVfPtWxMg+ZR3FbmjeI1hhWO4l8tiASNxwR6j6+lKUedeZE4N2lE6iK7k09pbW4QGQ4ALH5XHb8qsBzHEiw75YmG1lPJHrxWJP4k066thDLG5RVwrbCQOex7D2qzpFnp2osfKu54k64Dkd+mD2qHGSV5IORWvLQ0rq2RIDPGMQqMs3YD/PrWLsE8q3GcJjCcc49alvNMkt0bypptjcGGSTO8ex6fgahgu1it+MAJ8pHt2FJJPYErK8XcgvmECbmPJ4A65+lUBMRukkikaRuFG3AAq2ihne4nXcCPl/2ajlkicnaevTJ71aDYz8MxLyN854AHQConGDhjxnqetWpigIxnHTpVKaePf5UYaRh1wf61VmVF3egydtihVI8xuAPT3qJUSNQi/dX1pszmO486Rfk27cA5A96Y5DYIOc9MdKEipJkU8ixhmz8o5LelZ7M0zmUjYpGEU9VX1+pp0z/a5Co/1CNyezH/AOtTZJEQfNIn1Jq/JBbl9SORhk5wPX3qrJIDkjPvxTpZmdf3fyp/eI/kKpPGCDvZn+p4osWkQPKqs0ZZfkPBJqvJIpP3i/pipCUWdlCgKVBwKr3DDPPbpVJajaInkJUggD29ao3DqFIwKleXrgc+1Zd/MFRmPQetbwjd2JlZIxtYm3ShAeBWx8J/+Sp+Df8AsM2X/o9K5iVzJIWPUmun+E//ACVPwb/2GrL/ANHpWtR3dl0PLk+Z3P0poooqBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4B+2t/wAks0r/ALDUX/oieviqvtX9tb/klmlf9hqL/wBET18VUATwvg4q5C+PrWaDg1ahbvmh6q5vRm07Gqj/AC5zirEMo3jI4FZ8b5FTxtzWTR6EZXNhJTjgkVfspugzjnmsNJQOKt203ABJ4rJxNNzo4J2BwpGPQ1qW13g4/i9K5e3uPUg+9acE+WGCRnriptYmSudXBO3BVwD6+lWllie6hDllSYbSw/hf1Fc7a3HHJPvS3dywktmBJG/kdqLXZMY6nd266fyP3u44xk5/OtWK3sGs5YwdxKFVw23aezD3riLe6KtknmrwvPlJPSs+XsxNPudELnVdM08LOyX9i6nYzZ8yPHT/AOtTYY7i/jN5BNG0j4yrcK+B0+tVbDWM2/2edt0R7g8j6e/vSXDLBemSwmieIqN8bJtw3cg9MnvVO7ev3/5kp26al2K7jdmUo8Uyf6yJuv4eoqO4BizuQqBzuI4rF1nVoJ7y1CjZKilGz3HHP+FS3d9YJGE+0lh6GXcKag+wnDZ9xXk+0OVgb92By2MFj7e1CQeUpzxnnOMZquNS0+NcpcZ74EeaZPrdoyFQZyfaOr5JdgafRD5isau0jED1xxWNc+ZKSLEvBEwwS3RvoO1Pe6S7nHmNsReViJwT71LJNxxgUWaGnylBW8pFW6R1VRgHqn5UrGMg+WYznuuKSedieelZM6xu7PsH4cUW7l/EXZ2BAODn1rOnuUjBy6D8cmq00cZXoT/wI1XYRqfkjUfQc01YtQQ2W8Vn3Rq7jGOBiq807c/uW9+amYgZ4xVOd+MVUdWXy26Fee4fnCKnp3NYGq3DO4QtnHWtO6mAB5rCvOZdw711w91XODFS92yK9dX8J/8Akqfg3/sNWX/o9K5Sur+E/wDyVPwb/wBhqy/9HpWZwn6U0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgH7a3/JLNK/7DUX/oieviqvtX9tb/AJJZpX/Yai/9ET18VUAFPRtpzTKKA2L0UnSrUT5NZcb7TVuGVAeWH50pI7aNW+5oq2asxMQOe/FZyTR8gyJ/30KnW4ixjzU/FhWbR1wmu5qxSDHJ4rQt5yvHT0xWAl1COk0Y/wCBCrMV/ABzNF+DiocWaXj3Olgn7AipJp995bRZ55ZlHcVgw6jakf8AHzEv1cVJZ6lbNPJLJdQKTwMyAcUlHqJOK1udrDLxnOW9/SpBPtOc5rmk1ezB5vrc8/8APVf8alXWLDkG+tsf9dV5/WsXFgnHudH9pKjeDggcjHUVZW6JIw2f61zH9tWGM/b7X/v8v+NRprljDH8l7bE5IUeav689KauDUXszpzJHJckTKGVIiSMdyf8A61TxLbIyukSK4PBx0rkl1mzi2yDULZ5P48zL83t1qePX7Dys/b7b2BlXOPzqlEmTVtGdO86gDaqAewFQPKMjbwD1Arnv7dsSvN/af9/lzj86jbXbEsT9utvbEq8frTUTOy7mxfqkzBs4kH3XHUVSjv3abyLjCyr0PaQeoqg+tWRxi9tv+/q/41UuNUsJiwe5tiBwP3o4+nNWuw1y9WbUsuTtJ496p3EoCVhtqccOfLvYJo/7ryjI+hpP7XtZQAtxGvrucCnydi1buX5ZCV4qtJIAD3FVpdRtzwLmH/v4KrtfW/I8+LH++KaiXzR7lh5uvPNZ13c+WGZjgCopbyIKf3qH6MKxru5Mz+i9hW8IJas56+IUFZbhPdySOcHA9KrsxbrTaKbm2eY5N7sK6v4T/wDJU/Bv/Yasv/R6VyldX8J/+Sp+Df8AsNWX/o9KkR+lNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A) Granulomatous keratic precipitates and posterior synechiae in 12-year-old girl.",
"    <br/>",
"    (Panel B) Fundus examination shows neuroretinitis in the right eye.",
"    <br/>",
"    (Panel C) Fundus examination shows optic neuritis in the left eye.",
"    <div class=\"footnotes\">",
"     TB: tuberculosis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6772=[""].join("\n");
var outline_f6_39_6772=null;
var title_f6_39_6773="Pathway of hemoglobin synthesis";
var content_f6_39_6773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Pathway of erythroid heme synthesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 392px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ALAS2: 5-aminolevulinate synthase; PLP: pyridoxal 5'-phosphate; FECH: ferrochelatase; Tf: transferrin.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Bottomley, SS. Iron overload in sideroblastic and other non- thalassemic anemias. In: Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Barton, JC, Edwards, CQ (Eds), Cambridge University Press, Cambridge UK 2000. p.422.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6773=[""].join("\n");
var outline_f6_39_6773=null;
var title_f6_39_6774="Enfuvirtide: Pediatric drug information";
var content_f6_39_6774=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Enfuvirtide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"    see \"Enfuvirtide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/33/21013?source=see_link\">",
"    see \"Enfuvirtide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fuzeon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fuzeon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Fusion Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"      see \"Enfuvirtide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ (use in combination with other antiretroviral agents):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neonates, Infants, and Children &lt;6 years: Not approved for use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-16 years: 2 mg/kg twice daily (maximum dose: 90 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescent &gt;16 years and Adults: 90 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;35 mL/minute: Clearance of enfuvirtide is not affected; no dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;35 mL/minute: Limited data showed decreased clearance; however, no dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     End-stage renal disease (on dialysis): Limited data showed decreased clearance; however, no dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     No dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fuzeon&reg;: 108 mg [90 mg/mL following reconstitution]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstitute vial with 1.1 mL SWI to result in delivery of 90 per 1 mL; to avoid foaming, gently tap vial for 10 seconds and roll gently between hands to ensure contact of drug with liquid; allow vial to stand until lyophilized powder goes completely into solution; this may require up to 45 minutes; to reduce reconstitution time, may gently roll vial between hands until drug is completely dissolved; visually inspect vial to ensure complete dissolution of drug; solution should be clear, colorless, and without particulate matter or bubbles; do not use vials that contain particulate matter.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Vial does not contain preservatives; reconstituted solutions should be injected immediately or refrigerated and used within 24 hours; bring refrigerated reconstituted vials to room temperature before injection and visually inspect vial again as outlined above.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Inject SubQ into upper arm, abdomen, or anterior thigh. Do not inject I.M. (severity of reactions is increased). Do not inject into skin abnormalities including directly over a blood vessel, into moles, bruises, scar tissue, near the navel, surgical scars, burn sites, or tattoos. Do not inject in or near sites where large nerves are close to the skin including near the elbow, knee, groin, and inferior or medial sections of the buttocks. Rotate injection site (ie, give injections at a site different from the preceding injection site); do not inject into any site where an injection site reaction is present. After injection, apply heat or ice to injection site or gently massage area to better disperse the dose, to minimize local injection reactions; discard unused portion of the vial (vial is for single use only).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1052505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store unreconstituted vials at controlled room temperature, 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Store reconstituted solution under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); use within 24 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV-1 infection in combination with other antiretroviral agents in treatment-experienced patients who are failing current antiretroviral therapy. (",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended. However, in published studies, enfuvirtide was added onto a new optimized background regimen of 3-5 antiretroviral agents, in patients failing their current antiretroviral regimen. Selection of the new optimized regimen was based on medication history, genotyping, and phenotyping. Due to the lack of studies, enfuvirtide cannot be recommended as initial therapy in patients who are antiretroviral na&iuml;ve.)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F165029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Folliculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite decreased, diarrhea, nausea, pancreatitis, weight loss,  xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site infection, injection site reactions (may include pain, erythema, induration, pruritus, ecchymosis, nodule or cyst formation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased, limb pain, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bacterial pneumonia, cough, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, herpes simplex, infection, lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abacavir hypersensitivity worsening, amylase increased, angina, anxiety, constipation, depression, GGT increased, glomerulonephritis, Guillain-Barr&eacute; syndrome, hepatic steatosis, hyperglycemia; hypersensitivity reactions (symptoms may include rash, fever, nausea, vomiting, hypotension, and transaminase increases); insomnia, lipase increased, lymphadenopathy, neutropenia, peripheral neuropathy, pneumopathy, renal failure, renal insufficiency, respiratory distress, sepsis, sixth nerve palsy, suicide attempt, taste disturbances, thrombocytopenia, toxic hepatitis, triglycerides increased, tubular necrosis, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to enfuvirtide or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Efficacy data is limited in pediatric patients &ge;6 years of age; safety and pharmacokinetics in children &lt;6 years is not established. Use of enfuvirtide may theoretically result in the production of anti-enfuvirtide antibodies, which may cross react with HIV-1 gp41; this could potentially result in a false positive ELISA test in noninfected HIV individuals; the western blot test would be expected to be negative; use of enfuvirtide in non-HIV infected individuals has not been studied.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents, including enfuvirtide; this syndrome may require further patient assessment and therapy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local injection site reactions occur in the majority of patients (98% incidence); most patients have first injection site reaction during initial week of therapy; reactions are usually mild to moderate in severity, but may be more severe; symptoms may include discomfort, ecchymosis, erythema, induration, pain, pruritus, and nodule or cyst formation; infection, including cellulitis or abscess, occurs in 1.7% of adults, but in 11% of adolescent patients; 11% of patients require analgesics or limitation of usual activities; reactions often occur at &gt;1 injection site; 26% of patients have 6-14 injection site reactions and 1.3% have &gt;14 injection site reactions at any given time; average duration of single injection site reaction is 3-7 days in 41% of patients and &gt;7 days in 24%; 7% of patients discontinue therapy either due to injection site reactions (4%) or problems with administering injections (3%). Instruct patient or caregiver on proper injection method; monitor patients for local infection or cellulitis. Administration using a needle-free device (Biojector&reg; 2000) has been associated with nerve pain (including neuralgia and/or paresthesia lasting up to 6 months) when administered at sites where large nerves are close to the skin, bruising, and hematomas; administer medication only in recommended sites. A higher risk of postinjection bleeding may occur in patients receiving anticoagulants and in those with hemophilia or other coagulation disorders.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Bacterial pneumonia was observed at a higher rate in patients receiving enfuvirtide during clinical trials (6.7 events per 100 patient years vs 0.6 events per 100 patient years in control group; about 50% of patients with pneumonia required hospitalization); certain patients may be at greater risk (eg, those with a history of lung disease, low CD4 cell count, high initial viral load, I.V. drug use, or smoking); monitor patients closely for signs and symptoms of pneumonia. Systemic hypersensitivity reactions may occur; discontinue enfuvirtide and do not restart in patients with systemic hypersensitivity reactions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Enfuvirtide may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F164992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Limited data suggest that enfuvirtide does not cross the placenta. The DHHS Perinatal HIV Guidelines note that data are insufficient to recommend use during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum triglycerides, CBC, liver enzymes, CD4 cell count, HIV RNA plasma levels; local injection site reactions, local infection, cellulitis; signs and symptoms of pneumonia, especially in patients at risk",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enfuvirtide is a synthetic protein consisting of a linear sequence of 36 amino acids. It mimics the amino acid sequence HR2 (heptad repeat 2) found in the C-terminal portion of gp41 (an HIV-1 transmembrane glycoprotein) and competitively binds with HR1 (sequence heptad repeat 1). Normally, the HR1 sequence interacts with HR2 to form a hairpin structure needed for gp41 to initiate the fusion between the HIV-1 viral membrane and host CD4 cell membrane. By mimicking HR2 and binding with HR1, enfuvirtide inhibits the fusion of viral and cellular membranes and interferes with the entry of HIV-1 into cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: SubQ: Absorption is comparable when injected into abdomen, arm, or thigh",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Adults: V",
"     <sub>",
"      d",
"     </sub>",
"     (mean &plusmn; SD): 5.5 &plusmn; 1.1 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CSF concentrations (2-18 hours after administration; n=4): Nondetectable (&lt;0.025 mcg/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein Binding: 92%; primarily to albumin, but also to alpha-1 acid glycoprotein (to a lesser extent); CNS penetration: Unknown (but expected to be minimal due to large molecule and high protein binding)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Expected to undergo catabolism via peptidases and proteinases in the liver and kidneys to amino acids; amino acids would then be recycled in the body pool. A deaminated metabolite (with 20% activity compared to parent drug) was formed via hydrolysis during",
"     <i>",
"      in vitro",
"     </i>",
"     human microsomal and hepatocyte studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Not bioavailable by this route",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: Absolute: 84.3% &plusmn; 15.5%;",
"     <b>",
"      Note:",
"     </b>",
"     Bioequivalence was found to be similar in a study comparing standard administration using a needle versus a needle-free device.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 3.8 &plusmn; 0.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Single dose: Median: 8 hours (range: 3-12 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multiple dosing: Median: 4 hours (range: 4-8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Plasma clearance is decreased in adults with lower body weight and in females after adjusting for body weight (clearance in adults females is 20% lower compared to adults males). However, no adjustment in dose is recommended for gender or weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Compared to patients with normal renal function, enfuvirtide clearance is decreased by 38% in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     11-35 mL/minute) and by 14% to 28% in patients with end-stage renal disease who are maintained on dialysis. However, no adjustment in dose is recommended for patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Apparent clearance: Multiple dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 40 &plusmn; 17 mL/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 30.6 &plusmn; 10.6 mL/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dialysis: Hemodialysis does not significantly affect clearance of enfuvirtide",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/33/21013?source=see_link\">",
"      see \"Enfuvirtide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enfuvirtide can only be administered by injection; follow exact injection instructions that come with your medication. Do not mix any other medications in the same syringe with enfuvirtide. Inject subcutaneously into the upper arm, abdomen, or anterior thigh. Do not inject in the same area you did the time before or where there is an injection site reaction. Do not inject into skin abnormalities including directly over a blood vessel, into moles, bruises, scar tissue, near the navel, surgical scars, burn sites, or tattoos. Do not inject in or near sites where large nerves are close to the skin including near the elbow, knee, groin, and inferior or medial sections of the buttocks. After injection, apply heat or ice to injection site or gently massage area to better disperse the dose, to minimize local injection reactions; discard unused portion of the vial (vial is for single use only).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Enfuvirtide may cause injection site reactions such as itching, swelling, redness, pain, hardened skin, or bumps (each local reaction usually lasts for &lt;7 days); notify physician immediately if reaction is severe or if injection site becomes infected. Nerve pain and tingling up to 6 months (from injecting enfuvirtide too close to large nerves or near joints), bruising, and a collection of blood under the skin have occurred with the use of a needle-free injection device. The risk of bruising or bleeding may be increased in patients taking blood thinners and in those with hemophilia or other bleeding disorders. Patients receiving enfuvirtide may experience bacterial pneumonia or hypersensitivity reactions; notify physician if you experience cough, fever, rapid breathing, trouble breathing, vomiting, chills, rash, blood in the urine, or swelling of the feet. Enfuvirtide may cause dizziness and impair ability to perform activities requiring mental alertness or physical coordination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Enfuvirtide is not a cure for HIV; take enfuvirtide everyday as prescribed; do not change dose or discontinue without physician's advice; if a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do not double the next dose; make sure you have adequate supply of medication; do not allow supply to run out.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1052517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstituted injection has a pH &sim;9.0.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Briars LA, Hilao JJ, and Kraus DM, &ldquo;A Review of Pediatric Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Journal of Pharmacy Practice",
"      </i>",
"      , 2004, 17(6):407-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Church JA, Cunningham C, Hughes M, et al, &ldquo;Safety and Antiretroviral Activity of Chronic Subcutaneous Administration of T-20 in Human Immunodeficiency Virus 1-Infected Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2002, 21(7):653-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6774/abstract-text/12237598 /pubmed\" id=\"12237598 \" target=\"_blank\">",
"        12237598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" October 14, 2011, 1-167. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" August 16, 2010. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hardy H and Skolnik PR, &ldquo;Enfuvirtide, a New Fusion Inhibitor for Therapy of Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(2):198-211.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6774/abstract-text/14998221/pubmed\" id=\"14998221\" target=\"_blank\">",
"        14998221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morris JL and Kraus DM, \"New Antiretroviral Therapies for Pediatric HIV Infection,\"",
"      <i>",
"       J Pediatr Pharmacol Ther",
"      </i>",
"      , 2005, 10:215-47.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soy D, Aweeka FT, Church JA, et al, &ldquo;Population Pharmacokinetics of Enfuvirtide in Pediatric Patients With Human Immunodeficiency Virus: Searching for Exposure-Response Relationships,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2003, 74(6):569-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6774/abstract-text/14663459/pubmed\" id=\"14663459\" target=\"_blank\">",
"        14663459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12810 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-3033BD7A4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6774=[""].join("\n");
var outline_f6_39_6774=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165005\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165006\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052510\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052502\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164985\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164973\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052513\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052505\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052512\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165029\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052516\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052501\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052500\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299263\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164980\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164982\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164992\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052509\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052499\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052515\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052507\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052517\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12810\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12810|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=related_link\">",
"      Enfuvirtide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/33/21013?source=related_link\">",
"      Enfuvirtide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_39_6775="Pathogenesis of allergic rhinitis (rhinosinusitis)";
var content_f6_39_6775=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of allergic rhinitis (rhinosinusitis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/39/6775/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/39/6775/contributors\">",
"     Richard D deShazo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/39/6775/contributors\">",
"     Stephen F Kemp, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/39/6775/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/39/6775/contributors\">",
"     Jonathan Corren, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/39/6775/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/39/6775/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/39/6775/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic rhinitis is associated with a symptom complex characterized by paroxysms of sneezing, rhinorrhea, nasal obstruction, and itching of the eyes, nose, and palate. It is also frequently associated with postnasal drip, cough, irritability, and fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of allergic rhinitis is presented in this topic review. The clinical manifestations, diagnosis, and treatment of this condition are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF UPPER AIRWAY ALLERGIC REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon exposure to an allergen, atopic individuals respond by producing allergen-specific IgE. These IgE antibodies bind to IgE receptors on mast cells in the respiratory mucosa and to basophils in the peripheral blood. When the same allergen is subsequently inhaled, the IgE antibodies are bridged on the cell surface by allergen, resulting in activation of the cell. Mast cells in the nasal tissues release preformed and granule-associated chemical mediators, which cause the symptoms of allergic rhinitis.",
"   </p>",
"   <p>",
"    Models of nasal allergen challenge in patients with allergic rhinitis have provided information about the pathogenesis of allergic rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In this model study system, individuals known to have allergic rhinitis on exposure to a particular allergen are exposed to incremental doses of that allergen placed in the nose. The subsequent reaction is then monitored over time with nasal biopsies or washes. This allows direct quantitation of cell types by stains and surface markers and assessment of message for transcription or direct measurement of cellular cytokines and other mediators of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/6\">",
"     6",
"    </a>",
"    ]. Rhinomanometry, the measurement of nasal airway resistance, permits measurement of both resistance and airflow following allergen provocative challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7945?source=see_link&amp;anchor=H25#H25\">",
"     \"Occupational rhinitis\", section on 'Rhinomanometry techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Immunogenetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The expression of allergic diseases of the upper airways reflects an autosomal dominant pattern of inheritance with incomplete penetrance. This inheritance pattern is manifested as a propensity to respond to inhalant allergen exposure by producing high levels of allergen specific immunoglobulin E (IgE). The IgE response appears to be controlled by immune response genes located within the major histocompatibility complex (MHC) on chromosome 6. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The immunologic mechanisms of atopy have been studied in murine models and in humans. These mechanisms involve the expression of a repertoire of responses associated with the Th2 type of T-helper lymphocyte. There are probably multiple genetic and environmental influences that lead to overexpression of Th2 type T cell responses relative to Th1 responses (",
"    <a class=\"graphic graphic_figure graphicRef53928 \" href=\"UTD.htm?13/1/13328\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Th2 lymphocytes and IgE production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensitization to allergen is necessary to elicit an IgE response (",
"    <a class=\"graphic graphic_figure graphicRef75380 \" href=\"UTD.htm?29/42/30381\">",
"     figure 2",
"    </a>",
"    ). After inhalation, the allergen must first be internalized by antigen presenting cells, which include macrophages, CD1+ dendritic cells, B-lymphocytes, and possibly epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/8\">",
"     8",
"    </a>",
"    ]. After allergen processing, peptide fragments of the allergen are exteriorized and presented with class II (MHC) molecules of host antigen presenting cells to CD4+ T lymphocytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nasal provocation with allergen has been associated with increases of such HLA-DR and HLA-DQ positive cells in the lamina propria and epithelium in allergic subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/9\">",
"     9",
"    </a>",
"    ]. These lymphocytes have receptors specific for the particular MHC peptide complex and this interaction results in the release of cytokines by the CD4+ cell.",
"   </p>",
"   <p>",
"    The switch from the Th1 phenotype to the Th2 phenotype is the crucial early event in allergic sensitization and is",
"    <strong>",
"     key",
"    </strong>",
"    to the development of allergic inflammation. Allergic inflammation conceptually derives from two major Th2 mediated pathways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One involves the secretion of interleukin-4 (IL-4) and IL-13 that results in isotypic switching of B-lymphocytes to secrete IgE [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The second pathway involves the secretion of the eosinophil growth factor, IL-5 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the release of IL-4, IL-5, and IL-13 are cardinal features of allergic inflammation.",
"   </p>",
"   <p>",
"    B-lymphocytes require two signals for isotypic switch to IgE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .) In the first signal, IL-4 or IL-13 stimulate transcription at the Ce locus, the site of exons that encode the constant region of the IgE heavy chain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=see_link\">",
"     \"The biology of IgE\"",
"    </a>",
"    .) Interaction of CD40 on the B cell membrane with CD40 ligand on the surface of T lymphocytes provides the second signal that activates genetic recombination in the functional IgE heavy chain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/13\">",
"     13",
"    </a>",
"    ]. IL-4 and IL-13 also up-regulate vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells promoting adhesion of inflammatory cell populations and facilitate their migration into areas of allergic inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In situ hybridization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antibody studies have demonstrated increased numbers of cells with messenger RNA for",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    expression of IL-3, IL-4, IL-5, IL-13, eotaxin, and GM-CSF within the nasal mucosa after allergen provocation (",
"    <a class=\"graphic graphic_picture graphicRef77315 \" href=\"UTD.htm?31/53/32597\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Interferon-gamma (IFN-gamma), a Th1 type cytokine that inhibits B-lymphocyte activation and IgE synthesis is absent. Il-12 and IL-18, major inducers of IFN-gamma, are also absent.",
"   </p>",
"   <p>",
"    Thus, atopy appears to be the result of a predisposition toward Th2 type responses, which results in the formation of large quantities of allergen specific IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mast cell activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;After IgE antibodies specific for a certain allergen are synthesized and secreted, they bind to high-affinity receptors on mast cells (and basophils). When allergen is inhaled into the nose, it cross links these allergen specific cell bound IgE antibodies on the mast cell surface in a calcium dependent process, resulting in rapid degranulation and mediator release. The mediators stimulate blood vessels, nerves, and glands to cause the clinical manifestations of allergic rhinitis and feed back to other elements of the immune system to perpetuate the process.",
"   </p>",
"   <p>",
"    The superficial nasal epithelium in patients with allergic rhinitis has 50-fold more basophilic cells (mast cells and basophils) per specimen than does epithelium from nonallergic subjects. Increased concentrations of mast cells are found near post capillary venules, where they increase vascular permeability; near sensory nerves, where they initiate the sneeze reflex; and near glands, where they facilitate secretion. Nasal mast cells are predominately located in the nasal lamina propria as connective tissue mast cells, although 15 percent are epithelial and called mucosal mast cells. Mucosal mast cells express tryptase without chymase and proliferate in allergic rhinitis under the influence of Th2 cytokines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=see_link\">",
"     \"Mast cells: Development, identification, and physiologic roles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mast cell mediators are either preformed, associated with granules, formed during degranulation, or generated after transcription [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=see_link\">",
"     \"Mast cell derived mediators\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Histamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histamine is the most important preformed mediator in allergic rhinitis. Histamine reproduces",
"    <strong>",
"     all",
"    </strong>",
"    of the acute symptoms of allergic rhinitis when sprayed into the noses of normal volunteers. Histamine causes mucus secretion, vasodilatation leading to nasal congestion, increased vascular permeability leading to tissue edema, and sneezing through stimulation of sensory nerve fibers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Prostaglandins and leukotrienes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cross linking of IgE antibody on mast cells activates phospholipase A2 and releases arachidonic acid from the A2 position of cell membrane phospholipids. Mast cells then metabolize arachidonic acid either via the cyclooxygenase pathway to form prostaglandin and thromboxane mediators or via the lipoxygenase pathway to form leukotrienes. Prostaglandin D2 (PGD2), the sulfidopeptide leukotrienes LTC4, LTD4, and LTE4 are thus formed during degranulation. PGD2 is synthesized by mast cells, but not basophils, and appears to be more potent than histamine in causing nasal congestion. LTB4 is the most potent chemotactic factor yet described in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet activating factor (PAF) and bradykinin (generated by the action of tryptase) are also formed during degranulation. PAF is a potent chemotactic factor, and the bradykinins are vasoactive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cellular infiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once allergic reactions begin, mast cells amplify such reactions by releasing not only vasoactive agents, but also cytokines, including GM-CSF, tumor necrosis factor alpha (TNF-alpha), transforming growth factor beta (TGF-beta), IL-1 to IL-6, and IL-13 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tissue eosinophilia is characteristic of allergic rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/19\">",
"     19",
"    </a>",
"    ]. It appears that mast cell derived cytokines promote further IgE production, mast cell and eosinophil growth, chemotaxis, and survival. As an example, IL-5, TNF-alpha, and IL-1 promote eosinophil movement by increasing the expression of adhesion receptors on endothelium. In turn, eosinophils secrete a plethora of cytokines including IL-3, IL-4, IL-5, IL-10, and GM-CSF which favor, among others, Th2 cell proliferation and mast cell growth. Eosinophils also serve an autocrine function in these reactions by producing the cytokines IL-3, IL-5, and GM-CSF, which are important in hematopoiesis, differentiation, and survival of eosinophils themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eosinophils release oxygen radicals and proteins including eosinophil major basic protein, eosinophil cationic protein, and eosinophil peroxidases; these have been shown to be associated with nasal epithelial injury and desquamation, subepithelial fibrosis, and hyperresponsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/6,22\">",
"     6,22",
"    </a>",
"    ]. As a result of mast cell and eosinophil activation in the allergic response, the following events occur in succession:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vascular endothelial cell expression of adhesion molecules",
"     </li>",
"     <li>",
"      Adhesion of leukocytes to vascular endothelium",
"     </li>",
"     <li>",
"      Transendothelial migration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chemotaxis and increased survival of eosinophils occur within areas of allergic inflammation. In addition to the families of adhesion molecules, chemokine molecules that affect the expression and function of adhesion molecules on endothelium and leukocytes are also expressed in these reactions. Increased numbers of cells positive for chemokines, such as RANTES, eotaxins, MCP-3, and MCP-4 are present in the mucosa after allergen challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/4,23\">",
"     4,23",
"    </a>",
"    ]. These chemokines further enhance the recruitment and activation of inflammatory cells possessing their cell surface receptors in allergic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/6\">",
"     6",
"    </a>",
"    ]. Nitric oxide (NO), a vasodilator, is also produced in the nasal mucosa of patients with allergic rhinitis and may play a role in the production of nasal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/24\">",
"     24",
"    </a>",
"    ]. Nitric oxide synthetase is expressed by mast cells, neutrophils, and endothelial cells, among others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     IMMEDIATE AND LATE NASAL REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposing the nasal mucosa to ragweed in ragweed sensitive subjects (nasal challenge) provokes the immediate onset of sneezing and nasal itching associated with significantly increased concentrations of inflammatory mediators. The time course of histamine concentration, symptoms (sneezing), and increases in nasal airway resistance are closely correlated (",
"    <a class=\"graphic graphic_figure graphicRef65419 \" href=\"UTD.htm?8/0/8207\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Immediate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within seconds to minutes of allergen exposure, an immediate allergic response is observed, which peaks in 15 to 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/19\">",
"     19",
"    </a>",
"    ]. Sneezing correlates with the appearance of measurable histamine, the kininogen product tosyl-L-arginine methyl ester (TAME esterase), and PGD2 in nasal washes. Increased levels of sulfidopeptide leukotrienes C4 and B4, tryptase, kinins, albumin, eosinophil major basic protein, and platelet activating factor are also present in nasal washes after allergen challenges [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/27\">",
"     27",
"    </a>",
"    ]. The presence of histamine, tryptase, and prostaglandin D2 indicate the central role of the mast cell in the early response to allergen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After about 30 minutes, PGD2 and histamine levels return to baseline, whereas TAME esterase concentrations remain elevated. Biopsy specimens of the nasal mucosa at this time show an increased number of degranulated mast cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Late",
"    </span>",
"    &nbsp;&mdash;&nbsp;A late phase nasal allergic reaction develops in approximately 50 percent of patients with seasonal rhinitis, which peaks at 6 to 12 hours after nasal allergen challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/19\">",
"     19",
"    </a>",
"    ]. This secondary inflammatory response is thought to be important in establishing the chronicity of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/20\">",
"     20",
"    </a>",
"    ]. During this later phase, symptoms may recur after a second release of mast cell mediators coincident with maximum mast cell cytokine production [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The late phase allergic reaction is associated with elevated levels of the same mediators noted in the immediate reaction, except that PGD2 is not detected. Thus, basophils appear to be partly responsible for such late phase reactions because histamine is generated by both mast cells and basophils, whereas only mast cells can produce PGD2. In support of this concept, marked basophil influx into the nasal mucosa has been noted 3 to 11 hours after allergen challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/28\">",
"     28",
"    </a>",
"    ]. Large numbers of neutrophils, mononuclear cells, and eosinophils also migrate into the nasal mucosa at this time. Increases in eosinophil cationic protein and other eosinophil products also become detectable in nasal secretions. After allergen challenge, lymphocytes remain the predominant cells in the nasal mucosa. These cells actively transcribe messages for IL-3, IL-4, IL-5, and GM-CSF and have increased expression of the IL-2 receptor. IL-1 through IL-5 and GM-CSF, among others, have been recovered from nasal washes after allergen challenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ALTERATIONS OF NASAL PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under normal conditions, the nose accounts for one-half to two-thirds of the resistance to airflow in the airway. It is lined by pseudostratified epithelium resting upon a basement membrane that separates it from deeper submucosal layers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/19\">",
"     19",
"    </a>",
"    ]. The submucosa contains mucous, seromucous, and serous glands. The small arteries, arterioles, and arteriovenous anastomoses determine regional blood flow. Capacitance vessels consisting of veins and cavernous sinusoids determine nasal patency. The cavernous sinusoids lie beneath the capillaries and venules, are most dense in the inferior and middle turbinates, and contain smooth muscle cells controlled by the sympathetic nervous system. Withdrawal of sympathetic tone, or to a lesser degree, cholinergic stimulation, causes this sinusoidal erectile tissue to become engorged. Cholinergic stimulation causes arterial dilation and promotes the passive diffusion of plasma protein into glands and active secretion by mucous glands in cells.",
"   </p>",
"   <p>",
"    The role of neurotransmitters may be important in the pathogenesis of allergic rhinitis. Novel neurotransmitters, including substance P, a chemical that increases vascular permeability, calcitonin gene related peptide, and vasointestinal peptide, have been detected in nasal secretions after nasal allergen challenge of patients with allergic rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/11\">",
"     11",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     Capsaicin",
"    </a>",
"    , which depletes sensory nerves of SP and CGRP, reduces symptoms induced by nasal allergen challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/29\">",
"     29",
"    </a>",
"    ]. Antidromic stimulation of sensory nerve fibers in the nose can release a variety of neurotransmitters, including substance P. Neurotransmitters also produce changes in regional blood flow and glandular secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INVOLVEMENT OF THE PARANASAL SINUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are data indicating that the inflammatory response noted in the mucosa of patients with allergic rhinitis is often present in the paranasal sinuses as well [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6775/abstract/6\">",
"     6",
"    </a>",
"    ]. There is concomitant epithelial denudation, extracellular matrix deposition, and basement membrane disruption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/8/41092?source=see_link\">",
"       \"Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atopic individuals respond to allergen exposure by producing allergen-specific IgE. IgE antibodies bind to IgE receptors on mast cells throughout the respiratory mucosa and to basophils in the peripheral blood. When the same allergen is subsequently inhaled, the allergen binds to and crosslinks IgE on the mast cell surface, resulting in activation and release of inflammatory mediators. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms of upper airway allergic reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nasal mast cells release histamine, prostaglandins, leukotrienes, PAF, and bradykinin, among other mediators. These result in the signs and symptoms of allergic rhinitis. Tissue eosinophilia is also a feature of allergic rhinitis, and eosinophil-derived mediators are associated with nasal epithelial injury and desquamation, subepithelial fibrosis, and hyperresponsiveness. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mast cell activation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Cellular infiltration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The allergic nasal response consists of an immediate phase, which peaks at 15 to 30 minutes after allergen exposure and corresponds to mast cell degranulation and mediator release, and a late phase, which peaks at 6 to 12 hours after exposure and corresponds to infiltration of the nasal tissues by eosinophils, basophils, and other inflammatory cells. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Immediate and late nasal reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with allergic rhinitis usually have similar inflammatory changes in the linings of the paranasal sinuses. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Involvement of the paranasal sinuses'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/1\">",
"      Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/2\">",
"      Ng ML, Warlow RS, Chrishanthan N, et al. Preliminary criteria for the definition of allergic rhinitis: a systematic evaluation of clinical parameters in a disease cohort (I). Clin Exp Allergy 2000; 30:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/3\">",
"      Ng ML, Warlow RS, Chrishanthan N, et al. Preliminary criteria for the definition of allergic rhinitis: a systematic evaluation of clinical parameters in a disease cohort (II). Clin Exp Allergy 2000; 30:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/4\">",
"      Borish L. Allergic rhinitis: systemic inflammation and implications for management. J Allergy Clin Immunol 2003; 112:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/5\">",
"      Braunstahl GJ. The unified immune system: respiratory tract-nasobronchial interaction mechanisms in allergic airway disease. J Allergy Clin Immunol 2005; 115:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/6\">",
"      Christodoulopoulos P, Cameron L, Durham S, Hamid Q. Molecular pathology of allergic disease. II: Upper airway disease. J Allergy Clin Immunol 2000; 105:211.",
"     </a>",
"    </li>",
"    <li>",
"     Dunagan DP, Georgitis JW. Intranasal disease and provocation. In: Diagnostic testing of allergic disease, Kemp SF, Lockey RF (Eds), Marcel Dekker, 151 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/8\">",
"      Fokkens WJ. Antigen-presenting cells in nasal allergy. Allergy 1999; 54:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/9\">",
"      Godthelp T, Fokkens WJ, Kleinjan A, et al. Antigen presenting cells in the nasal mucosa of patients with allergic rhinitis during allergen provocation. Clin Exp Allergy 1996; 26:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/10\">",
"      Chomarat P, Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol 1998; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/11\">",
"      Broide DH, Paine MM, Firestein GS. Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest 1992; 90:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/12\">",
"      Worm M, Henz BM. Molecular regulation of human IgE synthesis. J Mol Med (Berl) 1997; 75:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/13\">",
"      Oettgen HC, Geha RS. IgE in asthma and atopy: cellular and molecular connections. J Clin Invest 1999; 104:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/14\">",
"      Walls AF, He S, Buckley MG, McEuen AR. Roles of the mast cell and basophil in asthma. Clin Exp Allergy Rev 2001; 1:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/15\">",
"      Haberal I, Corey JP. The role of leukotrienes in nasal allergy. Otolaryngol Head Neck Surg 2003; 129:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/16\">",
"      Iwasaki M, Saito K, Takemura M, et al. TNF-alpha contributes to the development of allergic rhinitis in mice. J Allergy Clin Immunol 2003; 112:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/17\">",
"      Cates EC, Gajewska BU, Goncharova S, et al. Effect of GM-CSF on immune, inflammatory, and clinical responses to ragweed in a novel mouse model of mucosal sensitization. J Allergy Clin Immunol 2003; 111:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/18\">",
"      Salib RJ, Kumar S, Wilson SJ, Howarth PH. Nasal mucosal immunoexpression of the mast cell chemoattractants TGF-beta, eotaxin, and stem cell factor and their receptors in allergic rhinitis. J Allergy Clin Immunol 2004; 114:799.",
"     </a>",
"    </li>",
"    <li>",
"     Orban NT, Saleh H, Durham SR. Allergic and non-allergic rhinitis. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby, St. Louis 2009. p.973.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/20\">",
"      Baraniuk JN. Pathogenesis of allergic rhinitis. J Allergy Clin Immunol 1997; 99:S763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/21\">",
"      Moqbel R, Levi-Schaffer F, Kay AB. Cytokine generation by eosinophils. J Allergy Clin Immunol 1994; 94:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/22\">",
"      Ponikau JU, Sherris DA, Kephart GM, et al. Striking deposition of toxic eosinophil major basic protein in mucus: implications for chronic rhinosinusitis. J Allergy Clin Immunol 2005; 116:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/23\">",
"      Hanazawa T, Antuni JD, Kharitonov SA, Barnes PJ. Intranasal administration of eotaxin increases nasal eosinophils and nitric oxide in patients with allergic rhinitis. J Allergy Clin Immunol 2000; 105:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/24\">",
"      Arnal JF, Didier A, Rami J, et al. Nasal nitric oxide is increased in allergic rhinitis. Clin Exp Allergy 1997; 27:358.",
"     </a>",
"    </li>",
"    <li>",
"     Baroody FM, Naclerio RM. Allergic rhinitis. In: Clinical immunology. Principles and practice, 2nd ed, Rich RR, Fleisher TA, Shearer WT, et al (Eds), Mosby, London 2001. p.481.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/26\">",
"      Hansen I, Klimek L, M&ouml;sges R, H&ouml;rmann K. Mediators of inflammation in the early and the late phase of allergic rhinitis. Curr Opin Allergy Clin Immunol 2004; 4:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/27\">",
"      Baroody FM, Ford S, Proud D, et al. Relationship between histamine and physiological changes during the early response to nasal antigen provocation. J Appl Physiol 1999; 86:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/28\">",
"      Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985; 313:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6775/abstract/29\">",
"      Banov C, LaForce C, Lieberman P. Double blind trial of Astelin nasal spray in the treatment of vasomotor rhinitis. Ann Allergy Asthma Immunol 2000; 84:138.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7530 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6775=[""].join("\n");
var outline_f6_39_6775=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF UPPER AIRWAY ALLERGIC REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Immunogenetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Th2 lymphocytes and IgE production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mast cell activation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Histamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Prostaglandins and leukotrienes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other mediators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cellular infiltration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      IMMEDIATE AND LATE NASAL REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Immediate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Late",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ALTERATIONS OF NASAL PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INVOLVEMENT OF THE PARANASAL SINUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/7530\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/7530|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/1/13328\" title=\"figure 1\">",
"      Pathophys allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/42/30381\" title=\"figure 2\">",
"      Differentiation of ThO cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/0/8207\" title=\"figure 3\">",
"      Nasal allergen challenge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/7530|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/53/32597\" title=\"picture 1\">",
"      In situ hybridization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=related_link\">",
"      Mast cell derived mediators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=related_link\">",
"      Mast cells: Development, identification, and physiologic roles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7945?source=related_link\">",
"      Occupational rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/8/41092?source=related_link\">",
"      Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=related_link\">",
"      The biology of IgE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_39_6776="Trastuzumab: Drug information";
var content_f6_39_6776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trastuzumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/23/44404?source=see_link\">",
"    see \"Trastuzumab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Herceptin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Herceptin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F230173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Anti-HER2;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Monoclonal Antibody;",
"     </li>",
"     <li>",
"      Monoclonal Antibody",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F230146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Missed dose recommendation (Canadian labeling, 2012): If a dose is missed by &le;1 week, the usual maintenance dose (based on patient&rsquo;s schedule) should be administered as soon as possible (do not wait until the next planned cycle); if a dose is missed by &gt;1 week, then a loading dose (4 mg/kg if patient receives trastuzumab weekly; 8 mg/kg if on an every-3-week schedule) should be administered, followed by the usual maintenance dose and schedule.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, adjuvant treatment, HER2+:",
"     </b>",
"     I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      With concurrent paclitaxel or docetaxel:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial loading dose: 4 mg/kg infused over 90 minutes, followed by",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose: 2 mg/kg infused over 30 minutes weekly for total of 12 weeks, followed 1 week later (when concurrent chemotherapy completed) by 6 mg/kg infused over 30-90 minutes every 3 weeks for total therapy duration of 52 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      With concurrent docetaxel/carboplatin:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial loading dose: 4 mg/kg infused over 90 minutes, followed by",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose: 2 mg/kg infused over 30 minutes weekly for total of 18 weeks, followed 1 week later (when concurrent chemotherapy completed) by 6 mg/kg infused over 30-90 minutes every 3 weeks for total therapy duration of 52 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Following completion of anthracycline-based chemotherapy:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial loading dose: 8 mg/kg infused over 90 minutes, followed by",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose: 6 mg/kg infused over 30-90 minutes every 3 weeks for total therapy duration of 52 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, metastatic, HER2+ (either as a single agent or in combination with paclitaxel):",
"     </b>",
"     I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial loading dose: 4 mg/kg infused over 90 minutes, followed by",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose: 2 mg/kg infused over 30 minutes weekly until disease progression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gastric cancer, metastatic, HER2+ (in combination with cisplatin and either capecitabine or fluorouracil for 6 cycles followed by trastuzumab monotherapy; Bang, 2010; Van Cutsem, 2009):",
"     </b>",
"     I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial loading dose: 8 mg/kg infused over 90 minutes, followed by",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose:  6 mg/kg infused over 30-90 minutes every 3 weeks until disease progression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, metastatic, HER2+ (unlabeled combinations):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trastuzumab, pertuzumab, and docetaxel (in patients with no prior anti-HER2 therapy or chemotherapy to treat metastatic disease): Initial: 8 mg/kg followed by a maintenance dose of 6 mg/kg every 3 weeks until disease progression or unacceptable toxicity (Baselga, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trastuzumab and lapatinib (in patients with progression on prior trastuzumab containing therapy): Initial: 4 mg/kg followed by a maintenance dose of 2 mg/kg every week (Blackwell, 2010; Blackwell, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F230147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F230148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling, although data suggest that the disposition of trastuzumab is not altered based on serum creatinine (up to 2 mg/dL)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14852080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F3881664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Cardiotoxicity:",
"     </i>",
"     LVEF &ge;16% decrease from baseline or LVEF below normal limits and  &ge;10% decrease from baseline: Withhold treatment for at least 4 weeks and repeat LVEF every 4 weeks. May resume trastuzumab treatment if LVEF returns to normal limits within 4-8 weeks and remains at  &le;15% decrease from baseline value. Discontinue permanently for persistent (&gt;8 weeks) LVEF decline or for &gt;3 incidents of treatment interruptions for cardiomyopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Infusion-related events:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-moderate infusion reactions: Decrease infusion rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dyspnea, clinically significant hypotension: Interrupt infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe or life-threatening infusion reactions: Discontinue.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Herceptin&reg;: 440 mg [contains benzyl alcohol (in diluent)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F230129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Check label to ensure appropriate product is being administered (conventional trastuzumab and ado-trastuzumab are different products and are",
"     <b>",
"      NOT",
"     </b>",
"     interchangeable).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Administered by I.V. infusion; loading doses are infused over 90 minutes; maintenance doses may be infused over 30 minutes if tolerated. Do not administer with D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"     <b>",
"      Do not administer I.V. push or by rapid bolus.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Observe patients closely during the infusion for fever, chills, or other infusion-related symptoms. Treatment with acetaminophen, diphenhydramine, and/or meperidine is usually effective for managing infusion-related events.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F230178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Stable in NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F230127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment (adjuvant) of HER2 overexpressing breast cancer as part of a combination regimen with doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; in combination with docetaxel and carboplatin; as a single agent following anthracycline-based combination treatment; treatment of HER2 overexpressing metastatic breast cancer in combination with paclitaxel as first-line treatment or as a single agent in patients who have received prior chemotherapy regimens for treatment of metastatic disease; treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma in combination with cisplatin and either capecitabine or fluorouracil in patients who have not received prior treatment for metastatic disease",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14852078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HER2-positive metastatic breast cancer (in combination with pertuzumab and docetaxel) in patients who have not received prior anti-HER2 therapy or chemotherapy to treat metastatic disease; treatment of HER2 overexpressing metastatic breast cancer (in combination with lapatinib) which had progressed on prior trastuzumab containing therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3402345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Trastuzumab may be confused with ado-trastuzumab emtansine, pertuzumab",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Conventional trastuzumab (Herceptin&reg;) may be confused with ado-trastuzumab emtansine (Kadcyla&trade;); products are",
"       <b>",
"        not",
"       </b>",
"       interchangeable.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F230171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Percentages reported with single-agent therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: LVEF decreased (4% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (47%), fever (6% to 36%), chills (5% to 32%), headache (10% to 26%), insomnia (14%), dizziness (4% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (4% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (6% to 33%), diarrhea (7% to 25%), vomiting (4% to 23%), abdominal pain (2% to 22%), anorexia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (4% to 42%), back pain (5% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (5% to 26%), dyspnea (3% to 22%), rhinitis (2% to 14%), pharyngitis (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infusion reaction (21% to 40%, chills and fever most common; severe: 1%), infection (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (5% to 10%), edema (8%), HF (2% to 7%; severe: &lt;1%), tachycardia (5%), hypertension (4%), arrhythmia (3%), palpitation (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne (2%), nail disorder (2%), pruritus (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (2%), dyspepsia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (3% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (4%), leukopenia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (2% to 9%), bone pain (3% to 7%), arthralgia (6% to 8%), myalgia (4%), muscle spasm (3%), peripheral neuritis (2%), neuropathy (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (2% to 9%), nasopharyngitis (8%), upper respiratory infection (3%), epistaxis (2%), pharyngolaryngeal pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (2% to 10%), accidental injury (6%), influenza (4%), allergic reaction (3%), herpes simplex (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening; as a single-agent or with combination chemotherapy): Acute respiratory distress syndrome (ARDS), amblyopia, anaphylaxis, anaphylactoid reaction, angioedema, apnea, ascites, asthma, ataxia, bone necrosis, bronchospasm, cardiac arrest, cardiomyopathy, cellulitis, coagulopathy, colitis, confusion, deafness, esophageal ulcer, gastroenteritis, glomerulonephritis (membraneous, focal and fibrillary), glomerulopathy, glomerulosclerosis, hematemesis, hemorrhage, hemorrhagic cystitis, hepatic failure, hepatitis, herpes zoster, hydrocephalus, hydronephrosis, hypercalcemia, hypersensitivity, hypotension, hypothyroidism, hypoxia, ileus, intestinal obstruction, interstitial pneumonitis, laryngitis, leukemia (acute), lymphangitis, mania, mural thrombosis, myopathy, nephrotic syndrome, neutropenia, oligohydramnios, pancreatitis, pancytopenia, paroxysmal nocturnal dyspnea, pathological fracture, pericardial effusion, pleural effusion, pneumonitis, pneumothorax, pulmonary edema (noncardiogenic), pulmonary fibrosis, pulmonary hypertension, pulmonary infiltrate, pyelonephritis, radiation injury, renal failure, respiratory distress, respiratory failure, seizure, sepsis, shock, skin ulcers, stroke, syncope, stomatitis, thyroiditis (autoimmune), vascular thrombosis, ventricular dysfunction, volume overload",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F230132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to trastuzumab, Chinese hamster ovary (CHO) cell proteins, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F230115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiomyopathy:",
"     <b>",
"      [U.S. Boxed Warning]: Trastuzumab is associated with symptomatic and asymptomatic reductions in left ventricular ejection fraction (LVEF) and heart failure (HF); the incidence is highest in patients receiving trastuzumab with an anthracycline-containing chemotherapy regimen. Evaluate LVEF in all patients prior to and during treatment; discontinue for cardiomyopathy.",
"     </b>",
"     Extreme caution should be used in patients with pre-existing cardiac disease or dysfunction. Prior or concurrent exposure to anthracyclines or radiation therapy significantly increases the risk of cardiomyopathy; other potential risk factors include advanced age, high or low body mass index, smoking, diabetes, hypertension, and hyper-/hypothyroidism. Discontinuation should be strongly considered in patients who develop a clinically significant reduction in LVEF during therapy; treatment with HF medications (eg, ACE inhibitors, beta-blockers) should be initiated. Withhold treatment for &ge;16% decrease from pretreatment levels or LVEF below normal limits and &ge;10% decrease from baseline (see Dosage Adjustment for Cardiotoxicity). Cardiomyopathy due to trastuzumab is generally reversible over a period of 1-3 months after discontinuation. Trastuzumab is also associated with arrhythmias, hypertension, mural thrombus formation, stroke, and even cardiac death.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Infusion reactions (including fatalities) have been associated with use; discontinue for anaphylaxis or angioedema. Most reactions occur during or within 24 hours of the first infusion; interrupt infusion for dyspnea or significant hypotension; monitor until symptoms resolve.",
"     </b>",
"     Infusion reactions may consist of fever and chills, and may also include nausea, vomiting, pain, headache dizziness, dyspnea, hypotension, rash and weakness. Retreatment of patients who experienced severe hypersensitivity reactions has been attempted (with premedication). Some patients tolerated retreatment, while others experienced a second severe reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause serious pulmonary toxicity (dyspnea, hypoxia, interstitial pneumonitis, pulmonary infiltrates, pleural effusion, noncardiogenic pulmonary edema, pulmonary insufficiency, acute respiratory distress syndrome [ARDS], and/or pulmonary fibrosis); discontinue for ARDS or interstitial pneumonitis.",
"     </b>",
"     Use caution in patients with pre-existing pulmonary disease or patients with extensive pulmonary tumor involvement; these patient populations may have more severe toxicity. Pulmonary events may occur during or within 24 hours of administration; delayed reactions have occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity: Rare cases of nephrotic syndrome with evidence of glomerulopathy have been reported, with an onset of 4-18 months from trastuzumab initiation; complications may include volume overload and HF. The incidence of renal impairment was increased in metastatic gastric cancer patients when trastuzumab is added to chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chemotherapy: When used in combination with myelosuppressive chemotherapy, trastuzumab may increase the incidence of neutropenia (moderate-to-severe) and febrile neutropenia. The incidence of anemia may be higher when trastuzumab is added to chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Trastuzumab exposure during pregnancy may result in oligohydramnios and oligohydramnios sequence (pulmonary hypoplasia, skeletal malformations and neonatal death).",
"     </b>",
"     Effective contraception is recommended during and for 6 months after treatment for women of childbearing potential.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Do not interchange: Conventional trastuzumab and ado-trastuzumab emtansine are",
"     <b>",
"      not",
"     </b>",
"     interchangeable. Verify product label prior to reconstitution and administration to prevent medication errors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HER2 expression: Establish HER2 status prior to treatment; has only been studied in patients with evidence of HER2 protein overexpression, either by validated immunohistochemistry (IHC) assay or fluorescence in situ hybridization (FISH) assay. Tests appropriate for the specific tumor type (breast or gastric) should be used to assess HER2 status.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F230120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Anthracycline, Systemic): Trastuzumab may enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: Trastuzumab may enhance the neutropenic effect of Immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PACLitaxel: May increase the serum concentration of Trastuzumab. Trastuzumab may decrease the serum concentration of PACLitaxel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F230122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F949978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproductive studies in cynomolgus monkeys showed no evidence of impaired fertility or fetal harm. However, trastuzumab inhibits HER2 protein, which has a role in embryonic development.",
"     <b>",
"      [U.S. Boxed Warning]: Trastuzumab exposure during pregnancy may result in oligohydramnios and oligohydramnios sequence (pulmonary hypoplasia, skeletal malformations and neonatal death).",
"     </b>",
"     Oligohydramnios (reversible in some cases) has been reported with trastuzumab use alone or with combination chemotherapy. If trastuzumab exposure occurs during pregnancy, monitor for oligohydramnios. Effective contraception is recommended during and for 6 months after treatment for women of childbearing potential. Women exposed to trastuzumab during pregnancy are encouraged to enroll in MotHER (the Herceptin Pregnancy Registry; 1-800-690-6720).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The National Comprehensive Cancer Network (NCCN) breast cancer guidelines (v.1.2013) consider pregnancy a contraindication to trastuzumab treatment and recommend (if indicated) administering trastuzumab in the postpartum period.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F230154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F230134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known whether trastuzumab is secreted in human milk. Because many immunoglobulins are secreted in milk, and the potential for serious adverse reactions in the nursing infant exists, the decision to discontinue trastuzumab or discontinue breastfeeding during treatment should take in account the benefits of treatment to the mother. The extended half-life should also be considered for decisions regarding breast-feeding after therapy completion.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F6857803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Herceptin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     440 mg (1): $3972.56",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F230124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Assessment for HER2 overexpression and HER2 gene amplification by validated immunohistochemistry (IHC) or fluorescence",
"     <i>",
"      in situ",
"     </i>",
"     hybridization (FISH) methodology (pretherapy); test should be specific for cancer type (breast vs gastric cancer). Pregnancy test (prior to treatment). Monitor vital signs during infusion; signs and symptoms of cardiac dysfunction; LVEF (baseline, every 3 months during treatment, upon therapy completion and if component of adjuvant therapy, every 6 months for at least 2 years; if treatment is withheld for significant LVEF dysfunction, monitor LVEF at 4-week intervals); signs and symptoms of infusion reaction; if pregnancy inadvertently occurs during treatment, monitor amniotic fluid volume",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F230135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Herceptin (AR, AT, AU, BB, BE, BF, BG, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CZ, DE, DK, EC, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HN, ID, IE, IL, IT, JM, KE, KP, LR, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, PE, PH, PL, PT, PY, RU, SC, SD, SE, SG, SK, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UG, UY, VE, ZA, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F230114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trastuzumab is a monoclonal antibody which binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER-2); it mediates antibody-dependent cellular cytotoxicity by inhibiting proliferation of cells which overexpress HER-2 protein.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F230131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 44 mL/kg; not likely to cross the (intact) blood-brain barrier (due to the large molecule size)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Weekly dosing: Mean: 6 days (range: 1-32 days); every 3 week regimen: Mean: 16 days (range: 11-23 days)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bader AA, Schlembach D, Tamussino KF, et al, &ldquo;Anhydramnios Associated With Administration of Trastuzumab and Paclitaxel for Metastatic Breast Cancer During Pregnancy,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2007, 8(1):79-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/17196514/pubmed\" id=\"17196514\" target=\"_blank\">",
"        17196514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bang YJ, Van Cutsem E, Feyereislova A, et al, &ldquo;Trastuzumab in Combination With Chemotherapy Versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2010, 376(9742):687-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/20728210/pubmed\" id=\"20728210\" target=\"_blank\">",
"        20728210",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baselga J, Albanell J, Molina MA, et al, \"Mechanism of Action of Trastuzumab and Scientific Update,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2001, 28(5 Suppl 16):4-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baselga J, Carbonell X, Castaneda-Soto NJ, et al, &ldquo;Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(10):2162-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/15800309/pubmed\" id=\"15800309\" target=\"_blank\">",
"        15800309",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baselga J, Cort&eacute;s J, Kim SB, et al, &ldquo;Pertuzumab Plus Trastuzumab Plus Docetaxel for Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(2):109-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/22149875/pubmed\" id=\"22149875\" target=\"_blank\">",
"        22149875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blackwell KL, Burstein HJ, Storniolo AM, et al, &ldquo;Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(21):2585-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/22689807/pubmed\" id=\"22689807\" target=\"_blank\">",
"        22689807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blackwell KL, Burstein HJ, Storniolo AM, et al, &ldquo;Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(7):1124-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/20124187/pubmed\" id=\"20124187\" target=\"_blank\">",
"        20124187",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carver JR, Shapiro CL, Ng A, et al, &ldquo;American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(25):3991-4008.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/17577017/pubmed\" id=\"17577017\" target=\"_blank\">",
"        17577017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ewer SM and Ewer MS, &ldquo;Cardiotoxicity Profile of Trastuzumab,&rdquo;",
"      <i>",
"       Drug Safety",
"      </i>",
"      , 2008, 31(6):459-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/18484781/pubmed\" id=\"18484781\" target=\"_blank\">",
"        18484781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ewer MS, Vooletich MT, Durand JB, et al, &ldquo;Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(31):7820-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/16258084/pubmed\" id=\"16258084\" target=\"_blank\">",
"        16258084",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fedele C, Riccio G, Malara AE, et al, &ldquo;Mechanisms of Cardiotoxicity Associated With ErbB2 Inhibitors,&rdquo;",
"      <i>",
"       Breast Cancer Res Treat",
"      </i>",
"      , 2012, 134(2):595-602.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/22674190/pubmed\" id=\"22674190\" target=\"_blank\">",
"        22674190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feldman AM, Lorell BH, and Reis SE, &ldquo;Trastuzumab in the Treatment of Metastatic Breast Cancer: Anticancer Therapy Versus Cardiotoxicity,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2000, 102(3):272-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/10899087/pubmed\" id=\"10899087\" target=\"_blank\">",
"        10899087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gianni L, Pienkowski T, Im YH, et al, &ldquo;Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women With Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer (Neosphere): A Randomised Multicentre, Open-Label, Phase 2 Trial,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2012, 13(1):25-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/22153890/pubmed\" id=\"22153890\" target=\"_blank\">",
"        22153890",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guarneri V, Lenihan DJ, Valero V, et al, &ldquo;Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(25):4107-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/16908934/pubmed\" id=\"16908934\" target=\"_blank\">",
"        16908934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hudis CA, &ldquo;Trastuzumab - Mechanism of Action and Use in Clinical Practice,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(1):39-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/17611206/pubmed\" id=\"17611206\" target=\"_blank\">",
"        17611206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ismael G, Hegg R, Muehlbauer S, et al, &ldquo;Subcutaneous versus Intravenous Administration of (Neo)Adjuvant Trastuzumab in Patients With HER2-Positive, Clinical Stage I&ndash;III Breast Cancer (HannaH Study): A Phase 3, Open-Label, Multicentre, Randomised Trial,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2012, 13(9):869-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/22884505/pubmed\" id=\"22884505\" target=\"_blank\">",
"        22884505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lemmens K, Doggen K, and De Keulenaer GW, &ldquo;Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease: Implications for Therapy of Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(8):954-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/17709650/pubmed\" id=\"17709650\" target=\"_blank\">",
"        17709650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leyland-Jones B, Gelmon K, Ayoub JP, et al, &ldquo;Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(21):3965-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/14507946/pubmed\" id=\"14507946\" target=\"_blank\">",
"        14507946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moja L, Tagliabue L, Balduzzi S, et al, &ldquo;Trastuzumab Containing Regimens for Early Breast Cancer,&rdquo;",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2012, 4:CD006243.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/22513938/pubmed\" id=\"22513938\" target=\"_blank\">",
"        22513938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Breast Cancer,&rdquo; Version 1.2013. Available at  file://www.nccn.org/professionals/physician_gls/PDF/breast.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pituskin E, Haykowsky M, Mackey JR, et al, &ldquo;Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): A Randomized, Placebo-Controlled Trial to Determine if Conventional Heart Failure Pharmacotherapy Can Prevent Trastuzumab-Mediated Left Ventricular Remodeling Among Patients With HER2+ Early Breast Cancer Using Cardiac MRI,&rdquo;",
"      <i>",
"       BMC Cancer",
"      </i>",
"      , 2011, 11:318.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/21794114/pubmed\" id=\"21794114\" target=\"_blank\">",
"        21794114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Portera CC, Walshe JM, Rosing DR, et al, &ldquo;Cardiac Toxicity and Efficacy of Trastuzumab Combined With Pertuzumab in Patients With [Corrected] Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2008, 14(9):2710-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/18451236/pubmed\" id=\"18451236\" target=\"_blank\">",
"        18451236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Procter M, Suter TM, de Azambuja E, et al, &ldquo;Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(21):3422-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/20530280/pubmed\" id=\"20530280\" target=\"_blank\">",
"        20530280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Romond EH, Perez EA, Bryant J, et al, &ldquo;Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(16):1673-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/16236738/pubmed\" id=\"16236738\" target=\"_blank\">",
"        16236738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seicean S, Seicean A, Alan N, et al, &ldquo;Cardioprotective Effect of Beta-Adrenoceptor Blockade in Breast Cancer Patients Undergoing Chemotherapy: A Follow-Up Study of Heart Failure,&rdquo;",
"      <i>",
"       Circ Heart Fail",
"      </i>",
"      , 2013  [epub ahead of print].",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/23425978/pubmed\" id=\"23425978\" target=\"_blank\">",
"        23425978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seidman A, Hudis C, Pierri MK, et al, &ldquo;Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(5):1215-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/11870163/pubmed\" id=\"11870163\" target=\"_blank\">",
"        11870163",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sekar R and Stone PR, &ldquo;Trastuzumab Use for Metastatic Breast Cancer in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol,",
"      </i>",
"      2007, 110(2 Pt 2):507-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/17666645/pubmed\" id=\"17666645\" target=\"_blank\">",
"        17666645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Serrano C, Cort&eacute;s J, De Mattos-Arruda L, et al, &ldquo;Trastuzumab-Related Cardiotoxicity in the Elderly: A Role for Cardiovascular Risk Factors,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2012, 23(4):897-902.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/21828361/pubmed\" id=\"21828361\" target=\"_blank\">",
"        21828361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Slamon DJ, Leyland-Jones B, Shak S, et al, &ldquo;Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer That Overexpresses HER2,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(11):783-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/11248153/pubmed\" id=\"11248153\" target=\"_blank\">",
"        11248153",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suter TM, Procter M, van Veldhuisen DJ, et al, &ldquo;Trastuzumab Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(25):3859-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/17646669/pubmed\" id=\"17646669\" target=\"_blank\">",
"        17646669",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tarantini L, Gori S, Faggiano P, et al, &ldquo;Adjuvant Trastuzumab Cardiotoxicity in Patients Over 60 Years of Age With Early Breast Cancer: A Multicenter Cohort Analysis,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      ,  2012, 23(12):3058-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/22700991/pubmed\" id=\"22700991\" target=\"_blank\">",
"        22700991",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Cutsem E, Kang Y, Chung H, et al, &ldquo;Efficacy Results From the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy (CT) in First-Line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer (GC),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(18s):LBA4509 [abstract LBA4509 from 2009 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watson WJ, &ldquo;Herceptin (Trastuzumab) Therapy During Pregnancy: Association With Reversible Anhydramnios,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 105(3):642-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/15738038/pubmed\" id=\"15738038\" target=\"_blank\">",
"        15738038",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Witzel ID, Muller V, Harps E, et al, &ldquo;Trastuzumab in Pregnancy Associated With Poor Fetal Outcome,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2008, 19(1):191-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/39/6776/abstract-text/18084047/pubmed\" id=\"18084047\" target=\"_blank\">",
"        18084047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10101 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6776=[""].join("\n");
var outline_f6_39_6776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708899\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230142\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230143\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230173\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230146\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230147\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230148\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14852080\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3881664\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230126\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230111\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230129\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230178\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230127\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14852078\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3402345\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230171\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230132\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230115\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300161\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230120\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230122\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949978\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230154\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230134\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6857803\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230124\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230135\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230114\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230131\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10101\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10101|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/23/44404?source=related_link\">",
"      Trastuzumab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_39_6777="Acute liver failure in children: Management";
var content_f6_39_6777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute liver failure in children: Management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/39/6777/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/39/6777/contributors\">",
"     Robert H Squires, Jr, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/39/6777/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/39/6777/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/39/6777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/39/6777/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/39/6777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24093412\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric acute liver failure (PALF) is a complex, rapidly progressive clinical syndrome that is the final common pathway for many disparate conditions, some known and others yet to be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The estimated frequency of acute liver failure (ALF) in all age groups in the United States is about 17 cases per 100,000 population per year, but the frequency in children is unknown. PALF accounts for 10 to 15 percent of pediatric liver transplants performed in the United States annually.",
"   </p>",
"   <p>",
"    PALF is a rapidly evolving clinical condition. There are no adequately powered studies to inform diagnostic algorithms, to assess markers of disease severity and trajectory, and to guide decisions about liver transplant. The clinician must construct an individualized diagnostic approach and management strategy. Management requires a multidisciplinary team involving the hepatologist, critical care specialist, and liver transplant surgeon.",
"   </p>",
"   <p>",
"    Management of PALF and its complications in children are discussed here. An organized approach to diagnosing the cause of PALF is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=see_link\">",
"     \"Acute liver failure in children: Etiology and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ALF in adults is addressed in separate reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link\">",
"     \"Acute liver failure in adults: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340146\">",
"    <span class=\"h1\">",
"     GENERAL MANAGEMENT PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the initial characterization of the patient presentation, proper patient management needs to be conducted along multiple parallel paths [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluate the cause of pediatric acute liver failure (PALF), guided by the patient&rsquo;s age and prioritizing the diagnosis of treatable disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=see_link\">",
"       \"Acute liver failure in children: Etiology and evaluation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Monitor the function of each organ system",
"     </li>",
"     <li>",
"      Identify and treat complications",
"     </li>",
"     <li>",
"      Provide medical support to maximize health and survival",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24093559\">",
"    <span class=\"h2\">",
"     Clinical setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of PALF requires admission to a highly skilled nursing environment (in most cases, a pediatric intensive care unit), which allows close monitoring, particularly for changes in mental status. Careful and frequent bedside assessment by an experienced nurse or clinician is essential, and cannot be replaced by indirect monitors such as a cardiorespiratory and oxygen saturation monitor. Care givers must carefully examine the child multiple times during the day and night to assess evidence of changing mental status or hepatic encephalopathy, increased respiratory effort, changing heart rate or changes in blood pressure that might be signs of infection, increasing cerebral edema, or electrolyte imbalance. Fluid balance (input and output) should be strictly monitored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24093566\">",
"    <span class=\"h2\">",
"     Laboratory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory monitoring should include a complete blood count, electrolytes, renal function tests, glucose, calcium, phosphorous, ammonia, coagulation profile, total and direct bilirubin, and blood cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/3\">",
"     3",
"    </a>",
"    ]. The frequency of laboratory monitoring should be at least daily, but multiple tests obtained regularly throughout the day may be necessary to monitor the dynamic changes that can occur in PALF.",
"   </p>",
"   <p>",
"    For measurement of ammonia, arterial samples are ideal but not always clinically practical. For children with stage 0 to II hepatic encephalopathy (HE), ammonia can generally be monitored with venous samples obtained from a free-flowing catheter, and promptly placed on ice and transported to the laboratory. Children with more advanced HE often require elective intubation and ventilatory support accompanied by placement of an arterial catheter. If available, ammonia samples should be obtained from the arterial catheter, but the arterial catheter should not be placed solely for ammonia testing.",
"   </p>",
"   <p>",
"    Laboratory studies for diagnosing the cause of the PALF are also important, and should be planned based on the patient&rsquo;s age and presentation, prioritizing those diagnoses that may be amenable to specific treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=see_link&amp;anchor=H6018198#H6018198\">",
"     \"Acute liver failure in children: Etiology and evaluation\", section on 'Laboratory testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24093585\">",
"    <span class=\"h2\">",
"     Fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the child is in shock, fluid resuscitation and pressor support is needed to stabilize cardiovascular status. However, as a general rule, intravenous and oral fluid intake should be modestly restricted for most patients with PALF. Total daily fluid intake (including medications and blood products) should initially be restricted to between 85 to 95 percent of the maintenance fluid requirement. Patients with PALF are sensitive to fluid volume and can develop pulmonary and peripheral edema if they receive excessive fluid. At the same time, the serum glucose should be maintained between 90 and 110",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Therefore, a central venous catheter may be required if concentrations of intravenous glucose over 12.5 percent are needed to maintain the serum glucose while restricting fluid volume. Adjustment in fluid rates is based upon the clinical conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340153\">",
"    <span class=\"h1\">",
"     CENTRAL NERVOUS SYSTEM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340160\">",
"    <span class=\"h2\">",
"     Encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic encephalopathy (HE) is a neuropsychiatric syndrome associated with hepatic dysfunction. In a large registry of patients with pediatric acute liver failure (PALF), some degree of encephalopathy was present on admission in 50 percent of patients, and developed within the next seven days in an additional 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HE is determined by serial clinical evaluations of behavior, cognition, neurological examination, and, occasionally, electroencephalogram (EEG) to categorize the patient into one of five clinical stages of encephalopathy, ranging from stage 0 (minimal or no evidence of neurological dysfunction) to stage IV (coma) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/4\">",
"     4",
"    </a>",
"    ]. Stages of encephalopathy are defined slightly differently in infants and children up to 48 months of age (",
"    <a class=\"graphic graphic_table graphicRef83748 \" href=\"UTD.htm?33/44/34507\">",
"     table 1",
"    </a>",
"    ) as compared with older children and adults (",
"    <a class=\"graphic graphic_table graphicRef62922 \" href=\"UTD.htm?32/17/33051\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70740 \" href=\"UTD.htm?12/37/12883\">",
"     figure 1",
"    </a>",
"    ). Clinical staging of HE was originally developed to assess patients with cirrhosis rather than acute liver failure (ALF). Nonetheless, the scoring system has been found to have important clinical and prognostic implications in adults and children with ALF. The pathogenesis and diagnosis of HE in adults is discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hepatic encephalopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14506?source=see_link\">",
"     \"Hepatic encephalopathy: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of other modalities to assess neurological function, such as visual evoked potentials, transcranial Doppler, cerebral near infrared spectroscopy (NIRS), and biomarkers, in the detection of HE is unclear at the present time",
"    <em>",
"     .",
"    </em>",
"    While neurologic morbidity remains a major determinant of outcome following pediatric ALF, further studies are needed to improve early detection of neurologic injury, standardize management of seizures and HE, and to determine whether such interventions improve outcomes.",
"   </p>",
"   <p>",
"    Hepatic encephalopathy is not always clinically apparent in infants and young children. Distinguishing hepatic based encephalopathy from other causes of an altered mental status such as sepsis, hypotension, electrolyte disturbances, hypoglycemia, anxiety, or &ldquo;intensive care unit (ICU) psychosis&rdquo; is difficult for all age groups. Hyperammonemia plays a central role in the development of HE in most cases. However, a specific level of ammonia does not result in a predictable degree of encephalopathy. &nbsp;",
"   </p>",
"   <p>",
"    Initial treatment of HE includes minimizing excess stimulation, head elevation up to 30 degrees, initial restriction of protein intake to no more than 1",
"    <span class=\"nowrap\">",
"     g/kg/day,",
"    </span>",
"    treating suspected sepsis, and, if possible, removing sedative medications that might affect mental status. For patients with progressive HE, we suggest medical therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/24/39299?source=see_link\">",
"     lactulose",
"    </a>",
"    , which is used empirically although there is only weak evidence to suggest that it is effective. The starting dose of lactulose is 0.4 to 0.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    every two hours by mouth or via nasogastric tube, with the dose adjusted as needed to produce two to three soft stools daily [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/5\">",
"     5",
"    </a>",
"    ]. Bowel &ldquo;decontamination&rdquo; with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/42/29348?source=see_link\">",
"     neomycin",
"    </a>",
"    can be used as a second-tier treatment, but ototoxicity and nephrotoxicity are potential risks when neomycin is used. Medical management of HE has not been studied in children, and practices are extrapolated from the clinical experience in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=see_link\">",
"     \"Hepatic encephalopathy in adults: Treatment\"",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Some patients with HE develop a clinically important increase in intracranial pressure, which can have devastating consequences. Direct monitoring of intracranial pressure is the most sensitive and specific procedure to use when compared with less invasive neuroradiographic procedures, such as cranial computed tomography (CT) or transcranial ultrasonography. (See",
"    <a class=\"local\" href=\"#H18340167\">",
"     'Cerebral edema'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Children with ALF may experience generalized or focal seizures, or nonconvulsive (electrographic) seizures (NCS). In most cases, treatment begins with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    , but practices are variable and there is no definitive standard of care. For seizures which are refractory to phenytoin, therapeutic options may include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    infusion,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/0/25608?source=see_link\">",
"     levetiracetam",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"     topiramate",
"    </a>",
"    . The selection of drug depends on the patient&rsquo;s mental status, physiologic stability, availability of EEG monitoring to titrate drug infusions, and institutional experience. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340167\">",
"    <span class=\"h2\">",
"     Cerebral edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral edema is a life threatening complication of ALF. It may lead to ischemic and hypoxic brain injury, or brainstem herniation and death [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/6\">",
"     6",
"    </a>",
"    ]. It occurs most commonly in those with advanced hepatic encephalopathy (stage III or IV) and can progress rapidly. Detection of cerebral edema in the early stages is difficult, because noninvasive monitoring with clinical assessment or radiographic studies lacks sensitivity. The most sensitive measure of intracranial pressure (ICP) requires surgical placement of an ICP monitor. However, ICP monitor placement requires adequate cranial calcification and cannot be used in infants; therefore it is not a common practice at most pediatric centers. Reported risks include bleeding in 10 and 20 percent, although the amount of bleeding is often minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/7\">",
"     7",
"    </a>",
"    ]. Once the ICP monitor is in place and properly functioning, it can be a valuable tool to continually assess response to ICP and its treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/8\">",
"     8",
"    </a>",
"    ]. The ICP monitor is also felt to be valuable during surgical procedures, including liver transplantation, to gauge fluid and medical management of the unconscious patient. Monitoring of intracranial pressure in children remains controversial due to associated complications of the procedure and lack of evidence that monitoring improves survival. The indications, types, and complications of ICP pressure monitoring in adults are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link&amp;anchor=H5#H5\">",
"     \"Acute liver failure in adults: Management and prognosis\", section on 'Intracranial pressure monitoring'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    The pathogenesis of cerebral edema is complex, involving the interaction among ammonia, cerebral blood flow, and inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/9\">",
"     9",
"    </a>",
"    ]. Elevated levels of ammonia are generated as a consequence of the failing liver, which leads to increased intracerebral concentrations. Ammonia enters the astrocyte, which is rich in glutamine synthetase. Conversion of ammonia and glutamate to glutamine, a potent intracellular osmolyte, results in an osmotic gradient that favors astrocyte swelling that contributes to cerebral edema and intracranial hypertension. Changes in the inflammatory milieu, sepsis, fluid or blood product administration, and other factors can result in a sudden and often unanticipated increase in intracranial pressure. &nbsp;",
"   </p>",
"   <p>",
"    Management of cerebral edema involves meticulous supportive care to maintain the following goals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oxygen saturation above 95 percent",
"     </li>",
"     <li>",
"      Total daily fluid between 85 and 90 percent of maintenance",
"     </li>",
"     <li>",
"      Diastolic pressure &gt;40 mmHg",
"     </li>",
"     <li>",
"      Adequate sedation",
"     </li>",
"     <li>",
"      Head elevation of 20&deg; to 30&deg;",
"     </li>",
"     <li>",
"      Consideration of empiric broad spectrum antibiotics to minimize the development of bacterial infection &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therapies targeted specifically to improve cerebral edema have not met scientific rigor, but they include hypertonic saline to maintain serum sodium between 145 and 150",
"    <span class=\"nowrap\">",
"     mEq/L,",
"    </span>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"     mannitol",
"    </a>",
"    keeping serum osmolarity less than 320",
"    <span class=\"nowrap\">",
"     mOsm/L",
"    </span>",
"    to create a more favorable osmotic gradient to extract water from the brain. Hypothermia has been used in adults with acute liver failure with some success, but has not been studied in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link&amp;anchor=H6#H6\">",
"     \"Acute liver failure in adults: Management and prognosis\", section on 'Treatment of intracranial pressure elevation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340174\">",
"    <span class=\"h1\">",
"     HEMATOLOGIC",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340182\">",
"    <span class=\"h2\">",
"     Coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prothrombin time (PT) and international normalization ratio (INR) are used to assess the severity of liver injury in the setting of acute liver failure (ALF), because these tests reflect hepatic production of clotting factors, particularly factors V and VII, which have the shortest half-lives. However, the PT and INR are not good markers for the risk of bleeding in patients with ALF. This is because ALF reduces both procoagulant proteins (eg, factor V, VII, X, and fibrinogen) and anticoagulant proteins (eg, antithrombin, protein C, and protein S) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link\">",
"     \"Coagulation abnormalities in patients with liver disease\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    This balanced reduction in the procoagulant and anticoagulant proteins may account for the relative infrequency of clinically important bleeding in the pediatric acute liver failure (PALF) patient in the absence of a provocative event such as infection or increased portal hypertension. A single dose of vitamin K should be administered once to initially assess response of the coagulation profile. However, daily administration of vitamin K is unnecessary. Efforts to &ldquo;correct&rdquo; the",
"    <span class=\"nowrap\">",
"     PT/INR",
"    </span>",
"    with plasma or other procoagulation products such as recombinant Factor VII should be avoided. Correction of the",
"    <span class=\"nowrap\">",
"     PT/INR",
"    </span>",
"    should be limited to patients with active bleeding or in anticipation of an invasive surgical procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340189\">",
"    <span class=\"h2\">",
"     Aplastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow failure, characterized by a spectrum of features ranging from mild pancytopenia to aplastic anemia, occurs in a significant minority of children with ALF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/10\">",
"     10",
"    </a>",
"    ]. It is identified most commonly in the setting of indeterminate PALF and may not be clinically evident until after emergent liver transplantation or recovery without transplantation. A possible association with human herpesvirus 6 (HHV6) has been suggested, but not established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=see_link&amp;anchor=H18338382#H18338382\">",
"     \"Acute liver failure in children: Etiology and evaluation\", section on 'Infection with viruses other than hepatitis viruses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment includes immunomodulatory medications that include steroids,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A, and antilymphocyte or antithymocyte globulin, as well as hematopoietic stem cell transplant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340196\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340204\">",
"    <span class=\"h2\">",
"     Ascites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascites develops in some but not all patients with acute liver failure (ALF). Precipitating factors include hypoalbuminemia, excessive fluid administration, and infection. The primary treatment is moderate fluid restriction. Diuretics should be reserved for patients with respiratory compromise or generalized fluid overload. Overly aggressive diuresis may precipitate hepatorenal syndrome. (See",
"    <a class=\"local\" href=\"#H18340225\">",
"     'Renal'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340211\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal bleeding is surprisingly infrequent, given the degree of coagulopathy. This is probably because of a balanced reduction in the procoagulant and anticoagulant proteins, described above. (See",
"    <a class=\"local\" href=\"#H18340182\">",
"     'Coagulopathy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Prophylactic use of acid-reducing agents is often initiated when the patient is admitted, but their usefulness is difficult to assess. Causes for bleeding include gastric erosions or ulcers due to nonsteroidal anti-inflammatory drugs (NSAIDs), or idiopathic gastroduodenal ulceration. Infection can precipitate bleeding in this vulnerable population, so blood cultures and initiation of antibiotics should also be considered when bleeding develops. Administration of platelets, blood, and plasma is necessary if bleeding is hemodynamically significant. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340218\">",
"    <span class=\"h2\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biochemical and clinical pancreatitis is increasingly recognized as a condition associated with multisystem failure in critically ill children. In patients who develop pancreatitis in the setting of acute liver failure, glucose and fluid management may become even more challenging. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340225\">",
"    <span class=\"h1\">",
"     RENAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with evidence of renal insufficiency and acute liver failure (ALF) on admission should be assessed for evidence of a medication or toxin as the precipitating cause (including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , inhaled solvents, mushrooms, recreational drugs, or medication induced pediatric acute liver failure [PALF]). During the hospital course, prerenal azotemia can develop if fluid restriction is too excessive for the patient&rsquo;s needs. Acute deterioration of renal function after presentation with ALF may result from systemic hypotension due to sepsis or hemorrhage.",
"   </p>",
"   <p>",
"    Hepatorenal syndrome (HRS) is a feared renal complication associated with ALF, although it occurs more commonly in the setting of chronic liver disease with established cirrhosis. The diagnosis is suspected when there is evidence of deteriorating renal function in the absence of bleeding, hypotension, sepsis, or nephrotoxic medications. Unlike prerenal azotemia, the urine sodium typically is low, and there is no improvement with volume expansion. It can progress rapidly over the course of two weeks (type 1 HRS) or more slowly (type II HRS) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/2\">",
"     2",
"    </a>",
"    ]. Renal replacement therapy with continuous venovenous hemofiltration or dialysis may be necessary in some cases, but only liver transplantation can reverse HRS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340232\">",
"    <span class=\"h1\">",
"     METABOLIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic abnormalities often seen in patients with acute liver failure (ALF) include [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoglycemia &ndash; Hypoglycemia is caused by impaired hepatic gluconeogenesis and depleted glycogen stores. Hypoglycemia is treated with continuous infusion of glucose, which is infused via a central venous catheter to accommodate the hypertonic solution. Glucose infusion rates of 10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg/minute",
"      </span>",
"      may be required to achieve stable serum glucose levels.",
"     </li>",
"     <li>",
"      Hypokalemia &ndash; Hypokalemia may be caused by dilution from volume overload, ascites, or renal wasting.",
"     </li>",
"     <li>",
"      Hypophosphatemia &ndash; Serum phosphorus should be monitored frequently, as hypophosphatemia can be profound. While the mechanism is unknown, hypophosphatemia is presumed to result from increased needs due to active liver cell regeneration. Hyperphosphatemia, often associated with renal insufficiency, is considered a poor prognostic sign [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/11\">",
"       11",
"      </a>",
"      ]. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Acid-base disturbances &ndash; Acid-base disturbances are caused by a variety of mechanisms, including respiratory alkalosis from hyperventilation, respiratory acidosis from respiratory failure, metabolic alkalosis from hypokalemia, and metabolic acidosis from hepatic necrosis, shock, and increased anaerobic metabolism or as the result of inborn errors of metabolism. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340239\">",
"    <span class=\"h1\">",
"     INFECTIOUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute liver failure (ALF) are susceptible to bacterial infection and sepsis because of immune system dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/2\">",
"     2",
"    </a>",
"    ]. Evidence of infection may be subtle, such as tachycardia, gastrointestinal bleeding, reduced renal output, or changes in mental status. Fever may or may not be present.",
"   </p>",
"   <p>",
"    Thus, blood cultures should be obtained with any evidence of clinical deterioration, and antibiotics should be initiated to cover both gram positive and gram negative organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340246\">",
"    <span class=\"h1\">",
"     CARDIOPULMONARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive fluid administration contributes to pulmonary edema and should be avoided. For patients who develop pulmonary edema, careful fluid restriction and discrete use of diuretics may be needed in some instances, but should be used with caution because these interventions can reduce organ perfusion and precipitate renal failure. Central venous pressure monitoring may assist in assessing volume needs for the child. Ionotropic support may be needed to maintain perfusion of vital organs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340253\">",
"    <span class=\"h1\">",
"     NUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutrition support should be maintained to avoid a catabolic state. If it is not safe for the child to receive oral or enteral feeding, intravenous alimentation (parenteral nutrition [PN]) should be initiated.",
"   </p>",
"   <p>",
"    We suggest the following parameters for PN in patients with pediatric acute liver failure (PALF):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total fluid input including PN, blood products, and medications should generally be limited to between 85 to 95 percent of the maintenance fluid requirement to avoid excessive hydration.",
"     </li>",
"     <li>",
"      Protein input should generally be no more than 1",
"      <span class=\"nowrap\">",
"       g/kg/day,",
"      </span>",
"      but this may need to be reduced to 0.5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      for patients with elevated serum ammonia levels. &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/41/1686?source=see_link\">",
"       Trace metals",
"      </a>",
"      (trace elements) should generally be eliminated or reduced. This is because copper and manganese are metabolized in the liver. Moreover, chromium, molybdenum, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      should be eliminated or reduced if renal disease is also present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340260\">",
"    <span class=\"h1\">",
"     LIVER SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of approaches are being developed to perform some functions of the liver in an attempt to delay or avoid the need for liver transplantation. These include artificial hepatic assist devices (eg, the membrane-adsorbent recirculating system [MARS]). To date, none have been established as a valuable treatment for acute hepatic failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link&amp;anchor=H233808218#H233808218\">",
"     \"Acute liver failure in adults: Management and prognosis\", section on 'Artificial hepatic assist devices and hepatocyte transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasmapheresis or plasma exchange facilitates the removal of suspected toxins in the blood to facilitate a milieu in which the liver might recover or regenerate, but has not been helpful in the management of children or adults with acute liver failure (ALF). While coagulation profiles may improve, the procedure has not been shown to improve neurological outcome or ability of the liver to recover spontaneously. An exception is that for patients with ALF due to Wilson disease, plasma exchange can be valuable because it rapidly removes large amounts of copper. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of Wilson disease\", section on 'Acute liver failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of specific interventions have been studied, but are unhelpful for ALF and should generally not be used. These include glucocorticoids (except in the setting of autoimmune hepatitis), hepatic &ldquo;regeneration therapy&rdquo; using insulin and glucagon, charcoal hemoperfusion, and prostaglandin E. Furthermore, a randomized, doubly masked, controlled trial in pediatric acute liver failure (PALF) demonstrated that intravenous N-acetylcysteine (NAC) was not beneficial in children with non-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    -induced ALF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/13\">",
"     13",
"    </a>",
"    ]. One-year survival with native liver was significantly worse for those receiving NAC than placebo, particularly for those children younger than two years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link&amp;anchor=H233810228#H233810228\">",
"     \"Acute liver failure in adults: Management and prognosis\", section on 'Unhelpful treatments'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340283\">",
"    <span class=\"h1\">",
"     DISEASE SEVERITY ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently no reliable tools to predict survival or death in patients with pediatric acute liver failure (PALF). Biochemical tests (lactate, total bilirubin, phosphorous, international normalization ratio [INR], prothrombin time, ammonia, Gc-globulin), clinical features (encephalopathy, cerebral edema), diagnosis (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ), or combinations of the three have been tried without reliable success. &nbsp;",
"   </p>",
"   <p>",
"    Existing liver failure scoring systems, including the Kings College Hospital Criteria (KCHC), the Clichy score, Model for End-Stage Liver Disease (MELD) score, and Pediatric End-Stage Liver Disease (PELD) score, are not adequate prognostic tools because they are only weakly associated with outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/2\">",
"     2",
"    </a>",
"    ]. Among these, only PELD is specific to the pediatric age group, but it was developed for chronic rather than acute liver disease, and includes factors such as growth failure that are less relevant to prognosis in acute liver failure (ALF). KCHC is commonly used to predict prognosis and need for liver transplantation in adults with ALF, and is stratified by whether the ALF is caused by",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    toxicity. However, KCHC are not useful in PALF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link&amp;anchor=H233813088#H233813088\">",
"     \"Acute liver failure in adults: Management and prognosis\", section on 'King's College Criteria'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    The Liver Injury Unit (LIU) score has been developed specifically for PALF and is somewhat more useful [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/15\">",
"     15",
"    </a>",
"    ]. It includes factors for peak total bilirubin, prothrombin time (PT) or international normalization ratio (INR), and ammonia. A study tested the validity of the LIU score using data from the Pediatric Acute Liver Failure Study Group (PALFSG), and after optimization sensitivity and specificity were 74 and 80 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/16\">",
"     16",
"    </a>",
"    ]. While this represents an improvement compared with the other scoring systems mentioned above, LIU is not sufficient to make critical decisions about liver transplantation. We believe the ideal scoring system should reflect the dynamic nature of PALF and incorporate periodic clinical changes into deriving the likelihood of death or survival [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340290\">",
"    <span class=\"h1\">",
"     LIVER TRANSPLANT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340298\">",
"    <span class=\"h2\">",
"     Liver transplant decisions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the era before liver transplantation (LT) was available, the natural history of pediatric acute liver failure (PALF) was for children to either survive or die. LT interrupts the natural course of PALF, and can save the life of a patient with acute liver failure (ALF) if he or she has a condition that is not amenable to treatment or fails to respond to treatment (",
"    <a class=\"graphic graphic_figure graphicRef83763 \" href=\"UTD.htm?32/47/33534\">",
"     figure 2",
"    </a>",
"    ). However, because the cause of PALF often is not known, and the course of PALF is difficult to predict, it is likely that some patients may receive LT in situations in which spontaneous recovery may have occurred.",
"   </p>",
"   <p>",
"    LT decisions are difficult because of uncertainty regarding the patient&rsquo;s outcome without transplant, the potential morbidity and mortality of the transplant procedure, and the limited number of organs available. Moreover, long-term outcomes following LT for PALF are less favorable as compared with LT for chronic liver diseases such as biliary atresia. This is likely due to multiple factors, including the severity of illness at the time of LT, and the possibility that LT was performed in circumstances in which death was inevitable regardless of LT. When living donor LT is considered, the decision also includes consideration of potential risks to the donor.",
"   </p>",
"   <p>",
"    As discussed above, none of the current scoring systems are adequate to direct decisions about LT for patients with PALF. A more reliable modeling scheme is needed to readily and effectively distinguish the patient who would die from the one who would survive without LT and recognize when it would be futile to proceed with LT. Until then, the best solution is a global clinical assessment by a team of clinicians with experience in PALF and LT, incorporating the prognosis associated with the cause of the ALF, and the patient&rsquo;s dynamic course, based on repeated assessments of the probability of survival with native liver from one time interval to the next. &nbsp;",
"   </p>",
"   <p>",
"    LT decisions are particularly challenging for patients with PALF caused by a mitochondrial disease. Multisystem mitochondrial dysfunction is a contraindication to liver transplantation. However, patients who do not have extrahepatic manifestations of disease may have isolated hepatic mitochondrial dysfunction and could be candidates for liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/17\">",
"     17",
"    </a>",
"    ]. Unfortunately, multisystem involvement may not be apparent at the time of LT, placing the child at risk for developing symptoms in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340305\">",
"    <span class=\"h2\">",
"     Organ allocation in acute liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organ allocation for children with ALF remains an evolving process. Organ allocation in the United States is managed by United Network for Organ Sharing (UNOS), and is based largely on disease severity scores for adults (Model for End-Stage Liver Disease [MELD]) and children (Pediatric End Stage Liver Disease [PELD]) to support organ allocation for patients with chronic liver disease. PELD is calculated by UNOS or by using a calculator (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/40/9860?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). MELD is used for patients 12 years and older and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PELD and MELD are used to allocate organs for patients with chronic liver disease; they were not designed for use in ALF. The urgency of liver transplantation for PALF is typically not reflected by their",
"    <span class=\"nowrap\">",
"     PELD/MELD",
"    </span>",
"    score. Patients with ALF and in need of liver transplantation are given priority over those listed with a",
"    <span class=\"nowrap\">",
"     PELD/MELD",
"    </span>",
"    score and are listed as Status 1A, the category with the highest priority status. Status 1A is reserved for children in an intensive care unit (ICU) in one of four diagnostic categories, including fulminant liver failure. The three other diagnostic categories qualifying for Status 1A are primary graft nonfunction following liver transplantation, hepatic artery thrombosis, and acute decompensated Wilson disease.",
"   </p>",
"   <p>",
"    To qualify for Status 1A for fulminant liver failure, UNOS uses the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Onset of hepatic encephalopathy within eight weeks of the first symptoms of liver disease in the absence of preexisting liver disease, AND one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ventilator dependence",
"     </li>",
"     <li>",
"      Need for dialysis, continuous venovenous hemofiltration, or continuous venovenous hemodialysis",
"     </li>",
"     <li>",
"      INR &gt;2.0",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children who are classified as Status 1A require reassessment of their listing status after seven days. At any time, the child can be removed from the transplantation list if",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    becomes too ill to undergo transplantation or recovers to a point that transplantation is not necessary. If the child is still on the list after seven days, options would be to continue to list the patient as Status 1A by providing supportive clinical information, remove the child from the list, or &ldquo;demote&rdquo; the urgency by changing the listing status from Status 1A to the calculated PELD score. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340312\">",
"    <span class=\"h2\">",
"     Types of grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;LT has improved overall survival for children with ALF. Because the supply of appropriately sized organs from deceased donors is inadequate, some children with PALF die while waiting for LT, and pretransplant mortality is worse than for patients with chronic liver failure. As a result, technical variants to whole grafts such as split and living donors have been introduced.",
"   </p>",
"   <p>",
"    In a report of LT for PALF from centers in the United States and Canada, deceased-donor whole livers were used in 46 percent of transplants, split or cut-down grafts were used in 38 percent, and grafts from living donors were used in 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/18\">",
"     18",
"    </a>",
"    ]. Outcomes for patients receiving donor or split liver grafts were not different from those receiving whole liver grafts. However, in a separate study that focused on patients with ALF and concurrent multiorgan failure, living donor transplant was associated with improved 30-day and 6-month survival compared with recipients of a deceased donor liver allograft [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/19\">",
"     19",
"    </a>",
"    ]. Improved outcome for patients receiving a living donor LT is likely related to a reduced cold ischemia time and wait time, resulting in a more expeditious time to transplant for these seriously ill children.",
"   </p>",
"   <p>",
"    Auxiliary liver transplantation is an alternative approach that consists of placement of a graft adjacent to the patient's native liver (auxiliary heterotopic liver transplantation) or in the hepatic bed after a portion of the native liver (auxiliary orthotopic liver transplantation) has been removed. This technique has been used as a &ldquo;bridge&rdquo; to provide need time for the native liver to regenerate, but challenges remain as to the timing for withdrawal of immunosuppression and involution of the transplanted graft [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link&amp;anchor=H233808225#H233808225\">",
"     \"Acute liver failure in adults: Management and prognosis\", section on 'Auxiliary liver transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340319\">",
"    <span class=\"h2\">",
"     Hepatocyte transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of hepatocyte transplantation in PALF is yet to be determined and may be an opportunity for investigation in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/21\">",
"     21",
"    </a>",
"    ]. Hepatocyte transplantation may serve as a bridge to transplant or, perhaps, a &ldquo;cure&rdquo; for some children with metabolic diseases. It has been used in a small number of children with ALF. However, technical challenges as well as lack of a readily available source for hepatocytes have limited the opportunity for this procedure at most centers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31944?source=see_link\">",
"     \"Hepatocyte transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18340326\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the pretransplant era and using an adult definition of acute liver failure (ALF), spontaneous survival occurred in 28 percent of patients overall, and only 4 percent of those with stage IV coma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/22\">",
"     22",
"    </a>",
"    ]. More recently, with improvements in management of critically ill children, coupled with a more lenient definition of pediatric acute liver failure (PALF), outcomes have improved [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/1-3,23\">",
"     1-3,23",
"    </a>",
"    ]. However, it should be noted that all current studies of outcomes are affected by decisions about liver transplantation (LT), because LT interrupts the natural course of PALF. Some children who receive LT may have recovered spontaneously, and some die as a consequence of LT rather than of the underlying PALF. Patient outcome depends on a number of factors including the etiology, disease severity, supportive management, and treatment. However, outcomes vary among children with seemingly similar etiology, disease severity, and treatment. Additional factors are likely involved to explain these variations perhaps including the inflammatory milieu, end-organ damage, immune activation, and potential for liver regeneration. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Data from the Pediatric Acute Liver Failure Study Group (PALFSG) in North America and Europe revealed that 21-day outcome varied by diagnosis, age, and degree of encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/1,23\">",
"     1,23",
"    </a>",
"    ]. Spontaneous survival (survival with the native liver) was highest amongst those with liver failure due to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (94 percent). Spontaneous survival occurred less frequently for those with liver failure due to metabolic disease (44 percent), for those with non-acetaminophen drug-induced disease (41 percent), and for those with an indeterminate diagnosis (45 percent). As might be expected, those with higher stages of encephalopathy had lower spontaneous survival.",
"   </p>",
"   <p>",
"    Unexpectedly, in the same study, 21 percent of patients with minimal or no clinical evidence of encephalopathy (ie, those with peak hepatic encephalopathy stage 0) either died or received a LT [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/1\">",
"     1",
"    </a>",
"    ]. For children with an established diagnosis, between 20 to 33 percent received a LT; and of those with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    -induced PALF, only 2 percent received a LT. In comparison, among patients with a diagnosis of indeterminant PALF, 46 percent underwent LT. Therefore, children who do not have a specific diagnosis are more likely to receive a LT. The major causes of death for children with PALF who do not receive a liver transplant are multiorgan system failure, cerebral edema and herniation, and sepsis. &nbsp;",
"   </p>",
"   <p>",
"    Both early and late graft loss and death is higher among children who undergo LT for ALF than for those with chronic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/24\">",
"     24",
"    </a>",
"    ]. Reasons for these findings are uncertain, but one possibility includes immune dysregulation that may be associated with PALF, which could lead to increased susceptibility to infection or graft rejection. Among patients undergoing LT for PALF, overall survival rates are 74 percent at one year, and 69 percent at four years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6777/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1385130\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric acute liver failure (PALF) is a complex, rapidly progressive clinical syndrome that precipitates complications and failure in most other organ systems. Treatment of PALF requires management of each of these complications, supportive care, and informed decisions about liver transplantation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with PALF typically should initially be managed in a pediatric intensive care unit, which allows close monitoring, particularly fluid status and changes in mental status. (See",
"      <a class=\"local\" href=\"#H24093559\">",
"       'Clinical setting'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Laboratory monitoring should include a complete blood count, electrolytes, renal function tests, glucose, calcium, phosphorous, ammonia, coagulation profile, total and direct bilirubin, and blood cultures. (See",
"      <a class=\"local\" href=\"#H24093566\">",
"       'Laboratory monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluid intake should be modestly restricted for most patients with PALF. In the absence of the need for volume resuscitation, total intravenous fluids should initially be restricted to between 85 to 95 percent of the maintenance fluid requirement. (See",
"      <a class=\"local\" href=\"#H24093585\">",
"       'Fluids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hepatic encephalopathy (HE) develops in the majority of patients with PALF and is a relevant but inconsistent indicator of prognosis. Serial clinical evaluations of behavior, cognition, neurological examination, and electroencephalogram (EEG) are important to assess the presence and progress of HE and possible onset of cerebral edema. We suggest that patients with HE be treated initially with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/24/39299?source=see_link\">",
"       lactulose",
"      </a>",
"      , although the evidence to support this approach is weak (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18340160\">",
"       'Encephalopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of cerebral edema requires meticulous supportive care, sometimes guided by surgical placement of an intracranial pressure monitor. (See",
"      <a class=\"local\" href=\"#H18340167\">",
"       'Cerebral edema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prothrombin time (PT) and international normalization ratio (INR) are used to assess the severity of liver injury in the setting of PALF because these tests reflect hepatic production of clotting factors. However, the",
"      <span class=\"nowrap\">",
"       PT/INR",
"      </span>",
"      is not a good marker for the risk of bleeding in patients with PALF, because PALF reduces both procoagulant proteins and anticoagulant proteins. Therefore, we suggest NOT administering with plasma or other procoagulation products except in patients with active bleeding or in anticipation of an invasive surgical procedure (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18340182\">",
"       'Coagulopathy'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Hepatorenal syndrome (HRS) is a feared renal complication associated with PALF. Unlike prerenal azotemia, the urine sodium typically is low, and there is no improvement with volume expansion. Renal replacement therapy with hemofiltration or dialysis may be necessary in some cases, but only liver transplantation (LT) can reverse HRS. (See",
"      <a class=\"local\" href=\"#H18340225\">",
"       'Renal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metabolic disturbances often seen in patients with PALF include hypoglycemia, hypokalemia hypophosphatemia, and acid-base disturbances. Management requires close monitoring and replacement. Hypoglycemia may require a continuous infusion of hypertonic glucose solution via a central venous catheter. (See",
"      <a class=\"local\" href=\"#H18340232\">",
"       'Metabolic'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Patients with PALF are susceptible to bacterial infection and sepsis because of immune system dysfunction. Evidence of infection may be subtle, and fever may not be present. Thus, blood cultures should be obtained with any evidence of clinical deterioration, and antibiotics should be initiated if there is a clinical concern for sepsis. (See",
"      <a class=\"local\" href=\"#H18340239\">",
"       'Infectious'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Decisions about whether and when to perform a LT for a patient with PALF are difficult because of uncertainty regarding the patient&rsquo;s outcome without LT and the potential morbidity and mortality of the LT procedure. None of the current scoring systems are adequate to direct decisions about LT. (See",
"      <a class=\"local\" href=\"#H18340283\">",
"       'Disease severity assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18340298\">",
"       'Liver transplant decisions'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Outcomes for patients with PALF vary substantially by diagnosis;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      -related PALF typically has the highest likelihood of survival without LT (94 percent) as compared with non-acetaminophen drug-induced PALF (41 percent) or indeterminant PALF (45 percent). Other important prognostic factors include age, timing of diagnosis for treatable disorders, and degree of encephalopathy (although a significant minority of patients without encephalopathy die or require LT).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/1\">",
"      Squires RH Jr, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006; 148:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/2\">",
"      Squires RH Jr. Acute liver failure in children. Semin Liver Dis 2008; 28:153.",
"     </a>",
"    </li>",
"    <li>",
"     Squires RH, Alonso EM. Acute liver failure in children. In: Liver Disease in Children, 4th ed, Suchy FJ, Sokol RJ, Balistreri WF (Eds), Cambridge University Press, New York 2012.",
"    </li>",
"    <li>",
"     Whittington PF, Alonso AE. Fulminant hepatitis and acute liver failure. In: Diseases of the liver and biliary system in children, 2nd ed, Kelly DA (Ed), Blackwell, Oxford 2003. p.107.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/5\">",
"      Debray D, Yousef N, Durand P. New management options for end-stage chronic liver disease and acute liver failure: potential for pediatric patients. Paediatr Drugs 2006; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/6\">",
"      Wendon J, Lee W. Encephalopathy and cerebral edema in the setting of acute liver failure: pathogenesis and management. Neurocrit Care 2008; 9:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/7\">",
"      Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007; 35:2498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/8\">",
"      Kamat P, Kunde S, Vos M, et al. Invasive intracranial pressure monitoring is a useful adjunct in the management of severe hepatic encephalopathy associated with pediatric acute liver failure. Pediatr Crit Care Med 2012; 13:e33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/9\">",
"      Shawcross DL, Wendon JA. The neurological manifestations of acute liver failure. Neurochem Int 2012; 60:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/10\">",
"      Hadzi N, Height S, Ball S, et al. Evolution in the management of acute liver failure-associated aplastic anaemia in children: a single centre experience. J Hepatol 2008; 48:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/11\">",
"      Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology 2002; 36:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/12\">",
"      Rolando N, Harvey F, Brahm J, et al. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology 1990; 11:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/13\">",
"      Squires RH, Dhawan A, Alonso E, et al. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: A placebo-controlled clinical trial. Hepatology 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/14\">",
"      Sundaram V, Shneider BL, Dhawan A, et al. King's College Hospital Criteria for non-acetaminophen induced acute liver failure in an international cohort of children. J Pediatr 2013; 162:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/15\">",
"      Liu E, MacKenzie T, Dobyns EL, et al. Characterization of acute liver failure and development of a continuous risk of death staging system in children. J Hepatol 2006; 44:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/16\">",
"      Lu B, Zhang S, Narkewicz M, et al. Validation of a scoring system to predict survival in 455 patients with pediatric acute liver failure. Hepatology 2009; 50(4 Suppl):424A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/17\">",
"      Sokal EM, Sokol R, Cormier V, et al. Liver transplantation in mitochondrial respiratory chain disorders. Eur J Pediatr 1999; 158 Suppl 2:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/18\">",
"      Baliga P, Alvarez S, Lindblad A, et al. Posttransplant survival in pediatric fulminant hepatic failure: the SPLIT experience. Liver Transpl 2004; 10:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/19\">",
"      Mack CL, Ferrario M, Abecassis M, et al. Living donor liver transplantation for children with liver failure and concurrent multiple organ system failure. Liver Transpl 2001; 7:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/20\">",
"      Girlanda R, Vilca-Melendez H, Srinivasan P, et al. Immunosuppression withdrawal after auxiliary liver transplantation for acute liver failure. Transplant Proc 2005; 37:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/21\">",
"      Soltys KA, Soto-Guti&eacute;rrez A, Nagaya M, et al. Barriers to the successful treatment of liver disease by hepatocyte transplantation. J Hepatol 2010; 53:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/22\">",
"      Psacharopoulos HT, Mowat AP, Davies M, et al. Fulminant hepatic failure in childhood: an analysis of 31 cases. Arch Dis Child 1980; 55:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/23\">",
"      Sundaram SS, Alonso EM, Narkewicz MR, et al. Characterization and outcomes of young infants with acute liver failure. J Pediatr 2011; 159:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6777/abstract/24\">",
"      Soltys KA, Mazariegos GV, Squires RH, et al. Late graft loss or death in pediatric liver transplantation: an analysis of the SPLIT database. Am J Transplant 2007; 7:2165.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83172 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-90976AC03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6777=[""].join("\n");
var outline_f6_39_6777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1385130\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24093412\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18340146\">",
"      GENERAL MANAGEMENT PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24093559\">",
"      Clinical setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24093566\">",
"      Laboratory monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24093585\">",
"      Fluids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18340153\">",
"      CENTRAL NERVOUS SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18340160\">",
"      Encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18340167\">",
"      Cerebral edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18340174\">",
"      HEMATOLOGIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18340182\">",
"      Coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18340189\">",
"      Aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18340196\">",
"      GASTROINTESTINAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18340204\">",
"      Ascites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18340211\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18340218\">",
"      Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18340225\">",
"      RENAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18340232\">",
"      METABOLIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18340239\">",
"      INFECTIOUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18340246\">",
"      CARDIOPULMONARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18340253\">",
"      NUTRITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18340260\">",
"      LIVER SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18340283\">",
"      DISEASE SEVERITY ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18340290\">",
"      LIVER TRANSPLANT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18340298\">",
"      Liver transplant decisions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18340305\">",
"      Organ allocation in acute liver failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18340312\">",
"      Types of grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18340319\">",
"      Hepatocyte transplant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18340326\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1385130\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/83172\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/83172|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/37/12883\" title=\"figure 1\">",
"      Clinical features of hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/47/33534\" title=\"figure 2\">",
"      Schematic model of the course of PALF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/83172|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/44/34507\" title=\"table 1\">",
"      Stages of hepatic encephalopathy in young children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/17/33051\" title=\"table 2\">",
"      Stages hepatic encephalopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/40/9860?source=related_link\" title=\"calculator 1\">",
"      Calculator: PELD score for end-stage liver disease (patients less than 12 years old)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=related_link\">",
"      Acute liver failure in children: Etiology and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=related_link\">",
"      Clinical manifestations and diagnosis of hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=related_link\">",
"      Hepatic encephalopathy in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14506?source=related_link\">",
"      Hepatic encephalopathy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31944?source=related_link\">",
"      Hepatocyte transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=related_link\">",
"      Treatment of Wilson disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_39_6778="First-line chemotherapy for patients with extensive stage small cell lung cancer";
var content_f6_39_6778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   First-line chemotherapy for patients with extensive stage small cell lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/39/6778/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/39/6778/contributors\">",
"     Karen Kelly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/39/6778/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/39/6778/contributors\">",
"     Rogerio C Lilenbaum, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/39/6778/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/39/6778/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/39/6778/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small cell lung cancer (SCLC) is a neuroendocrine tumor that represents about 15 percent of all lung cancers. SCLC occurs predominantly in smokers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SCLC is distinguished clinically from most other types of non-small cell lung cancer (NSCLC) by its rapid doubling time, high growth fraction, and the early development of metastases. Large cell neuroendocrine carcinoma, a rare form of lung cancer, and extrapulmonary small cell carcinomas are generally treated with the same chemotherapy regimens used for SCLC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H24#H24\">",
"     \"Pathology of lung malignancies\", section on 'Large cell neuroendocrine carcinoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3578?source=see_link\">",
"     \"Extrapulmonary small cell cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SCLC usually presents with disseminated disease, and treatment strategies have focused on systemic therapy. Although SCLC is highly responsive to both chemotherapy and radiotherapy (RT), it commonly relapses within months despite treatment.",
"   </p>",
"   <p>",
"    The role of cytotoxic chemotherapy in the initial management of SCLC will be reviewed here, with a primary focus on the management of patients with extensive stage disease. Related topics include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link\">",
"       \"Pathobiology and staging of small cell carcinoma of the lung\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38469?source=see_link\">",
"       \"Role of surgery in multimodality therapy for small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=see_link\">",
"       \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1830?source=see_link\">",
"       \"Prophylactic cranial irradiation for patients with small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=see_link\">",
"       \"Treatment of refractory and relapsed small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8951?source=see_link\">",
"       \"Experimental approaches to treatment for small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BENEFIT OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SCLC rarely survive more than a few months without treatment. However, SCLC is highly responsive to multiple chemotherapeutic drugs, and chemotherapy dramatically prolongs survival compared to best supportive care [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/1\">",
"     1",
"    </a>",
"    ]. These benefits may be seen even in patients with advanced disease and severe organ dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Extent of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of treatment in SCLC differ according to the extent of disease spread at diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with limited stage SCLC (LS-SCLC), chemotherapy plus radiation therapy (RT) yields overall response rates of 80 to 90 percent, including 50 to 60 percent complete responses (CR). For patients with extensive stage disease (ES-SCLC), 60 to 80 percent of patients respond to chemotherapy, although CRs are observed in only 15 to 20 percent.",
"     </li>",
"     <li>",
"      Responses to treatment tend to be brief, with a median duration of six to eight months.",
"     </li>",
"     <li>",
"      Once disease recurs, median survival is about four months.",
"     </li>",
"     <li>",
"      From the time of original diagnosis, the median survival durations for LS-SCLC and ES-SCLC are 14 to 20 months and 8 to 13 months, respectively.",
"     </li>",
"     <li>",
"      Approximately 20 to 40 percent of patients with LS-SCLC survive two years, compared to less than 5 percent of those with ES-SCLC.",
"     </li>",
"     <li>",
"      Long term survival (beyond five years) is seen in only 10 to 13 percent of patients with LS-SCLC, even when patients are treated with both chemotherapy and RT [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect on survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progress in the treatment of SCLC has had a modest impact on survival:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with LS-SCLC, a review of 30 trials involving 6564 patients found that the median survival increased from 12 months in 1972 to 17 months between 1982 and 1992 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/4\">",
"       4",
"      </a>",
"      ]. Similar results were seen in the Surveillance, Epidemiology and End Results (SEER) database, which observed a 6.4 month increase in the median survival of patients with LS-SCLC and a greater than twofold higher five-year survival rate (12.1 versus 5.2 percent) over the same periods [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients with ES-SCLC, the progress has been more limited. An analysis of 21 North American cooperative group trials found a statistically significant improvement in overall survival when the period from 1982 to 1990 was compared to the period 1972 to 1981 (median 9 versus 7 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/5\">",
"       5",
"      </a>",
"      ]. Analysis of the SEER database showed a similar two month improvement in survival during this time period [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Active agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple chemotherapeutic agents have significant activity against SCLC either in the first or second line setting. These agents include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platinum compounds (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Podophyllotoxins (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/55/4983?source=see_link\">",
"       teniposide",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Camptothecins (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Alkylating agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anthracyclines (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      , amrubicin)",
"     </li>",
"     <li>",
"      Taxanes (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vinca alkaloids (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other drugs with modest single-agent activity that are used less frequently include the nitrosoureas,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Randomized trials have shown a survival benefit for combination regimens compared to single agent chemotherapy, and for simultaneous administration of multiple agents as compared to sequential administration of the same agents [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/6\">",
"     6",
"    </a>",
"    ]. No specific combination has established superiority in the treatment of SCLC.",
"   </p>",
"   <p>",
"    Platinum-based combinations are generally preferred based upon efficacy and toxicity profiles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Tumor lysis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although tumor lysis syndrome is rare in SCLC, patients with bulky or advanced stage disease may be classified as being at intermediate risk and prophylaxis against the complications of tumor lysis syndrome may be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PLATINUM-BASED COMBINATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platinum-based combinations are the standard of care for the initial systemic therapy in patients with SCLC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116211046\">",
"    <span class=\"h2\">",
"     Platinum plus etoposide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently used combinations are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (PE) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus etoposide (CE), based upon their clinical activity and toxicity profile. Representative chemotherapy regimens are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18881?source=see_link\">",
"     \"Treatment protocols for small-cell carcinoma of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cisplatin plus etoposide",
"    </span>",
"    &nbsp;&mdash;&nbsp;In multiple randomized trials, the PE regimen appears to be at least as effective as older regimens such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    (CAV) or cyclophosphamide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , and vincristine and has less toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    possess little mucosal toxicity, limited risk for interstitial pneumonitis, and modest hematologic toxicity, PE is the regimen of choice to use with concurrent chest RT in patients with LS-SCLC (",
"    <a class=\"graphic graphic_table graphicRef58176 \" href=\"UTD.htm?11/9/11422\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=see_link\">",
"     \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Efforts to improve on the results with PE have substituted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or replaced",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    with a camptothecin analogue (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Carboplatin plus etoposide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    is frequently substituted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    because of its more favorable toxicity profile. One small randomized trial directly compared cisplatin (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 2) to carboplatin (300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) both with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 2, and 3) in 35 patients with ES-SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/12\">",
"     12",
"    </a>",
"    ]. The cisplatin regimen was associated with slightly higher overall and complete response rates compared with the carboplatin regimen (64 versus 50 percent and 16 versus 10 percent, respectively). However, difference in overall survival was not statistically significant (median 11.8 versus 12.5 months). The rate of grade 3 or 4 neutropenia was significantly less with carboplatin plus etoposide (17 versus 50 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367024309\">",
"    <span class=\"h3\">",
"     Cisplatin versus carboplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinicians in the United States use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    to treat patients with ES-SCLC based upon its better toxicity profile (",
"    <a class=\"graphic graphic_table graphicRef75586 \" href=\"UTD.htm?40/39/41597\">",
"     table 2",
"    </a>",
"    ), while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus etoposide is preferred for those with LS-SCLC because of the possibility of a higher response rate (",
"    <a class=\"graphic graphic_table graphicRef58176 \" href=\"UTD.htm?11/9/11422\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    -based regimens have been compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    -based combinations in four randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. A meta-analysis that included individual patient data from these four trials found no statistically significant difference between cisplatin and carboplatin-based combinations in terms of overall survival, progression-free survival, or objective response rate (median overall survival 9.6 versus 9.4 months, 5.5 versus 5.3 months, and 67 versus 66 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Camptothecin-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple clinical trials have evaluated whether the substitution of a camptothecin analogue for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    in combination with a platinum compound can improve survival in patients with ES-SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. However, the bulk of evidence suggests that this strategy does not improve upon the results with a platinum plus etoposide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cisplatin plus irinotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least four large randomized trials have compared a PE regimen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/17-19,21\">",
"     17-19,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Japanese Cooperative Oncology Group trial (JCOG 9511), 154 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV on days 1 to 3) every three weeks or cisplatin (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 8, and 15) every four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/17\">",
"     17",
"    </a>",
"    ]. Enrollment was stopped prematurely based upon the results of an interim analysis. Patients treated with irinotecan plus cisplatin had a significantly higher response rate compared with the etoposide-based regimen (84 versus 68 percent), longer median survival (12.8 versus 9.4 months), and a higher two-year survival rate (19.5 versus 5.2 percent). Although hematologic toxicity was less pronounced (grade 3 or 4 neutropenia in 65 versus 92 percent), irinotecan caused more grade 3 or 4 diarrhea (17 versus 0 percent).",
"   </p>",
"   <p>",
"    However, three larger trials conducted outside Japan have failed to confirm this observation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/18,19,21\">",
"     18,19,21",
"    </a>",
"    ]. In the largest of these (the Southwest Oncology Group trial S0124), 671 patients with ES-SCLC were randomly assigned to the identical regimens used in JCOG 9511 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/19\">",
"     19",
"    </a>",
"    ]. There were no statistically significant differences in the median progression-free survival, median overall survival, or objective response rates (5.8 versus 5.2 months, 9.9 versus 9.1 months, 60 versus 57 percent, for the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    plus cisplatin regimens, respectively). The patterns of toxicity were similar to that in JCOG 9511.",
"   </p>",
"   <p>",
"    The differences between JCOG 9511 and the three other trials may reflect pharmacogenomic differences between the Japanese and American patient populations. Alternatively, the early termination of the JCOG 9511 may have contributed to a false positive result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Carboplatin plus irinotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized European phase III trials have compared the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    with carboplatin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    for patients with extensive stage SCLC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial found a slight prolongation in overall survival with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      combination compared with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      regimen (median survival 8.5 versus 7.1 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/20\">",
"       20",
"      </a>",
"      ]. However, that trial used a relatively low dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (AUC 4) and oral rather than intravenous etoposide, which may have contributed to the relatively short survival on both treatment arms.",
"     </li>",
"     <li>",
"      In contrast, the other trial used a higher dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (AUC 5) and intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/22\">",
"       22",
"      </a>",
"      ]. The difference in survival was not statistically significant (10 versus 9 months for the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      and etoposide-based regimens).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Topotecan plus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The camptothecin analogue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    is active in SCLC, and intravenous topotecan is the treatment of choice for patients with chemotherapy-sensitive relapsed disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=see_link&amp;anchor=H4085535#H4085535\">",
"     \"Treatment of refractory and relapsed small cell lung cancer\", section on 'Topotecan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     Topotecan",
"    </a>",
"    has been combined with many other agents as initial therapy for SCLC, but has not demonstrated an advantage over the standard PE combination [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Cisplatin plus etoposide'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This was illustrated by a trial in 784 previously untreated patients with ES-SCLC, in which patients were randomly assigned to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or to PE [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/23\">",
"     23",
"    </a>",
"    ]. There was no statistically significant difference in the response rate (63 versus 69 percent, with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    regimen) or overall survival (median 39 versus 40 weeks and one-year survival 31 percent with each combination). Both regimens were well tolerated although grade 3 or 4 granulocytopenia was less frequent with the topotecan regimen (84 versus 59 percent), while grade 3 or 4 anemia (37 versus 21 percent) and thrombocytopenia (38 versus 23 percent) were more common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Epirubicin plus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anthracycline",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    demonstrated significant activity as a single agent in phase II studies. Substitution of epirubicin for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    may offer advantages in terms of patient convenience, permitting treatment in one day per cycle.",
"   </p>",
"   <p>",
"    In a randomized phase III trial that included 207 patients with LS-SCLC and 192 patients with ES-SCLC, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , both administered on day 1 every three weeks, was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    on days 1 to 3 and cisplatin on day 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/25\">",
"     25",
"    </a>",
"    ]. For patients with limited stage disease, thoracic radiation was given after the completion of chemotherapy. The epirubicin regimen was similar in overall objective response rate (74 versus 69 percent, with the etoposide combination), median time to progression (7.6 months in both arms) and median survival (10.9 versus 10.1 months). Hematologic toxicity was lower in patients treated with epirubicin (grade 3 or 4 neutropenia in 42 versus 57 percent, respectively). The combination of epirubicin plus cisplatin is a reasonable alternative regimen for the treatment of patients with SCLC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     THREE OR FOUR DRUG COMBINATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various additional agents have been added to a two-drug platinum regimen in an effort to further improve results. However, these approaches have not resulted in a clinically meaningful benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Paclitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    to platinum plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    regimens is unclear.",
"   </p>",
"   <p>",
"    Two trials in patients with ES-SCLC have failed to show benefit from the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In the larger of these trials, 587 patients with newly diagnosed ES-SCLC were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 to 3) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 1) with or without paclitaxel (175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 1) and hematopoietic growth factor support [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/26\">",
"     26",
"    </a>",
"    ]. Treatment-related mortality was significantly higher in the paclitaxel group (6.5 versus 2.4 percent with PE alone), while the median survival (10.6 versus 9.9 months) and one-year survival rates (38 versus 37 percent) were similar.",
"   </p>",
"   <p>",
"    Based on the available data, the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    to a platinum plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    regimen in patients with either ES-SCLC should only be considered in the context of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ifosfamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least one trial comparing PE with and without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    in 171 patients with ES-SCLC suggested a modest but statistically significant survival advantage for ifosfamide (two-year survival 13 versus 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/28\">",
"     28",
"    </a>",
"    ]. However, a second small randomized trial failed to demonstrate a survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Four-drug regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher response rates and modestly prolonged survival can be achieved by including additional drugs in the chemotherapy regimen. However, these regimens are associated with added toxicity.",
"   </p>",
"   <p>",
"    This was illustrated in a trial sponsored by the French Federation of Cancer Institutes, in which 226 patients with ES-SCLC were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 to 3) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 2) or the same regimen plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 to 3) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1), with all drugs administered every four weeks for six courses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The four-drug regimen was associated with statistically significant increases in response rate (76 versus 61 percent) and survival (median 10.5 versus 9.3 months and one-year 40 versus 29 percent). The rate of hematologic toxicity, particularly febrile neutropenia, was also significantly higher in the four drug arm (70 versus 18 percent), as was the need for red cell and platelet transfusions (45 versus 13 percent and 38 versus 5 percent, respectively). The difference in treatment-related mortality was not statistically significant (9 versus 6 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Alternating and sequential regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Non-cross resistant\" alternating or sequential regimens have been studied to overcome drug resistance if there are a small number of tumor cells that are intrinsically resistant to the administered agents [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/31\">",
"     31",
"    </a>",
"    ]. This strategy of alternating two comparably effective chemotherapy regimens for treatment of SCLC has been evaluated in randomized trials in patients with both LS-SCLC and ES-SCLC. Alternating or sequential regimens have included CAV with PE [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/8,9,32,33\">",
"     8,9,32,33",
"    </a>",
"    ], CDE (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ) with VIMP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/34\">",
"     34",
"    </a>",
"    ], and PE with single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These trials have not demonstrated a survival benefit with alternating completely or incompletely cross-resistant regimens in patients with SCLC, and this approach should only be considered in the context of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     INCREASED DOSE INTENSITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased dose intensity has been studied in clinical trials to take advantage of the dose-response relationship that has been demonstrated in preclinical studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/36\">",
"     36",
"    </a>",
"    ]. Although some of these dose-intense approaches have been evaluated in randomized trials in patients with advanced SCLC, the results have not demonstrated consistent benefit; none of these approaches has replaced platinum-based two-drug combinations as the standard approach for initial treatment of patients with SCLC.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dose escalation",
"      </strong>",
"      &ndash; One of the simplest methods to overcome drug resistance is to escalate the dose of individual drugs as high as can be tolerated without the need for stem cell support. Several randomized trials have compared higher-dose to conventional dose chemotherapy in patients with SCLC [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/37-43\">",
"       37-43",
"      </a>",
"      ]. In all trials, a higher response rate was achieved in patients receiving higher than standard doses of chemotherapy. However, these higher doses were associated with substantially more toxicity in most studies, and most trials did not demonstrate a prolongation of survival.",
"     </li>",
"     <li>",
"      <strong>",
"       Dose dense therapy",
"      </strong>",
"      &ndash; Shortening the interval between individual drugs or chemotherapy cycles has been evaluated as an alternative to dose escalation to maximize dose intensity. Phase III trials have yielded conflicting results [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/44-50\">",
"       44-50",
"      </a>",
"      ]. At least four such trials did not demonstrate a survival benefit from dose-dense therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/44-47\">",
"       44-47",
"      </a>",
"      ], while three trials suggested a prolongation of survival [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/48-50\">",
"       48-50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Cytokine support",
"      </strong>",
"      &ndash; Chemotherapy doses can be increased to a greater degree with routine hematopoietic growth factor support (eg, granulocyte-macrophage colony stimulating factor [GM-CSF] or granulocyte CSF [G-CSF]). Increasing dose intensity using CSFs does not appear to improve survival beyond what can be achieved with maximally tolerated chemotherapy doses without CSF support [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/51-58\">",
"       51-58",
"      </a>",
"      ]. Furthermore, at least two trials have suggested that such an approach may actually have a detrimental impact [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/52,58\">",
"       52,58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"       \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hematopoietic cell transplantation",
"      </strong>",
"      &ndash; Hematopoietic cell transplantation (HCT) from either bone marrow or peripheral blood precursor cells (PBPCs) permits evaluation of the dose-responsiveness of SCLC to the limits of non-marrow organ tolerance. This approach has been studied in patients with SCLC, both as a late intensification following initial chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/59-61\">",
"       59-61",
"      </a>",
"      ] and as early intensification in conjunction with the initial treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/62-64\">",
"       62-64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     DURATION OF CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of induction chemotherapy for patients with SCLC is not well defined; our general approach is to give four to six cycles of induction therapy.",
"   </p>",
"   <p>",
"    A modest survival advantage for prolonged treatment (sometimes referred to as \"maintenance therapy\") was suggested in a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/65\">",
"     65",
"    </a>",
"    ]. However, randomized trials, some of which used maintenance with a non-cross-resistant agent, have given equivocal results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an Eastern Cooperative Oncology Group trial 402 patients with ES-SCLC were treated with four cycles of PE; non-progressing patients (n = 223) were then randomly assigned to either four courses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      or observation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/66\">",
"       66",
"      </a>",
"      ]. Median PFS from the date of randomization was modestly but significantly longer in the topotecan group (3.6 versus 2.3 months), but survival was not significantly better (median 8.9 versus 9.3 months). There were no differences in quality of life.",
"     </li>",
"     <li>",
"      The Hoosier Oncology Group studied the role of prolonged chemotherapy in a trial of 233 patients with ES-SCLC who initially received four cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      plus PE, after which non-progressing patients (n = 144) were randomly assigned to three additional courses of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      or to observation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/67\">",
"       67",
"      </a>",
"      ]. Maintenance therapy with etoposide resulted in a significantly longer median progression-free survival (8.2 versus 6.5 months without maintenance). However, the difference in survival was not statistically significant (median 12.2 versus 11.2 months and one-year survival 51 versus 40 percent, p = 0.07).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     ELDERLY PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of patients with SCLC are 70 years of age or older. Standard regimens have caused increased toxicity in this population although survival was similar to younger patients, while use of single agents or dose attenuation has produced acceptable toxicity but inferior survival [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/68-72\">",
"     68-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated by a trial from Italy, in which 95 elderly patients were randomly assigned to receive either full doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 and 2) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 to 3) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) or attenuated doses of cisplatin (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 and 2) and etoposide (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 to 3) without G-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/71\">",
"     71",
"    </a>",
"    ]. The response rate was higher with full doses compared with the low dose regimen (69 versus 39 percent) and survival was longer (median 41 versus 31 weeks), resulting in early closure of the trial.",
"   </p>",
"   <p>",
"    The substitution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    has been suggested as a less toxic alternative in elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/73\">",
"     73",
"    </a>",
"    ]. A large phase III trial demonstrated similar activity of the two agents in 220 patients with ES-SCLC who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 to 3) plus either cisplatin (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 to 3) or carboplatin (AUC 5 on day 1) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/39/6778/abstract/74\">",
"     74",
"    </a>",
"    ]. The study population included patients 70 years of age or older (92 percent) or those under 70 with performance status 3. Response rates and overall survival were similar with the cisplatin and carboplatin regimens (response rate 73 with both regimens, median survival 9.8 versus 10.6 months, and one-year survival rates 35 versus 41 percent, respectively). Toxicity was similar except for increased incidence of asymptomatic grade 3-4 thrombocytopenia with carboplatin compared with cisplatin (56 versus 16 percent).",
"   </p>",
"   <p>",
"    Special considerations for the use of chemotherapy in the elderly population are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/38/24162?source=see_link\">",
"       \"Patient information: Small cell lung cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=see_link\">",
"       \"Patient information: Small cell lung cancer treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small cell lung cancer (SCLC) usually presents with disseminated disease. SCLC is sensitive to cytotoxic chemotherapy, and the use of platinum-based combination regimens has resulted in a significant improvement in survival.",
"     </li>",
"     <li>",
"      For patients with extensive stage-SCLC, we recommend combination chemotherapy with a platinum-based regimen (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Benefit of therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Platinum-based combinations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest a two-drug combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef66855 \" href=\"UTD.htm?42/23/43389\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef75586 \" href=\"UTD.htm?40/39/41597\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Regimens substituting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      for etoposide are reasonable alternatives. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cisplatin plus irinotecan'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Topotecan plus cisplatin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Epirubicin plus cisplatin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of maintenance chemotherapy, three- or four-drug combinations, and alternating or sequential non-cross-resistant regimens have not been shown to offer substantial benefits compared to a two-drug combination; thus, these approaches are not routinely utilized and initial therapy is usually limited to four to six cycles of induction chemotherapy. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Duration of chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Three or four drug combinations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Alternating and sequential regimens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with extensive-stage SCLC with evidence of tumor response at the completion of chemotherapy and a good performance status, we recommend PCI (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1830?source=see_link&amp;anchor=H5#H5\">",
"       \"Prophylactic cranial irradiation for patients with small cell lung cancer\", section on 'Extensive stage SCLC'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Only limited data are available from randomized trials to guide treatment in elderly patients. We suggest that elderly patients be treated with the same doses and regimens as younger patients, if their overall medical condition is satisfactory (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A comprehensive geriatric assessment prior to initiating treatment may be useful in assessing whether or not an individual patient is a candidate for chemotherapy. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Elderly patients'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"       \"Comprehensive geriatric assessment for patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with LS-SCLC, combination chemotherapy with a platinum-based regimen is indicated in conjunction with concurrent thoracic radiation therapy (RT). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=see_link\">",
"       \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/1\">",
"      Agra Y, Pelayo M, Sacristan M, et al. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev 2003; :CD001990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/2\">",
"      Giordano KF, Jatoi A, Adjei AA, et al. Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution. Lung Cancer 2005; 49:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/3\">",
"      Gaspar LE, Gay EG, Crawford J, et al. Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. Clin Lung Cancer 2005; 6:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/4\">",
"      J&auml;nne PA, Freidlin B, Saxman S, et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 2002; 95:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/5\">",
"      Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999; 17:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/6\">",
"      Lowenbraun S, Bartolucci A, Smalley RV, et al. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 1979; 44:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/7\">",
"      Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/8\">",
"      Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/9\">",
"      Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/10\">",
"      Sundstr&oslash;m S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002; 20:4665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/11\">",
"      Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/12\">",
"      Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994; 5:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/13\">",
"      Joss RA, Alberto P, H&uuml;rny C, et al. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1995; 6:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/14\">",
"      Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007; 97:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/15\">",
"      Lee SM, James LE, Qian W, et al. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Thorax 2009; 64:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/16\">",
"      Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012; 30:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/17\">",
"      Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/18\">",
"      Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/19\">",
"      Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009; 27:2530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/20\">",
"      Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008; 26:4261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/21\">",
"      Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 2010; 21:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/22\">",
"      Schmittel A, Sebastian M, Fischer von Weikersthal L, et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 2011; 22:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/23\">",
"      Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006; 24:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/24\">",
"      Fink TH, Huber RM, Heigener DF, et al. Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. J Thorac Oncol 2012; 7:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/25\">",
"      Artal-Cort&eacute;s A, Gomez-Codina J, Gonzalez-Larriba JL, et al. Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. Clin Lung Cancer 2004; 6:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/26\">",
"      Niell HB, Herndon JE 2nd, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005; 23:3752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/27\">",
"      Mavroudis D, Papadakis E, Veslemes M, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001; 12:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/28\">",
"      Loehrer PJ Sr, Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995; 13:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/29\">",
"      Miyamoto H, Nakabayashi T, Isobe H, et al. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology 1992; 49:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/30\">",
"      Pujol JL, Daur&egrave;s JP, Rivi&egrave;re A, et al. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001; 93:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/31\">",
"      Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/32\">",
"      Evans WK, Feld R, Murray N, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 1987; 107:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/33\">",
"      Feld R, Evans WK, Coy P, et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 1987; 5:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/34\">",
"      Postmus PE, Scagliotti G, Groen HJ, et al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. Eur J Cancer 1996; 32A:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/35\">",
"      Baka S, Agelaki S, Kotsakis A, et al. Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer. Anticancer Res 2010; 30:3031.",
"     </a>",
"    </li>",
"    <li>",
"     Schabel, F, Griswold, et al. Testing therapeutic hypotheses in mice and man: observations on the therapeutic activity against advanced solid tumors of mice treated with anti-cancer drugs that have demonstrated or potential clinical utility for treatment of advanced solid tumors in man. In: Methods in cancer research: Cancer drug development, Vol. 17, Part B, Academic Press, New York 1979. p.p. 4.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/37\">",
"      Hande KR, Oldham RK, Fer MF, et al. Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer. Am J Med 1982; 73:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/38\">",
"      Johnson DH, Einhorn LH, Birch R, et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987; 5:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/39\">",
"      Figueredo AT, Hryniuk WM, Strautmanis I, et al. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985; 3:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/40\">",
"      Hong WK, Nicaise C, Lawson R, et al. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group. J Clin Oncol 1989; 7:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/41\">",
"      Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994; 12:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/42\">",
"      Arriagada R, Pignon JP, Le Chevalier T. Initial chemotherapeutic doses and long-term survival in limited small-cell lung cancer. N Engl J Med 2001; 345:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/43\">",
"      Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993; 329:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/44\">",
"      Murray N, Livingston RB, Shepherd FA, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999; 17:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/45\">",
"      Furuse K, Fukuoka M, Nishiwaki Y, et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol 1998; 16:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/46\">",
"      Ardizzoni A, Tjan-Heijnen VC, Postmus PE, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol 2002; 20:3947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/47\">",
"      Sculier JP, Paesmans M, Lecomte J, et al. A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Br J Cancer 2001; 85:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/48\">",
"      Steward WP, von Pawel J, Gatzemeier U, et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 1998; 16:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/49\">",
"      Thatcher N, Girling DJ, Hopwood P, et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 2000; 18:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/50\">",
"      Thatcher N, Qian W, Clark PI, et al. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. J Clin Oncol 2005; 23:8371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/51\">",
"      Woll PJ, Hodgetts J, Lomax L, et al. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995; 13:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/52\">",
"      Pujol JL, Douillard JY, Rivi&egrave;re A, et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J Clin Oncol 1997; 15:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/53\">",
"      Fukuoka M, Masuda N, Negoro S, et al. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 1997; 75:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/54\">",
"      Hamm J, Schiller JH, Cuffie C, et al. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. J Clin Oncol 1994; 12:2667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/55\">",
"      Miles DW, Fogarty O, Ash CM, et al. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 1994; 12:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/56\">",
"      Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/57\">",
"      Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/58\">",
"      Bunn PA Jr, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995; 13:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/59\">",
"      Elias AD, Ayash L, Frei E 3rd, et al. Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst 1993; 85:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/60\">",
"      Elias A, Ibrahim J, Skarin AT, et al. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol 1999; 17:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/61\">",
"      Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987; 5:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/62\">",
"      Leyvraz S, Perey L, Rosti G, et al. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol 1999; 17:3531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/63\">",
"      Buchholz, E, Drings, P, Pilz, L, et al. Final results from a single center, controlled study of standard versus dose intensified chemotherapy with sequential reinfusion of haematopoietic progenitor cells in small cell lung cancer (abstract). Proc Am Soc Clin Oncol 2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/64\">",
"      Lorigan P, Woll PJ, O'Brien ME, et al. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 2005; 97:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/65\">",
"      Bozcuk H, Artac M, Ozdogan M, Savas B. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials. Cancer 2005; 104:2650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/66\">",
"      Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/67\">",
"      Hanna NH, Sandier AB, Loehrer PJ Sr, et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol 2002; 13:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/68\">",
"      Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 1996; 348:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/69\">",
"      Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997; 89:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/70\">",
"      Shepherd FA, Amdemichael E, Evans WK, et al. Treatment of small cell lung cancer in the elderly. J Am Geriatr Soc 1994; 42:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/71\">",
"      Ardizzoni A, Favaretto A, Boni L, et al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 2005; 23:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/72\">",
"      Yau T, Ashley S, Popat S, et al. Time and chemotherapy treatment trends in the treatment of elderly patients (age &gt;/=70 years) with small cell lung cancer. Br J Cancer 2006; 94:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/73\">",
"      Okamoto H, Watanabe K, Nishiwaki Y, et al. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 1999; 17:3540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/39/6778/abstract/74\">",
"      Okamoto H, Watanabe K, Kunikane H, et al. Randomized phase III trial of carboplatin(C) plus etoposide (E) vs. split doses of cisplatin (P) plus etoposide (E) in elderly or poor-risk patients with extensive disease small cell lung cancer (abstract #7010). J Clin Oncol 2005.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4633 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6778=[""].join("\n");
var outline_f6_39_6778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BENEFIT OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Extent of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect on survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Active agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tumor lysis syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PLATINUM-BASED COMBINATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H116211046\">",
"      Platinum plus etoposide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cisplatin plus etoposide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Carboplatin plus etoposide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H367024309\">",
"      - Cisplatin versus carboplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Camptothecin-based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cisplatin plus irinotecan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Carboplatin plus irinotecan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Topotecan plus cisplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Epirubicin plus cisplatin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      THREE OR FOUR DRUG COMBINATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Paclitaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ifosfamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Four-drug regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Alternating and sequential regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      INCREASED DOSE INTENSITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      DURATION OF CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      ELDERLY PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4633\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4633|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/9/11422\" title=\"table 1\">",
"      Cisplatin 60 plus etoposide for small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/39/41597\" title=\"table 2\">",
"      Carboplatin plus etoposide for small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/23/43389\" title=\"table 3\">",
"      Cisplatin 80 plus etoposide for small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=related_link\">",
"      Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8951?source=related_link\">",
"      Experimental approaches to treatment for small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3578?source=related_link\">",
"      Extrapulmonary small cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/38/24162?source=related_link\">",
"      Patient information: Small cell lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=related_link\">",
"      Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1830?source=related_link\">",
"      Prophylactic cranial irradiation for patients with small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38469?source=related_link\">",
"      Role of surgery in multimodality therapy for small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=related_link\">",
"      Treatment of refractory and relapsed small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18881?source=related_link\">",
"      Treatment protocols for small-cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_39_6779="Indications biopsy genital wart";
var content_f6_39_6779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for biopsy of external genital warts",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Uncertain diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of response to standard treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prompt and frequent recurrences after therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient is immunocompromised",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rapid growth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Individual lesions larger than 1 cm or confluence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of atypical features, such as pigmentation, induration, fixation&nbsp;to underlying tissue, ulceration",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from APGO educational series on women's health issues. Sexually transmitted infections. Human Papillomavirus: The OB/Gyn's Role. Association of Professors of Obstetrics and Gynecology, Crofton, Maryland, 2002.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6779=[""].join("\n");
var outline_f6_39_6779=null;
var title_f6_39_6780="ASRM revised guidelines for embryo transfer";
var content_f6_39_6780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American Society for Reproductive Medicine guidelines for number of embryos (fresh or frozen) to transfer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristics",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of cleavage stage embryos to transfer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of blastocysts to transfer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;35 years old, most favorable prognosis*",
"       </td>",
"       <td>",
"        1 to 2 (1 recommended)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        other women &lt;35 years old",
"       </td>",
"       <td>",
"        &le;2",
"       </td>",
"       <td>",
"        &le;2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35 to 37 years old, more favorable prognosis*",
"       </td>",
"       <td>",
"        &le;2",
"       </td>",
"       <td>",
"        &le;2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        other women 35 to 37 years old",
"       </td>",
"       <td>",
"        &le;3",
"       </td>",
"       <td>",
"        &le;2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38 to 40 years old, more favorable prognosis*",
"       </td>",
"       <td>",
"        &le;3",
"       </td>",
"       <td>",
"        &le;2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        other women 38 to 40 years old",
"       </td>",
"       <td>",
"        &le;4",
"       </td>",
"       <td>",
"        &le;3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        41 to 42 years old, favorable prognosis and all others",
"       </td>",
"       <td>",
"        &le;5",
"       </td>",
"       <td>",
"        &le;3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * (1) first IVF cycle, good embryo quality, and sufficient excess embryos available for cryopreservation or (2) previous IVF success.",
"     <br/>",
"     Transfer of additional embryos may be considered for women with a less favorable prognosis or who have failed at least two IVF cycles.",
"     <br/>",
"     In donor egg cycles, the age of the donor is used to determine the number of embryos to transfer.",
"     <br/>",
"     Since all oocytes may not fertilize with gamete intrafallopian transfer (GIFT), one more oocyte than embryo may be transferred for each prognostic category.",
"     <br/>",
"     There are insufficient data to recommend a specific limit on embryos transferred in women 43 years of age or older.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: ASRM Practice Committee. Guidelines on number of embryos transferred. Fertil Steril 2013; 99:44.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6780=[""].join("\n");
var outline_f6_39_6780=null;
var title_f6_39_6781="Prolonged exposure therapy session outline";
var content_f6_39_6781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F60594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F60594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prolonged exposure therapy session outline",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Session",
"       </td>",
"       <td class=\"subtitle1\">",
"        Session outline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        1",
"       </td>",
"       <td>",
"        Present an overview of the program (10-15 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss the treatment procedures that will be used in the program",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Explain that the focus of the program is on PTSD symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Collect information relevant to the trauma using the Trauma Interview (45 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Introduce breathing retraining (10-15 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assign homework (5 minutes)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        2",
"       </td>",
"       <td>",
"        Review homework (5-10 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Present agenda for the session (5 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Educate client about PTSD symptoms by discussing common reactions to trauma (25-30 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss the rationale for exposure with emphasis on in vivo (10 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Introduce the Subjective Units of Discomfort Scale (SUDS) (5 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Construct in vivo hierarchy (20 minutes)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        3",
"       </td>",
"       <td>",
"        Review homework (10-15 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Present agenda for the session (5 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Present rationale for imaginal exposure (10-15 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conduct imaginal exposure on entire trauma memory (45-60 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Process imaginal exposure (15-20 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assign homework (5 minutes)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        4",
"       </td>",
"       <td>",
"        Review homework (10-15 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Present agenda for the session (5 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conduct imaginal exposure (45-60 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Process imaginal exposure (15-20 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assign homework (5 minutes)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        5-9",
"       </td>",
"       <td>",
"        Review homework (10 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Present agenda for the session (3 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conduct imaginal exposure to \"hot spots\" progressively more as therapy advances (45-60 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Process imaginal exposure (15-20 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss in vivo exposure (10-15 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assign homework (5 minutes)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        10",
"       </td>",
"       <td>",
"        Review homework (10 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Present agenda for the session (3 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conduct imaginal exposure to entire trauma memory (20-30 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Review progress and make suggestions for continued practice (30 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Terminate therapy; saying good-bye (5 minutes)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Foa EB, Hembree E, Rothbaum BO. In: Prolonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences, Therapist Guide, Oxford University Press, New York 2007. Copyright &copy; 2007 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6781=[""].join("\n");
var outline_f6_39_6781=null;
var title_f6_39_6782="Calcium intake and balance";
var content_f6_39_6782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relation between calcium intake and calcium balance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 266px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plot of the regression lines relating calcium balance to calcium intake in premenopausal or estrogen-treated postmenopausal women (top line) and untreated postmenopausal women (bottom line). Positive calcium balance was achieved with calcium intakes above 1000 mg/day in the former group and 1500 mg/day in the latter group.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Heaney, RP, Recker, RR, Saville, PD, J Lab Clin Med 1978; 92:953.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6782=[""].join("\n");
var outline_f6_39_6782=null;
var title_f6_39_6783="Trimalleolar fracture";
var content_f6_39_6783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Trimalleolar fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 320px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFAAgsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD53ooooAKKKKACiiigBRSikFKOtAFy16Cr1UrboKtKcjFAF6yGZRU/iIf6OgqGx/1gqbxB/qEp9CH8SOdWngcimjqakiGXApFmzYphFrWjGFFZ9mOAK0l4ABFWjKQrn5cn0qBsZ4qVgNpFRN1piQjDnJqBhyasNkAcVDJjr60hogbHTFRkcipWGPekIAFIoCPlGOtN6saccALzTFIzSGTt/qSB6Vyl5xcP9a6ocoe1ctfDFy/1oYRK1FLSUigooooAKKKKACq2o/8AHnJ+H8xVmq2o/wDHnJ+H8xQBi0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAdHRRRQAUUUUAFFFFAC0opKcO1AF234WpozUMAO2rSJ0IoAv6eP3i/WpfEI/dLTdPGJFqTX/wDVr9KroQ/iRzgqe1GZBUI61csFy/41JZt2anj0xV1Tu71XiXauB1qZBtB9atGLHN7VFJ1p7E5GKQ88GgENbpUDYxzUx4qFjQNEb8LUTEbeKllJIFR47+lIpDT0FJ6mnN2pnfApDJkPy49q5rURi5aujXjGPSue1MYuWoYIpmiiikUJRRRQAUUUUAFVtR/485Pw/mKs1W1H/jzk/D+YoAxaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOjooooAKKKKACiiigBacvWm0+MZYUAaFuvy5NXYhnFVouIhVi3fJoEaViv7xaTXxjb9KmscZqLxBzt+lV0I+0c33NaWlplhWceta+lrUlvY1osk57VKo9jTIRhDipj15qzJkbr1puCTxTieeaFHXNADCBjnrUTr2qcj5T61E4xn0zQNFZ8k8U3qwwKe/A+pqMEZ96kpDSSWqNuGFPxzTX/WkMcrZP0rD1UYuDWwpwwFZesDEwNA0Z1JS0hoGJRRRQAUUUUAFQ3qNJbOiDLHGB+NTUGgDF+xXH/PP/wAeFH2K4/55/wDjwrZooAxvsVx/zz/8eFH2K4/55/8AjwrZooAxvsVx/wA8/wDx4UfYrj/nn/48K2aWgDF+xXH/ADz/APHhR9huP+ef/jwrapaAMeLTbuV9scWW/wB4f41M2h6ip+a3x/wNf8a3tM/4+lrbucfSgTZwh0e+H/LD/wAfX/GlXRr9iAsGSf8AbX/GuubpT7df3q/WgDmR4V1kgEWfX/pqn+NL/wAInrWCfsXA/wCmqf416jCuIkOT0qdRnIz1GK05EYOq0eMy6RfRMVkgww7b1/xqI2FyP+Wf/jwrudcj2XbfSsRx8xrNm6d0YH2G4/55/wDjwo+w3H/PP/x4VuYooGYf2K4/55/+PCj7Fcf88/8Ax4Vt0lAGL9iuP+ef/jwo+xXH/PP/AMeFbVFAGL9iuP8Ann/48KPsVx/zz/8AHhW1SUAY32K4/wCef/jwo+xXH/PP/wAeFbNFAGN9iuP+ef8A48KPsVx/zz/8eFbNFAGN9iuP+ef/AI8KPsVx/wA8/wDx4Vs0UAY32K4/55/+PCoJEaNyrjDDqK6CsbUP+PyT8P5CgDaooooAKKKKACl4wOKSlFAAKmhHzioR1qxEMHNAF0tiJRToCQ4PaoCc49KmioA39P8Amwag11vmHsKsaX90e1VNc5f8KroZ/aMIcsPrW1py/pWMo+cfWt7TwAppIuWxpwjCVJIMioozx71K3I9qsxe5CRuHvTgOOaRQAKcOc0gGnBxioX4U59an2gfdqGTn60DRXfkAVCBwcVPLwBUSjtUstEWSCMU1z82akK4YGomGQTSGN3dD6VQ1gZ2NV0/d4qrqYzbqfSgZkUlLSUDEopaSgAooooAKKKKAEooooAKKKKAClpKWgApaQUooAtad/wAfSVuXWN1Yenf8fcf1rbuPvZoEyt9KkiGJFpCOakjGGFIDqYgDCnXGKfGVVhnNNj4hTHTFGDn8a3OQ57xPHicMOlcw/wB412fieMtbK/pXHSfeNZy3Omm7xIiKQ040hqSxtFLSUAJRS0UAJRRRQAlFLRQAlFFLQAlFFFABWNqH/H5J+H8hWzWNqP8Ax+Sfh/IUAbVFFFABRRRQAtFFFACr1q0owgre8R+AvFHhmNZta0W7t7dlDCcJvjwfV1yAfY4NYYGVxQA5eSKtwjoKpoMHHpV2EZI9KAN7TRxiqeu8N+FX9MGQDVHXsbjiqexkviMKLmUVvWX3TWJbLmTNblmCaSLkXoR096sMOBUaDCipSOBmrMWR4ytJjnpzUiqTzS46E0BciPXpULAE+lWDwSKhdPz9KQ0ysw3k+1QgYUk1Y6buKh2k8GkWiFsk01gMMT1qXHJqGXpgUiisTyKjuhvt3HpUjgBvXFR/eLL6ikMxjSU5xhiPemUDCiikoAKKKKACiiigBKKWigBKKWigBKWgdfWigBaUUgpaALWnf8fUf1rZnPzmsfTRm7SteQZcigTGgZqaBf3ijPFRgc1Pb/fUnqKEJnTJ/qUGO1I3DDvVy70+809Yor+1ntpGXKrLGVJHqM9qpzKQvNbHJ1KmrR+bp8q9SOa4Rly5Fd8G81ZY+uRXDzxmO4kBHRjUTOilorFVhzTDU0o5qM1BqNptOpKAEooooAKSlpKACiiigAooooAKKKKACsXUf+PyT8P5CtqsXUf+PyT8P5CgDaooooAKfEwSVGZFkVSCUYnDD0OCDj6EUyigDp/+Ek0r/oSvD/8A3+v/AP5JpV8SaWCCPBXh7j1mvz/7c1zFLQB9f+J/2jPC9nB5ei2l1q9w6cgjyYlJHQswyfwUj3r5v8beJj4p1Vr3+ydM0vP/ACzsIfLDe7ep965aEHNTnpQAd81o23zKKoLVq2lKMBQB0umjEYrN1n5iRV/T2HkgiqGo/M8gqnsZL4jMtFwwzWzZ8Ee9ZUI+YYrZshuK4HNJFyNAD5RxTwtOC5Ye3apQnFaHO2Q4wOBQRjnFTFCO3IphHPHNAFduQSBzUBHzZPWrJU7z6VE4weKTKRXcDBqHpx3NTvnoR1NRkfMTipLRBIAP5VA2SCTU0voOpqCTOMd6TKRUfkk96hB2tk1M5warOaRRRu12zNUFWrsZw1VaBhSUtJQAUUUUAFFFFACUtFFABRRRQAUUUtABSiiigC7pg/0pa39OksY73dqlvc3Ftg5S3nWFs9juZHH6VhaWP35PoK0xy9AjoxdeE8/8gXXf/BvF/wDItWIrrwpvDDRdb47f2vF/8jVzSjnirMS9OKaJbPr3xT8QfBcVh5F7LBqqsuRbRRCYdO5Pyg/jmvnvxlqOlX180ui6UNMgOR5fnGTcfXnp9BWVaJmMcDIGDVa8+abAHStErGDnzOxnwuRID0ycVieILfyr9iB8rjIroGj8teRz1qlrMX2ixEijLRnn6VLWhpF6nKzjGKhNWrpeBVYioNhhFJTyKaRQA2ilxSUAJRS0lACUUtFACUUtJQAUUUUAFYuo/wDH5J+H8hW1WLqP/H5J+H8hQBtUUUUAFFFFACinCm05aALEI4qTvUanApwNAEqdcVYVfnFV061ai4oA1LOXbEVqC4cneT3og64FMn5JoJtqQxcHit3S1GQaxbdfmrf0pMBjVR3JnsaES5OTUyr15oiTIBFSxoTk1ojnbGbPeoWUYY1aC8E54phUZxQCZTCE9etQyLgj3q8yAA+uaqup3d80mUmVpFw2e9V5FyTjrV114B71C6ENx3pFpmfOCMetVXz1NX5+pwATVKUc1DNEUpPvGoJAOtWJR371Xl6UiitKNykVTNXm6YqnIMNQMZSUtFACUUUUAFFFFABRRRQAUtAooAKdikpwFABijFLSigC7pvyh29eK0YRms+zGIx7mtO1XNAmTRjnvVyFDuUDuaIocsKuRx8Z5BHSqSMpM0lIWPAPJHNOgi3Ru38QNVbbJbkc1q264hJxg+larU5paGTdodnJ+aqwTho2xtcYNaU8RbJY+9Z84weOvrUs0i+hx+oRGNnjI5U1QroNdiDASgc/dasA1kdSd0NIpDTjTTQMaaSlpKAEoNLSUAJRS0lACUUtJQAUUUUAFYuo/8fkn4fyFbdYmo/8AH5J+H8hQBtUUUUAFLSUUALT0FMFSgYFADicGnpyc1F3qWP60ATx8GrsIxVSIdKvQqSM0ATwg/MahkbJNWIulV5BlzigRJbDJrpNOj2wA46muftVJZR6murghIto1Aq4GVRksXOe1SxCkiibvU0ac1oc7YjAY6UwqM9Ks7SeMcUzYA3egCo64B9e1VWXByCc1flGCfSqzDLCkykypMc49agPrmrUoHp3qErlTUlooXHDEgdaz5e5rSnjNUpUIJFSzWJnSCqstXZ1wDVGSpLIiagmHcVMaZIvynFAyrRSnrSUAJRRRQAUUUUAFFLRQAUUUUAKKcDTKWgB+aUU0U4UAaFp0Wti1Ssix5xXQ2ahgDjmmiZOxbhABGO1XI15xTrO0Z9uBWzDpTgZcAD1rWMWck5pGRB8rqfStmPJjGAeealh0fdIq5HXmtYaU3OwAgcDntWkYswnUTOamXJNYt4cOw7ZrrLzTJk3NtOMVy9/byIWypqJpmtKSZiXa742U/wAQrmpUKuwNdPdqVB4NYFyoL5FYs7Y7FM0009hhjSMjBQxUhW6EjrSKGGkp1IaAEpKWkoASkNOpDQAlJS0UAJRRS0AFYmo/8fkn4fyFbdYmo/8AH5J+H8hQBtUUUUAFLSCloAeg5pzHJpBwtAFACip4hkVEqmrEQxQBdt48gVowwHZmq9so2DNa8CgxU0iJOxngbcioHT959KsXDASfTrUSuGJakNFuyxuXPrXb2kQktUbHTrXF2IBk5rt9GIe3298VrA56xOkCk59qetsCDtxVyNAABipBGorWxz3KP2VtpxUDWrAitYrgEDioCp5HaiwXMuW2bBziqptuc5wK1pF4+YmoGjBwOaTRSZmPbKByaglhQKQo6VrvCCOapTRnawCnnvUtFKRh3IIBrMnJ5roLm3bBI7VjXMNZtG8GZUp7Gqc64OauXIwT3xVN352tUGyKr8U088U+Qcn0qIHBoGVpBhiKbU9yPmBHeoKAEopaSgApR1pK1vC1rHfa5BbSjKSLID/3w2P1oSuJuyuZVFT3tu1rdywP95GIqGgYlFLRQAUUUUALTxTBTxQBd09syBfWuz022yqNkAdya4OMlWBU8iur0TV2CoshHpyKqNr6mdRNrQ7iwjEaqsa5zxmtu3smkA3Y59TWVo2s2EMebohVxkuelWJ/GlhA+LCHzz/eY8V0pxS1Z5sozk9EdJpWk4LHA54rSOnlQSAK5Wz8ZahIAsUEQLdAqE1v2mratJgyWalfUgitItPYwnGa3KmoQSJER61yepRL8xkXB9q7+9ug0A8+ExnGTg5rj/ENzaxQMMjcama0LpN3OA1ZVdWWP7xP5Vz9zCsWA+cZ5x1reubqLz2ZsfUVharOsg+T1rke560E7WNzQ/8AhHdy/wDPx/09f0/h/rUvjhbRrayE8jx8tsMUYfIwP9ocdK4g9aRmYqFLEqvQE8CvT/tNfV3QdNa9tPv/AOHPL/sl/WY4hVXp31+7/hiadLMRkwT3Dv2Dwqo/MOf5VVpaSvMk03orHrRi4qzdxKKKKkoSkpaSgBKKU0lABRRRQAViaj/x+yfh/IVt1iaj/wAfkn4fyFAG1RRS0AFAooHUUAS0opF5NSAelAD0GPerNtGS+aijWrtupwOaAL0CgKBVuNiiHPSoIkwBkU8kn5VGaaIZm3c2WbmoreQg4PQ0+W1mlmOFpRZXCf8ALM/hSK0NOxkUSrmu50Nozg7wD6E153GkkbAlWH4VsWGoCIjcSKuErGNWHMtD1JI1ZAVKn2zSmJgenAri4NYOAFb8a07bXSABISfcVupJnI4NG9JGcE4qu8ZwMDimLqkbAHfmmvqCgfeFO6FZjWXg9c1Gy9yORUT6iofkjmmvqSgE4FK47MkK89DTdhJwV4qrLrCgHGM/Ss2bXXVvlFS2ilBs07i2LdErFvrQKCWGKjfxJMuelRDxAJztmjH1qW0zWMJIw75BGSAOKx58fjXSaiI5oy8RyK5q5HNZNHTF3RATSQwyTzbIkLNgnHoPU+1dR4Y0KG+sJprxSRIdsZBwVx1I/H+VZXiCKTSpTYRKUiYBjJnmb6+wPb+ddssDOnRjiKnwv7/6ff8A4Y4Y5hTq1pYan8S+7z9bdv8AhzHm5QH0qtUpORUVcJ6AUlFFABVnT7uWwvI7m3IEqZxn3BH9arUq9aA3J7u4mu53nnO52PJxUNbGpXLwmJEVPszxAquOvH86xzQJBRRRQMKKKKAFFPFMFOFAEinFdPoK27wl5OGWuXFdF4ZUCXLjI7CmtyZ7G+uh3GrOp3GOP+EAda7Hw14BjgKz3gJjHY8lq0vClohRZpOVrr1nGAB+VdcKS3Z5dXET+GJJpLWNmojt7SKHbxnaMn8a2A6upyAfwrEYhse1SxSleA30zW6ON6i6vbRSRgbcY7ivNfFdqCxBXKj0r0K9usgj+L26VyWtRBlJ61E1dGtF8rPH9Tj2SsF6A1mSjKkV3OqaK0u4xdT2rjbuB4JTHIMEVwyjZnsU5qS0MlqYalfqaiNSajaKWkoAKQ0tIaAEpKWigBppKdSGgBKKKKACsTUf+PyT8P5CtusTUf8Aj8k/D+QoA2qKWigApR1pKUdaAJY+TUo4NRR9alH60ATRHkZrTtBgCsyFckCtLcII+vzGgTLqyBmCKOa0beNY4ycfNWNZsx+bua2LcMyiqRnND4YN3OOavwwHjipbSD5Rmr8ceDjFaJGMpEMdoj43KD+FSNpMDdYx+VXIY+far6IAoJq1EycmYkejwZ4jIqwuiQnGGcA+9bflYAxjmpRETgCnyolzZhpogUcSPSPpJxxM9dAIm5pjxEAgijlQc7OXuNNfnEjA1ialb38CExtuUdsV3/kZJyKrXNqHU/LUuFy41LHmSXc2fnPPfNSM3mqeSD61b8R2LW9wZY1wpPIrNt5RuFYvR2Z1qzV0VJzIjEGoVmNbN1bGZNyjp1xWQ0exiCKlopO5NDOeQTVG52tMFZtqk4Leg9atog5bOKpXaEHcKEM2rvxV9nt0tdJh8uONQokkGTx3x/jXM3d1PdymS5leVz3Y5qN+tMNdNfF1cRpN6dun3HNh8FRw2tOOr69X8wY8UynGm1zHUJRRRQAVc0iGO41CKKfPltuzg4x8p5qnSqSDkEg+1AM0zPby2iwXDOGgY7HUZ3L6VSupFlmZkG1ewqGloAKKKKACloooABThSClFAE0S7mArqfDdufORTwCRzXM2wywx1zXaaKyRomcZP6U47kVH7p6Lo12EAQHAHGK3ku1z1H515tDfeQ+AckccVbOtMIwAxHFdSqWPLlRbZ6A+qQxKSxy3YeprPuNcZtyoNv8AOuIj1OR5CxYnsKtfat5G88+tP2lxewtudRHqm1csc/Wqd3qEM6EHHPasUyHnBqo+4uNoyD6UnIapouNOYpeOfTNYviG2gmhMrIASO1a4tJNm5m7d+1Yms3Ykt2hhw2DjNRLbU3p/FocHdxBHO2qhrWvLdgSWrPeIiuc9BFeinlKbg0AIaQ07FGKAGYop+KMUARmkNPIphoASiiigArE1H/j9k/D+QrbrE1H/AI/ZPw/kKANuiiigApR1pKKAJo+tWEUtVeI8itSwjDyDNAE1jbcGQjgetQXj4citLVbyC2tlhhIMnciueeVnfJoEtdTc09v3a10unxFgCRXMaV820V3OnwARg+1XBGVV2LNtFwP0q3GnOTSQryB6VehiGPWtkjkbFihJAH4irRhICcd6s2tuWAJ7CrZgGB6irSM2ynHGatpHk5xT0hyenPrVsRcgY5p2FcpPEO1MeE8jFaTW/OagkjKk4oFco+UcgU/7LuB4NSPkN9DV23X1FFh3PO/GsAiUgjHevOo323B9M16348tPNiyPSvI5YzHOQRyDXNVWp3Yd3idRZgC1yf4+lZl5atuZgM1rwoHtYccfLROPLXAGQaLXQJ2ZzDYQEYPNRSIGjJJ4rXuYFOTjisa9wgI6VDVjZO5jy4EhxUVPfljTKRQhpKU0lACUUtJQAUCigUAOopKWgAopaKAClpKcKACpI03fSmouevSrCDHQUATwKAR2rWtZthBHUVlovGe9TI+08UCaNqO52nI69M1KZ238c1jpJyPStjSTHJJscgZ6E1SdzOStqTxSPn5cnvWjbbpAOpPpio2t/LDOjK/bCnpUV3qptUWO3G2Q9T6Va03MH72xv2lnI7Dnr0ya3YNOjt4TJNtC9STXH6RfFI/Omy79snrTL3VdQvJMI5CnjHYD6VopJK5jKnKTtcl8Raw884s7BDgnGB1NVjp/2W1AlOZTyx9PatTSdPNvE07pmVurEc1U1RmfIOQKlq+rLi0vdictforOcdqyZ1AzW3dhVBwayrjnqKxZ2RM5gKjIqw4waiYe9IsiIpMU80dqAGYpcUtFADHHFRGrFQyDBoAjopaSgArE1H/j9k/D+QrbrE1H/j9k/D+QoA26KKKACiiigBynFTrcOBgGq1OFAD2YscscmnIMkUwVLF96gDf0Jd06L616JaQ4RVX8a4Pw1HtcSnoDgV6Ppw3oDjn1rWmjlrvUsQ25yFxzV+GEgcLyTT7WId+Sa07e1ZgMit0jkbIYAVIGKuQxk9R0q5b2BJBPUVcWzYGqsRczY4sNnFWCnzA1dFofSnNbnA4p2C5nOD+dVpOW4rWkg4qk9vtbOKVgMt1Ic/WrdqPl680lzHgE96W2YAYagZk+JoRLbsrdT0ryfWtNdJC6rwDya9k1OMTRsMZPauF1iNUgkjcc1lUjc3oz5Wc7bSEWcY7jilmc7STzVNHJhYA42tUM96I4+uaxudPLdjru5SKPk9q5q+uhITt5NJf3TTOeeKpGpbuaxVhppKU0hpFCUlLSUAFJS0lABRRRQAtLSUtABSikpRQAtKKB1q/aWRmQj+I9BQBDEhPNWVj9qms7YkFSMMpwatm1YCgVyiOKM1PLGUHNQ8E0AOV8VNBKRyMiq3U4FWUAjjLyEBfegGSC5e2IlRyJM5zmokvWuZ8ydT1PrVGaVppNsYJ7VpWVhLGMlSZP5UCdkdHG6R2aJuAb9a6PRdOhCrLLk9+a5CytiHVpmLEHoK7WCUvGAoKoo5reGu5x1tNEWb++4KjAQdBXI6nebmPPFXtXuR8wHQVy93LuJ+Y80TkFGn1K93NuJqhI241NIw/Gq0hOKwO1IhdvxqM0rUwmgYGkxRQDQAUYpaKAGkc0kq5QH0qTHenhcxn0oAoGkpzDBI9KSgBKxNR/4/ZPw/kK26xNR/4/ZPw/kKANuiiigAooooAKcKbThQA4VPEvNQp1q9boCwoA6jw8vzxIcY6mvQ9OX5toHB6VwPh1CZV+tel6Hbs2GYdK3pbHFXepr2FoVwW6Gt+zgyASOKr2kTHAwMVsRR/Kq4roSORsEXAAC8VMsf51LHEelTrH+dVYi5XEfsaUIfSrIQCgrQIpyQgjgVUlgwMkVrMtROmRgiiw0zmbyEnOB3rPkHl/XNdJdW5wTise4tHJJxwallpmTeSERF1Ncxq8QuEZsYwM118tofLYNwK5bxPPFZ2jqp5IqJbGkN9Dzi4jMckoBxk5rIviCpGc1rXMqvubqawrrvXIz0Ymc/U0ypH61GaRYhphp5phoASiiigBKKKKACiiigBaKKKAFFOFIKcOtAE0KcZrT08skqtnvVS1jMuNvTvWvFbELkDgUCbNSWzLqLu0AJx86+tQEiRcpnPcHtT7GeSA/ITj0q7KLa4Xcf3cvqtXa5i21uYlyvBGMVnlCGxW3LA75Ebo57Z4rAvTMs22XjHYVLNYu5Yhi53N0HYdTTxp11fzKPlUdFBPAqXTFRsIT1rfFpJboGX7vqKErkylYs6P4bsrCIPdXKPOfQZA9q0F061lYnzcjoCvFZNvcYfa/PuasS3ggIx0HUVqmjmkpt7mrb6PbQsHeXdjnFP1C+t4ItkbdP1rkNS1qVgUibAPpWHLeSOTljz70OolokONCUtZM2tRvvNkJ5xWXJLg8HIqr9oYDBNRO5rJu51RjbQnds96gkPNM3HPoaaTSKEamGnmmkZoASkpcUYoASkp1JigByHNWD8sX1qGNakn4UUAU58bjUNSSHJqM0AJWJqP/H5J+H8hW3WJqP8Ax+Sfh/IUAbdFFFABRRRQAU4UlKKAHqavWXzEetUBV2xYq60Ad34UhaWZAB1r1XTUAVVXjFcD4AjWVmbHQYr0ezQCRQO1dVNaHnV3eVjc05QcfrWvEg61n2K4XNatvgjBrdHKyRFqQLxTlT0p4SmIYFFKV4p+KO1MCIgflULirBHGajak0BSuUJUn2rHuJAvB4rpGQMpHasO/sSzcdKTKTOX1W9Ko2zHSvLPEF69zMwzkV61qWl5jmycZXAxXmOr6UYyXj+Zc81hUudNFpPU5ORPkNZN4vrXQXMZ3EVi3y8muZndFmPL1qOpphxUJpFjTTTTmppoASkoooAKKKKACiiigBaKKUUAKBk1ZjjBx3NRxrWhZw7mHHFAD7a1uEIktwW9Vrf04mddrKFkHVW4NXNCjWMAlcgcVvtplpdEOw2v2ZeDWkYN6nPUqpOzMJLTBPGDVe6gIYAA5PpXTC0MJxIyyKeh71kXfktMx3HI6BfWqcbGcal2Z0UaxsTIdzYPHYVnXsEbsFUAt1Jp9zO+5lDBQDjikgHPJ3ZrN9joSa1IP7Ol2b7diGHYHFa+g69LhrLUEBdfuseD9KbDIFXHbtVPV1STbOnE0fUjuKa01RL9/RmlfTQbsxHB64rFu7xmcgHj61TkuGOck5qF3yc1Ldy4wsSTPu5qsTinO/bHFR59aRYhalVqaT60oFAD8cUwnNLmkoABS49qQU4UAJikx7VIBmkIoAZilC04CpI0JPSgBYkxyahuW5NW3wowO1Z9w3NAFc9aaacelNoASsTUf+PyT8P5CtusTUf8Aj8k/D+QoA26KKKACiiigBaUUlOFADhVmDgjiq6DmtbQrB7+/hgQZ3MM+woBux6z8OLTytF+0P1kOR9K7ix4fnk1iWVotrbQW0YwkSgEitXTiwZnY59BXbFWVjypvmbZ1FscRjjFaEB6CsWCQ7UHQmta2PArRGTNKM1MozVaFulWU9qokUr7UbeaeBS460CIioxzUZUVYxTWWgZAExWfeA84rV21RuVyKQI5vUVwj56YrhL62GyQgZUk8V6HqcZ8thXKX9tsibjoKzkjWLPKtSi2O4HrxXNXq/MRXY6wgE7gdK5a9T52rkmj0aTujDnXrVRq0Lle1UHqDYjNIaU0hoAbRRRQAUUUUAFFFAoAWnoM0wc1ZgTccCgC1aQGRhxW3b2uwr6d6j0myl4ZMMP7prbSASMowRzyp6mqSuZzlYntB5UYz35q7HdMMnOcdKgaNzkBfl9MVDMDHwPrWmxztcxcuNQJQlmxgVhxSGV3xnOc026JdwQeBTtN2vMxXp3+tS3dlxioq5n3sflz4YYzzUPmFDgfjVrXpN19tUfdUZqgzDOah7m0dUWXnwtVnm55P4VFI/eqzMTnJpFJCzEK/sehqIMCetI5yMHpUB60DLBB7HNJtJqvmjcfU0AWdvfNHA71VzRQBa4pRj1FVM0uaALmF/vCnqqkffGaogmno/rQBdCe4o25NRxsa19F0XUdYjvpNNtWuEsbdrq4IYDy4l+8xye3tQBnJAXORU6qsackZphfb1I+gqW1sb7ULW+uLG2kmgso/OuHQcRpnGT7ZoEUriUDODVBzk5pzNuOTTDQMQ000prU8U6BqHhfXbrR9ZiWG/ttvmIrhwNyhxyODwwoAyKxNR/4/ZPw/kK26xNR/4/JPw/kKANuiiigAooooAWnCmipIxk0ATRLmvUPhhpBHmXkqdsLmvPtLtjcXUUSjljivojwppcdlpkMZHJUGtaUbu5z4mfLG3cURkrjuav2sG1B7VoJYxPjHBq5HZALjNdVjzmyjDw4Fa9t2qNbEiQFauxW7DHHSqSJbLEI5FXYxxUMMWMZq0oxVEjgKCKAfWloAQimkU+k9qAIyOKpzJnNXmNVZe9AGLfQls965bX42jtHC/ePArs7vABJrmdWQS5yM4qJI0izybU7SQM2RmubvrcgnivT9QtVy3Fcrq1kuGKiuecDrp1Dzq9TBrKmGGNdJqEG1mBFYN2mDxXOdqdyoetNNOPWmmgYlFFFABRRRQAUUVHcS+TC0mN2O2cd6AJlGTWnpyZbBHWubXVcf8sf/AB7/AOtWhY+Jltsb7LzP+2uP6UAzt7RjAoKnJrbsJhcf3d3oa89HjaIf8wv/AMmP/sacPHIQfu9NKn18/wD+xrRSSMJQcuh6TJPGqbZ1eF/Ujj86zbxzsypDA/xCuWi+JWIvLm0kSj3uP/sapXfjiGb/AFWk+Sfa5yPy203JERpyT1R0cjZ+Vep4FXrCBbS2eSTh+prgD4sYnItMN2Pm/wD1qsS+NnlhCPZcjqfN6/8AjtSmjVwbVjfun82RnIyW61TaM+lYX/CUjPNn/wCRf/rUreKwRj7F/wCRf/saktKxquvaoCOaym8Rhj/x6f8AkT/61MPiAc4tMf8AbT/61Io1HFQv14rLbWy3/LDH/A//AK1MOr/9Mf8Ax/8A+tQBqUVl/wBrf9Mf/H//AK1H9rf9Mf8Ax/8A+tQBp0tZX9q/9Mf/AB7/AOtR/a3/AEx/8f8A/rUAatFZX9rf9Mf/AB//AOtS/wBrf9Mf/H//AK1AGqKBWV/a3/TH/wAf/wDrUf2t/wBMf/H/AP61AGwJGHevU/gbe2n/ABWNlf6lp+nPf6FPaW8l9cLDG0j4AG5j79u1eKf2t/0x/wDH/wD61H9r/wDTH/x//wCtQB9CfDvR08L3utPL4s0KW8S1ilgh0/UbXbcDeQymeZGWPaBkgDJBHNdefEOnL4s8Z2/hjVNAtrjUdGt5bcmS3MMl0v3hvYbC2DyCAD1I44+TP7X/AOmH/j//ANaj+1/+mH/j/wD9agD6v8G6to9v4a01bZtGuLpZbga5by39nbRzyl2y8gkjJePH3TGwAHGK4LxJrunWPw58J6To82irJdSajb6hIscdxNbxG5+Qlsb1BQ5B4JAGK8N/tf8A6Yf+P/8A1qT+1v8Apj/4/wD/AFqAPqT4n3+jS/DrxTYXGraZqd1AbOXS5zeWjyy7pQJDFFCimMBcggluPQcny79oDULPVPi5r15pl3b3lnJ5Gye3kWRHxbxg4ZSQcEEfUV5WdV/6Y/8Aj3/1qP7U/wCmP/j3/wBagDRrE1H/AI/JPw/kKtf2p/0x/wDHv/rVRuZfOmaTG3OOM57UAb9FFFABRRS0AAqzbrzVdauWw6UAdl4KtFW8iuJVyN2ADXt8EpUqo44GK8f8K/6uMjkCvWbNhNBFKOoAFdVJWR5+Id5G1ayuQeeK04WO1Rmse3XCD1zWqp+Ue1bo5WWklIY5q5E5PWs6MZJJq7bDOcVRLL6NUynioEwKlHWgQ/rTqYAKcKYhRRwKAKG6Y6UDGOaqye1TuagYAUAZ96mV5rnrxSQR2ror77lYl5jmoZcTmNQTgnFcxfR7tw712F+pK81zd9CdxxWckaxZweuWe0E4rkdRiwpOK9K1eANbPnriuD1SLCNXNNWZ3UZXRzTU01I4wTUZrM3EooooAKKKKACq2o/8ecn4fzFWarah/wAecn4fzFAGLRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB0lFFdbpPw/13VPAuo+LbSKI6VYuUkDORI2Nu5lXHIG7k57H0oA5KlrvvDPws1nxBoFhq1vqGiWsF/K0FrHeXnkyTSKxXYoI5JI4ANcbrGmXei6rd6bqUJgvbWRopYyQdrA4PI4P1FAFVBzWhaLkiqMXUVp2Y5BoA7bwsNkIB7nNeqeGn86B4yfu4ryvQnXy1HpXpPhNz5ykDOetdVI8+vudZbRnzdtaKoSaeIguHA609F/KuhI5Wx8Scc9KtQgCmQqSDVlIyOlMkkX2qVajBx14qVcUxDxThTOacKAHZ4NRSNTnbtUTHFADWPFQtUh603FAypdDKGsa5jy1bdyuVNZksZwaloaOd1CPj3rn7uI4JNdddxAZya5zU8hW2r+NQ0aI4/WcLCyjqa4nVYvkb6V2WpAsWJJzXN6nH+7Nc80dlJ2OBlGHNRGp7kYmce9QGsDrEpKWkoAKKKKACq2o/8AHnJ+H8xVmq2o/wDHnJ+H8xQBi0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAdJX0Z4b+JvgrQrHw34VYT3WjDS5bXUb9GkSNHn5mBhMe6T5lGGB4DHGec/OdJQB7VafETRPDPw50DTdLt9M13V9N1C5lj+22022EeYxjmX7oyeDjOR6A15Jrmq3euaxeapqUnm3l3K00r4wCxOeB2HYCqNAoAngHNaloM4rMt+ta9kvSgGdJoT4lVe1es+EI8KC3c8V5PoUTPexKPWvXfDbCKNQx5FdVI4cRud5b/PEoNWEi59KzbOQ8bTxWzCcjkc10o4mORMYqYD0pAQD0pwPpTEOC8U4LgUimnZoABSk4FITgUxmzQKwjHNMPvR3oIoGMzhsUoHtTo0HU9aeeBQMqTqxUgd6oyW+R87Vflc8nNU55D0FAGXeIiA8fjXM6mA2RkV019koT3rnrpBk56+tQy0cJqSYdq5zUl+Qiuq1YfvmGK5rUh8hrnmdVM84vhi6kx61VNW785uZMepqma5juEopaSgAooooAKraj/x5yfh/MVZqtqP/HnJ+H8xQBi0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An oblique fracture of the lateral malleolus (white arrow on AP and lateral x-rays) proximal to the joint, in addition to fractures of the medial malleolus (blue arrow on AP view) and posterior malleolus (blue arrow on lateral view), are seen here. Note how the posterior malleolar fracture and the displacement of the fibular fracture can only be seen on the lateral view. The diastasis between the tibia and fibula reflects a syndesmotic injury. The highly unstable nature of trimalleolar fractures is reflected in the loss of joint congruence and the abnormal increased width between the medial malleolus and the talus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott M Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_39_6783=[""].join("\n");
var outline_f6_39_6783=null;
      